<<

THIEME 496 Narrative Review GLOBAL SPINE JOURNAL

Defining the Role of Cognitive Behavioral Therapy in Treating Chronic Low Back : An Overview

David A. Hanscom1 Jens Ivar Brox1 Ray Bunnage1

1 Swedish Medical Center, Seattle, Washington, United States Address for correspondence David A. Hanscom, MD, Swedish Neuroscience Institute, Swedish Medical Center, 550 17th Avenue, Seattle, Global Spine J 2015;5:496–504. WA 98122, United States (e-mail: [email protected]).

Abstract Study Design Narrative review of the literature. Objectives Determine if the term cognitive behavioral therapy (CBT) is useful in clinical care and research. What literature supports these variables being relevant to the experience of chronic pain? What effects of CBT in treating these factors have been documented? What methods and platforms are available to administer CBT? Methods Chronic low back pain (CLBP) is a complex neurologic disorder with many components. CBT refers to a broad family of therapies that address both maladaptive thoughts and behaviors. There are several ways to deliver it. CLBP was broken into five categories that affect the perception of pain, and the literature was reviewed to see the effects of CBT on these variables. Results The term cognitive behavioral therapy has little use in future research because it covers such a wide range of therapies. CBTshould always be defined by the problem it is Keywords intended to solve. The format and method of delivery should be defined because they ► cognitive behavioral have implications for outcomes. They are readily available even at the primary care level. therapy The effectiveness of CBT is unquestioned regarding its effectiveness in treating each of ► insomnia the variables that affect CLBP. It is unclear why it is not more widely implemented. ► structured care Conclusions CBT represents a family of therapies that are effective for a wide range of ► catastrophizing problems, many of which coexist with and influence CLBP. Each of the variables can be ► chronic pain improved with focused CBT. Early, widespread adoption of CBT in treating and ► expressive writing preventing CLBP is recommended. Future research and clinical care should focus on ► CBT implementation strategies to operationalize these well-documented treatments utilizing a public health ► presurgical screening approach.

Introduction psychological interventions on the treatment of CLBP. CBT was noted to be particularly effective.10 Cognitive behavioral therapy (CBT) is a form of psychotherapy The literature contains many studies that compare CBT that has been documented to be effective in treating anxiety, with isolated treatments for CLBP such as physical therapy insomnia, depression, addictions, and other mental disor- and surgery.1,2,11,12 The problem from a research perspective – ders.1 8 It has also been utilized in the treatment of chronic is that cognitive behavioral therapy is a general term that low back pain (CLBP).9 Hoffman et al conducted a detailed encompasses many variations and subentities under an um- meta-analysis demonstrating a strong therapeutic effect of brella term9; in addition, multiple factors affect the

received DOI http://dx.doi.org/ © 2015 Georg Thieme Verlag KG August 27, 2015 10.1055/s-0035-1567836. Stuttgart · New York accepted after revision ISSN 2192-5682. October 1, 2015 Cognitive Behavioral Therapy to Treat Chronic Low Back Pain Hanscom et al. 497

Table 1 Variables influencing the perception of chronic low more focused on the present situation rather than the influ- back pain ence of the past on your current experience. One premise of CBT is that thoughts create a physiologic 38 Sleep response that usually includes adrenaline and cortisol. Stress Thoughts may represent cognitive distortions that have little Anxiety to do with reality. The result may be unpleasant in that it includes a physical sense of alertness and tension to enable a Fear avoidance13,54 “fight or flight” response. CBT aims to create an awareness of 3,5 Catastrophizing these distortions and resultant maladaptive behaviors (i.e., to Anger49 identify automatic negative thoughts). CBT has been reported Injury conviction50 to be effective in treating anxiety and depression as well as other mental health conditions.6,8 CBT is particularly relevant Depression43 to the treatment of chronic pain,9 in that different stressors Medications and states of mind have an adverse effect on the perception of Compliance63 pain and functional outcomes.13 Physical conditioning1,2 Ehde et al summarized the literature regarding the goals of CBT to reduce pain and psychological distress and improve Life outlook physical and role function in the treatment of chronic pain by 27 Forgiveness decreasing maladaptive behaviors, increasing adaptive be- haviors, identifying and correcting maladaptive thoughts and beliefs, and increasing self-efficacy for pain management.9 perception of pain (►Table 1). Therefore, looking at CBT in the treatment of CLBP may provide limited clinically useful Background of Cognitive Behavioral Therapy information. The origins of CBT began with Albert Ellis in the 1950s. He is Indeed an extensive Cochrane review concluded: “There is considered one of the most influential psychologists in history, no need for more general RCTs [randomized controlled trials] publishing over 800 peer-reviewed papers. His term for this reporting group means, rather, different types of studies and treatment approach was rational emotive behavior therapy.He analyses are needed to identify which components of CBT founded the Albert Ellis Institute in 1959, which continues to work for which type of patient on which outcome/s, and to try disseminate these principles.14 Interestingly, he gave credit to to understand why.”7 the Stoics who were influential in Roman times for the The purpose of this article is to delineate the factors that formation of basic cognitive concepts. He particularly recog- have been reported to affect the perception of pain and what nized Epictetus (55 to 135 BC), a Greek philosopher who was role the different types of CBT might have in addressing them. exiled by the Romans, who stressed that human beings cannot The manner and setting in which CBT is delivered will also be control life, only their responses to it.15 considered. Aaron Beck, an internationally renowned psychiatrist who is considered the father of CBT, modified the concepts devel- Methods oped by Albert Ellis and conducted extensive research regard- ing the role of thoughts in creating emotions. His work became This study is a narrative educational review, and we note the influential beginning in the 1960s. The Beck Institute, founded potential for bias or omission of important articles. We sought to in 1994, actively promotes CBT concepts through research, perform a formal systematic literature review at the onset of this clinical care, and training health care professionals.16 project and after a midpoint review decided to base this article David Burns, a Stanford psychiatrist, popularized Beck’s primarily on the conclusions of systematic reviews and meta- work in a best-selling book, Feeling Good, published in 1980.17 analyses instead. Individual studies are presented to illustrate He also is actively engaged in research as well as teaching and promising areas for further research and clinical applications. In training. light of the vast nature of the literature regarding CBT for a multitude of different medical conditions, we decided to reframe Types of Cognitive Behavioral Therapy our project with the intent to clarify the basic CBT concepts that are applicable to CLBP and to suggest a direction for further “Cognitive Behavioral Therapy” studies. Our intent was to educate spine providers about the A more traditional psychological approach to pain is operant options of selectively using elements of CBT for the various conditioning, with which the various forms of CBT are often clinical scenarios that occur in the presence of CLBP. compared. This approach focuses on extinguishing maladap- tive behavior and reinforcing positive reactions to pain. It is Results traditionally based on reward and punishment of behaviors in contrast to addressing the cognitive component of pain.13 Defining Cognitive Behavioral Therapy CBT addresses both the cognitive and behavioral elements CBT describes a category of therapies that address the effect of a given problem. It is important to realize that there is no that thoughts have on behavior, emotions, and symptoms. It is standard CBT protocol, and indeed many different techniques

Global Spine Journal Vol. 5 No. 6/2015 498 Cognitive Behavioral Therapy to Treat Chronic Low Back Pain Hanscom et al.

are used to administer it. CBT may be perceived as a specific psychomotor therapy. This group had improved functional treatment paradigm but is really a descriptor for a “family” of disability, self-efficacy, outcomes expectancy, and less fear of treatments. Mansell proposed seven areas of CBT that need to movement/reinjury.22 be clarified to improve the delivery of CBT. The three most important are clarity (shared definitions of CBT and its Modes of Delivery terminology), coherence (shared therapeutic principles and theory), and cohesion (integration of individuals and sub- Individual Therapy groups using CBT).18 CBT is frequently administered in a one-to-one setting, which One problem when evaluating CBT is that the information is ideal if there is a good fit of the patient with the mental learned is limited unless the type of CBT is clearly defined and health professional. Such an arrangement provides guidance, the intended outcome of treatment is measured. therapeutic alliance, and support. Unfortunately, there is limited access to mental health Third-Wave Cognitive Behavioral Therapy resources, especially individual therapists. Access is limited CBT can be combined with treatments that calm the nervous because of both the availability of therapists and insurance system such as mindfulness and meditation. Instead of con- coverage. Despite the federal government mandating that fronting and addressing the content of the thoughts, the mental health be placed on even par with physical health, not participant learns to watch and disassociate from them. Tools much has changed to allow easier access to these resources. include relaxation, mindfulness, meditation, acupuncture, Nonetheless, this variable should be noted in directing pa- medical hypnosis, play, among others. The general term being tients to CBT. used for this more eclectic approach is Third-Wave CBT.19 With proper training, CBT can be administered by all who One review regarding the role of Third-Wave CBT in treat patients with pain such as family physicians, rehabilita- treating depression described seven different approaches.19 tion physicians, surgeons, physical therapists,11,12 nurses, Again, the term describes a family of therapies that include and occupational therapists.23 various relaxation techniques. Meaningful data regarding its efficacy would still have to focus on the specific variable being Group Treatments treated. Social isolation is a significant issue for many patients suffer- For example, Acceptance Commitment Therapy or adap- ing from chronic pain. Unfortunately, in this state, the brain is tive CBT was developed in the 1980s. Instead of challenging spending more time on pain pathways and obsessing about intrusive thoughts, patients learn to accept and separate from the problems. People in pain may not have the energy to them rather than judging or reacting to them. It is comple- associate with others and eventually lose interest if they mentary to core CBT, which is cognitive identification, cogni- become depressed. They are also not that enjoyable to be tive reappraisal, and behavior modification. As meditation with and they may drive friends and family away. and mindfulness have already been shown to be effective in Social isolation causes the same part of the brain to light treating pain, it is felt that this combination should be helpful, up on functional magnetic resonance imaging (MRI) as in but the evidence regarding the efficacy of this combination of physical pain; the pattern of responses are similar and therapies is limited.20 reproducible. Social pain and physical pain are essentially An extensive Cochrane Review regarding its applicability one and the same. This adaptation may be part of the to depression concluded that the data is promising but not evolutionary process that allowed the more social species robust enough to specifically recommend it compared with to survive.24 treatment as usual.19 The interaction with other people is a powerful way of creating a shift out of pain pathways as well as diminishing Problem-Focused Cognitive Behavioral Therapy the activity in the pain center.23 One study reported that By definition, all CBTs are problem-focused. The treatments teacher-administered CBT could decrease depression, anxi- are always targeted for specific issues and outcomes. Al- ety, and impulsivity in high-risk students.25 though anxiety is universal, CBT focuses on specific thoughts and behaviors around anxiety. Phobias would require an even Self-Administered more-specific approach.21 Bibliotherapy is the use of reading materials to learn and Brox’s group conducted a randomized prospective study implement CBT without the guidance of a mental health comparing a focused CBT for physical activation compared professional. Studies have reported a high success rate in with a spine fusion for low back pain. CBT was comparable to treating anxiety and depression with just this approach fusion surgery but at 1-year follow-up, there was less fear alone.26 Without access to mental health care, a self-admin- avoidance in the CBT group.2 A longer-term follow-up (4 istered approach can be considered as an option. years) of the same protocol confirmed these findings.1 Another platform for self-directed CBT is the Internet. A A prospective randomized study compared early rehabili- systematic review looked at how a computerized format tation after a lumbar fusion. One group was placed into a might be accepted in rural areas. The authors concluded it structured exercise program and the other into exercise plus was a viable and effective platform and that rural patients CBT geared toward modifying maladaptive pain conditions, might be more open to it than to face-to-face contact with behaviors, and motor control. This combination was termed practitioners.6

Global Spine Journal Vol. 5 No. 6/2015 Cognitive Behavioral Therapy to Treat Chronic Low Back Pain Hanscom et al. 499

For a patient, taking responsibility for the present situation • Mental and physical pain is sensed in close proximity with would logically be helpful for a successful long-term outcome. similar reaction patterns on functional MRI.24 One way of assessing this responsibility is the “locus of control” • Back pain circuits shift from the nociceptive center to the concept. Patients with an external locus of control look to the emotional center within 12 months of onset.34 environment as their source of happiness; patients with an • The neuroexcitatory effect of prolonged cytokine immune internal locus of control look inward for life satisfaction.27 When response leads to a “wind-up” increased pain response. using screening tools, determining the patient’s locus of control • With sustained pain, patients feel trapped and angry. The may be helpful. If a given patient refuses to engage in these tools resultant chemical hypersensitivity and inflammatory re- and still demands treatment, it is a clear indication that he or she sponse create a multitude of physical symptoms in addi- has an external locus of control. This scenario is a catch-22 of self- tion to magnifying the pain.35 directed care in that one of the aims of CBT is to develop a sense • Pain pathways, mental and physical, are structurally im- of responsibility and internal locus of control.28 bedded (central sensitization), and it takes neuroplastic reorganization to recover from chronic pain.36 Expressive Writing—with or without Cognitive Behavioral Therapy To successfully treat chronic pain, interventions that stim- An approach that has been studied extensively in 200 pub- ulate neuroplasticity to rewire the brain and also to calm lications since 1982 is the use of expressive writing. The original down the nervous system are warranted. All the factors that study by Pennebaker reported the course of volunteers who affect pain should be addressed to optimize the outcome were asked to write about an adverse life experience in detail.29 (►Table 1). CBT can be helpful in treating each of these They were asked to write for 20 minutes, 4 days in a row. The variables either directly or by improving compliance with control group just recorded the day’s events. A 2005 review care. article of the impact of this simple exercise reported improved immune system function, fewer stress-related visits to the Cognitive Behavioral Therapy and Sleep doctor, reduced blood pressure, improved lung function, fewer Poor sleep quality is common in patients suffering from inpatient days in the hospital, improved mood/affect, feeling of chronic pain. It is debated whether lack of sleep exacerbates greater psychological well-being, less depressive symptoms the pain or the pain prevents sleep.37 Regardless of the source before exams, reduced absenteeism from work, quicker reem- of insomnia, it is important to address it as part of the ployment after job loss, improved working memory, improved treatment program. One study suggests that poor sleep sporting performance, higher student grade point average, and quality is a better predictor of disability than the actual altered social and linguistic behavior.30 There was also improve- severity of the pain.38 ment in chronic pelvic pain as well as a decrease in sleep latency. A small prospective study looked at the effect of expressive Effect of Cognitive Behavioral Therapy in Addressing Sleep writing on the effectiveness of physical therapy. There were There are various stepwise approaches to address sleep 20 patients in each group. The writing cohort showed signifi- disturbance. Sleep hygiene refers to a set of strategies that cant improvements in pain, posture, and overall sense of well- improve the chances of falling asleep, such as avoiding being. Pain continued to decrease 6 months later only in the caffeine in the afternoon, not having a clock in the bedroom, writing group.31 only going to bed to sleep when you are tired, among other. CBT may be combined with expressive writing. There is However, it is more difficult to obtain adequate sleep when some evidence that it is more effective when combined with experiencing pain. Sleep medications may be required for a positive expression. Some advocate just writing a stream of defined period of time to break the cycle. CBT can be directed consciousness. Although expressive writing is often used with at insomnia or the depression and anxiety that may be the CBT, it is a different entity. CBT is based on challenging cause of insomnia. CBT-I (CBT-insomnia) is an example of a disruptive thought patterns and beliefs. The writing increases problem-focused therapy intended to improve the quality of the awareness of the negative thoughts, which is increasingly sleep.4 One study suggests that patients who have a successful seen as important for mental health.30,32 resolution of their depression have a much lower relapse if they are sleeping well.39 Cognitive Behavioral Therapy’s Role in Treating the Factors Affecting the Perception of Chronic Low Back Managing Stress: Role of Depression and Catastrophizing Pain in Exacerbating Chronic Pain The emergence of sophisticated functional MRI has allowed Linton did a meta-analysis of the link between psychosocial researchers to describe the neurologic basis of chronic pain. stress and chronic pain.40 He collected 913 articles, with the The nervous system is involved in the transition from acute to resultant meta-analysis utilizing 37 studies. Linton reported a chronic pain. Several basic changes have been reported: significant association between stress and pain and poorer outcomes of spine surgery in stressed patients.40 A review • There are changes in both gray and white matter in pain documented the relationship between depression and cata- processing regions. The pain brain map grows and the strophizing with rheumatologic disorders.3 Catastrophizing motor cortex map shrinks. Fortunately, these maps can be is reported to increase pain and decrease the effectiveness of reversed with treatment.33 biomedical interventions. Prolonged stress has a profound

Global Spine Journal Vol. 5 No. 6/2015 500 Cognitive Behavioral Therapy to Treat Chronic Low Back Pain Hanscom et al.

effect on almost every organ system including the immune Richmond et al conducted a meta-analysis comparing CBT system and inflammatory response.3 to usual care/wait list and guideline-based treatment for Carragee et al conducted a 5-year prospective study in CLBP. They included any duration of low back pain and all volunteers with persistent back pain.41 The researchers age groups. The significant benefits in decreasing pain and documented MRI findings and performed diskography in disability and improving quality of life were maintained at 25 patients. He demonstrated that psychosocial variables longer-term follow-up. Although the various types and ad- strongly predicted both long- and short-term disability ministration of CBT were documented, the results were events. He used the DRAM index, which is a combination of reported for the general category of CBT.65 a depression and somatization scale and the fear avoidance questionnaire. There was no correlation of the disk pathology Life Outlook—Cognitive Distortions with the development of disabling pain, except for a mild CBT identifies various common cognitive distortions that in correlation with the presence of Modic changes.41 chronic pain may become deeply ingrained and evolve into an Multiple studies have reported the poorer outcomes re- injury conviction and anger. Unrelenting anger may create a garding pain and function in the presence of coexisting hypervigilant state of arousal and adds to the magnitude of depression, catastrophizing, and fear avoidance belief.5,42,43 the pain. Eventually it evolves into rage.49 One study reported some improvement in mental health if Whether the original series of events that created the the surgery is successful.44 chronic pain were valid or become distorted over Several studies have reported that the use of presurgical time makes no difference. The ongoing bodily reaction of psychological screening can help predict surgical outcomes. anger creates a series of undesirable sequelae. One of The Texas Back Institute reported 82% accuracy in predicting those is “blame,” also referred to as an “external locus of a positive surgical outcome.45 Chou and Shekelle did an control.” Possibly one of the most important factors in extensive literature review (1966 to 2010) on the predictors determining long-term success in addressing chronic for developing persistent low back pain. The most effective pain is achieving a transition from an external to an internal components were maladaptive pain coping behaviors, non- locus of control.27 organic signs, functional impairment, general health status, A 2003 study reported a link between the hyperarousal and presence of psychiatric comorbidities.46 state of being angry and increased levels of pain. A majority of Most surgeons currently are not routinely evaluating patients remained angry with the person or situation that psychosocial risk factors and they may have a limited ability created the pain.50 Interestingly, one study showed that to do so.47 Daubs et al64 prospectively administered a DRAM patients were commonly angry at themselves. It was sug- index to a cohort of orthopedic spine patients in a clinical gested that CBT could improve pain by addressing the de- setting. However, the overall sensitivity for detecting patients pression around pain and anger.51 with high levels of distress was low. Using CBT to treat One prospective study concluded that there was a higher depression and catastrophizing was felt to be a meaningful external locus of control in treated patients versus those who intervention. were waiting to be treated with physical therapy. It raised the A meta-analysis compared the effectiveness of treating question of the providers reinforcing this belief system.52 anxiety compared with a psychological placebo and a waiting The locus of control can be switched in a multidisciplinary list group. There was moderate evidence that CBT was effec- pain clinic setting. This setting usually includes a form of tive in treating anxiety. The study suggests that the beneficial psychological intervention, but it is unclear whether CBT effect in the treatment of pain is mediated through decreased alone can accomplish this shift.53 pain catastrophizing.8 Interestingly, one study showed that In a review article, Vlaeyen and Linton wrote that fear of engaging patients in a graded physical conditioning program pain was more of a problem than the actual pain experience. could decrease catastrophizing without the use of CBT. CBT The resultant fear avoidance behavior reinforces chronic pain alone was also effective in reducing it. As patients gained and disability.54 more confidence in their ability to move, they were able to One foundational concept of CBT is to systematically calm themselves down.5 identify and challenge these distortions in thinking. Then the next steps of substituting more rational thoughts Cognitive Behavioral Therapy and Physical Health versus engaging in mindfulness or other options depends Edwards et al summarized the effects of depression and on the therapist’s approach. Catastrophizing is one of the catastrophizing on diminishing efforts to engage in healing cognitive distortions that has been associated with a poor behaviors.3 There was a strong effect in blocking positive self- prognosis.3 directed interventions. They cited references regarding knee If a patient has deep anger or rage, the capacity of the arthritis, medication noncompliance, lack of weight control, patient to listen and understand may be compromised. The and insufficient exercise among other self-destructive role of anger in creating depression and pain catastroph- behaviors. izing is beyond the discussion of this article. CBT is one Another prospective study demonstrated that an Internet- tool but, for example, if a patient has a history of severe based CBT program could be helpful for patients with residual trauma, more sophisticated and focused strategies must be symptoms after physical rehabilitation.48 utilized.

Global Spine Journal Vol. 5 No. 6/2015 Cognitive Behavioral Therapy to Treat Chronic Low Back Pain Hanscom et al. 501

A Framework of How Cognitive Behavioral Therapy Chronic Pain—Multidisciplinary Approach May Be Implemented for Patients with Chronic Low Should a patient’s pain persist more than 3 months, a Back Pain multidisciplinary approach is preferable. At this point, there As part of this review, we evaluated different types of CBT, as are almost always more substantial issues that require pro- well as methods and formats of delivery. A multipronged fessional assistance. CBT can be administered either in a rather than a multidisciplinary approach is suggested. group or an individual setting. Ideally, all the aspects of pain are addressed in these sessions.60 Possible Treatment Paradigm Finally, the ultimate goal for long-lasting successful The need for early identification of (and intervention for) at- outcomes is for the patient to develop an internal locus risk patients with chronic pain has been documented in the of control. Although the above-mentioned approach may literature for decades. Waddell reported a return to work rate work for a while, it is not sustainable unless the patient of less than 5% if a patient was disabled for more than takes full responsibility for his or her care. A challenging 2 years.55 Therefore, the goal of care for any patient in pain paradox arises when patients who have a strong external is to quickly treat the acute phase and prevent it from locus of control, such as a strong injury conviction, will not becoming chronic. It is noteworthy that in one study 50% of engage in any of the strategies needed for healing. CBT may the acute group progressed to CLBP.34 help shift the locus of control but alternate approaches may From a human suffering and cost perspective, patients at be needed. risk for developing chronic pain can actually be identified at In general, it seems desirable that a methodological the time of presentation. A small percentage of patients are approach that addresses mental health factors is utilized responsible for over half of all health care costs.56 Fear in every patient prior to the use of any invasive elective avoidance is consistently identified as a risk for disability.57 procedures. Distressed patients are more vulnerable to A 2008 meta-analysis also showed that worker expectations adverse events when undergoing procedures.61 The United have significant impact on return to work for nonspecificlow States Preventive Services Task Force recommended the use back pain.57 Early identification is important, and examples of of routine presurgical psychological screening if resources validated questionnaires to accomplish this task include the are available to address the identified problem.62 To date, DRAM index,44 Fear Avoidance Behavior Questionnaire only a minority of surgeons have implemented this (FABQ),42 and the Battery for Health Improvement (long practice.47 and short form).58 This process could be accomplished at the primary care level. Interestingly, one study showed that Future Research to Better Specify the Effectiveness of primary care physicians who expressed a special interest in Cognitive Behavioral Therapy for Treating Chronic Low musculoskeletal care were more likely to have faulty belief Back Pain systems regarding the management of low back pain.59 It is The evidence that psychosocial factors negatively affect out- also important to understand that mental and physical pain comes of any treatment is irrefutable.40 Yet few surgeons are processed in the same part of the brain and should be assess or treat these issues.47 Methodologies should be treated in a similar manner.24 developed and documented to ensure that every patient has mental health disorders defined and treated before Acute and Subacute Pain—Multipronged Approach undergoing elective procedures, especially in more invasive If a patient has acute pain and is at low risk for developing procedures such as spine fusions. The utilization of mental chronic pain, then simple symptomatic care should be health screening and follow-up therapy might be of interest sufficient. However, if there are risk factors and/or the from a public health perspective. pain persists for more than 6 weeks, then additional The term cognitive behavioral therapy used in isolation interventions should be implemented targeting all the should probably be discarded. Future research should always relevant factors affecting the situation. Linton, in a system- identify what aspect of a person’s problem is to be addressed atic review, found that psychological factors influenced by what type of CBT. By definition, CBT always targets a development of chronic neck and back pain for acute, specific set of behaviors and/or thought patterns. Many of subacute, and persistent pain.40 these affect the perception of pain. The questions should be, Linton also demonstrated a ninefold decrease in long-term “Did the CBT successfully treat a given variable? If so, how did disability with a six-session CBT intervention in acute and the resolution of that specific problem affect the CLBP? How subacute patients with spinal pain compared with patients many issues need to be solved before the pain resolves? Are only given information in pamphlets. This approach can be there core problems that are more important to address applied to primary care settings.40 first?” Only by breaking CBT down to specific focused out- Resources to address the cognitive and behavioral issues comes will we better understand its role in treating CLBP. are easily available and do not require a full pain clinic setting One important challenge is the development of resources to implement. Treatment can be accessed through books and and pathways to enable early identification and treatment of the Internet. Delivery can be given in a group setting, self- at-risk patients. Different validated questionnaires exist to administered, or administered individually by nontraditional profile this risk, and treatments could be made readily providers such as nurses, occupational therapists, and physi- available. We recommend that future research focus on cal therapists. methodologies to implement and sustain known effective

Global Spine Journal Vol. 5 No. 6/2015 502 Cognitive Behavioral Therapy to Treat Chronic Low Back Pain Hanscom et al.

treatments, which would hold true for focused CBT as well as 8 Zhu Z, Zhang L, Jiang J, et al. Comparison of psychological placebo addressing other aspects of chronic pain. Questions include: and waiting list control conditions in the assessment of cognitive behavioral therapy for the treatment of generalized anxiety • Who can develop these systems and tools and sustain disorder: a meta-analysis. Shanghai Arch Psychiatry 2014;26(6): them? 319–331 • What payment model must be developed to make these 9 Ehde DM, Dillworth TM, Turner JA. Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and direc- types of nonprocedural treatments equitable? tions for research. Am Psychol 2014;69(2):153–166 • What percent of money spent on procedures with poorly 10 Hoffman BM, Papas RK, Chatkoff DK, Kerns RD. Meta-analysis of documented outcomes should be spent on strategies that psychological interventions for chronic low back pain. Health are effective? Psychol 2007;26(1):1–9 • What is the best way to create accountability? 11 Bruflat AK, Balter JE, McGuire D, Fethke NB, Maluf KS. Stress management as an adjunct to physical therapy for chronic neck – Conclusion pain. Phys Ther 2012;92(10):1348 1359 12 Hunt MA, Keefe FJ, Bryant C, et al. A physiotherapist-delivered, CLBP is a neurophysiological disorder that is affected by combined exercise and pain coping skills training intervention for individuals with knee osteoarthritis: a pilot study. Knee 2013; multiple factors. Theoretically, the most effective treatment 20(2):106–112 would systematically address every relevant variable for any 13 Sturgeon JA. Psychological therapies for the management of given patient. Ideally, the patient would also be a partner in a chronic pain. Psychol Res Behav Manag 2014;7:115–124 shared decision-making process, which means he or she must 14 The Albert Ellis Institute. Available at: http://albertellis.org. have internal locus of control. Accessed November 1, 2015 CBT can have an impact on most of these factors affecting 15 Lebell S. The Art of Living: Interpretation of Epictetus. New York, NY: HarperCollins; 1995 the perception of pain. There are many types of CBT and ways 16 Perelman School of Medicine. Aaron T. Beck, M.D. 2015. Available of implementing it. Each has unique characteristics that must at: http://www.med.upenn.edu/suicide/beck/. Accessed November be considered when evaluating the role of CBT in treating 1, 2015 CLBP in a given patient. 17 Burns D. Feeling Good. New York: Harper Collins; 1980 CBT can be accessible through delivery models than can be 18 Mansell W. The Seven C’s of CBT: a consideration of the future implemented early in a patient’s care. Prompt identification challenges for cognitive behaviour therapy. Behav Cogn Psy- chother 2008;36:641–649 of at-risk patients for the development of CLBP is necessary to 19 Hunot V, Moore TH, Caldwell DM, et al. “Third wave” cognitive and take advantage of these resources. behavioural therapies versus other psychological therapies for depression. Cochrane Database Syst Rev 2013;10:CD008704 Disclosures 20 Marino P. Cognitive behavior therapy with mindfulness and acceptance skills for treatment of older adults. Clin Case Stud David A. Hanscom, none 2015;14:262–273 Jens Ivar Brox, none 21 Vitiello MV, Rybarczyk B, Von Korff M, Stepanski EJ. Cognitive Ray Bunnage, none behavioral therapy for insomnia improves sleep and decreases pain in older adults with co-morbid insomnia and osteoarthritis. J Clin Sleep Med 2009;5(4):355–362 22 Abbott AD, Tyni-Lenné R, Hedlund R. Early rehabilitation References targeting cognition, behavior, and motor function after lumbar 1 Brox JI, Nygaard OP, Holm I, Keller A, Ingebrigtsen T, Reikerås O. fusion: a randomized controlled trial. Spine 2010;35(8): Four-year follow-up of surgical versus non-surgical therapy for 848–857 chronic low back pain. Ann Rheum Dis 2010;69(9):1643–1648 23 Lamb SE, Mistry D, Lall R, et al; Back Skills Training Trial Group. 2 Brox JI, Sørensen R, Friis A, et al. Randomized clinical trial of Group cognitive behavioural interventions for low back pain in lumbar instrumented fusion and cognitive intervention and primary care: extended follow-up of the Back Skills Training Trial exercises in patients with chronic low back pain and disc degen- (ISRCTN54717854). Pain 2012;153(2):494–501 eration. Spine (Phila Pa 1976) 2003;28(17):1913–1921 24 Eisenberger NI, Lieberman MD, Williams KD. Does rejection hurt? An 3 Edwards RR, Cahalan C, Mensing G, Smith M, Haythornthwaite JA. FMRI study of social exclusion. Science 2003;302(5643):290–292 Pain, catastrophizing, and depression in the rheumatic diseases. 25 O’Leary-Barrett M, Topper L, Al-Khudhairy N, et al. Two-year Nat Rev Rheumatol 2011;7(4):216–224 impact of personality-targeted, teacher-delivered interventions 4 Manber R, Edinger JD, Gress JL, San Pedro-Salcedo MG, Kuo TF, on youth internalizing and externalizing problems: a cluster- Kalista T. Cognitive behavioral therapy for insomnia enhances randomized trial. J Am Acad Child Adolesc Psychiatry 2013; depression outcome in patients with comorbid major depressive 52(9):911–920 disorder and insomnia. Sleep 2008;31(4):489–495 26 Smith NM, Floyd MR, Scogin F, Jamison CS. Three-year follow-up of 5 Smeets RJ, Vlaeyen JW, Kester AD, Knottnerus JA. Reduction of pain bibliotherapy for depression. J Consult Clin Psychol 1997;65(2): catastrophizing mediates the outcome of both physical and cog- 324–327 nitive-behavioral treatment in chronic low back pain. J Pain 2006; 27 Carson JW, Keefe FJ, Goli V, et al. Forgiveness and chronic low back 7(4):261–271 pain: a preliminary study examining the relationship of forgive- 6 Vallury KD, Jones M, Oosterbroek C. Computerized cognitive ness to pain, anger, and psychological distress. J Pain 2005;6(2): behavior therapy for anxiety and depression in rural areas: a 84–91 systematic review. J Med Internet Res 2015;17(6):e139 28 Kerns RD, Rosenberg R, Jamison RN, Caudill MA, Haythornthwaite 7 Williams AC, Eccleston C, Morley S. Psychological therapies for the J. Readiness to adopt a self-management approach to chronic pain: management of chronic pain (excluding headache) in adults. the Pain Stages of Change Questionnaire (PSOCQ). Pain 1997; Cochrane Database Syst Rev 2012;11:CD007407 72(1–2):227–234

Global Spine Journal Vol. 5 No. 6/2015 Cognitive Behavioral Therapy to Treat Chronic Low Back Pain Hanscom et al. 503

29 Pennebaker JW. Traumatic experience and psychosomatic disease. surgery: use and clinical impact. J Spinal Disord Tech 2014;27(2): Exploring the roles of behavioural inhibition. Can Psychol 1985; 76–79 26:82–95 48 Buhrman M, Fredriksson A, Edström G, et al. Guided Internet- 30 Baikie KWK. Emotional and physical health benefits of expressive delivered cognitive behavioural therapy for chronic pain patients writing. Adv Psychiatr Treat 2005;11:338–346 who have residual symptoms after rehabilitation treatment: 31 Pepe L, Milani R, Di Trani M, Di Folco G, Lanna V, Solano L. A more randomized controlled trial. Eur J Pain 2013;17(5):753–765 global approach to musculoskeletal pain: expressive writing as an 49 Sarno J. Mind Over Back Pain. New York, NY: Penguin; 1982 effective adjunct to physiotherapy. Psychol Health Med 2014; 50 DeGood DE, Kiernan B. Perception of fault in patients with chronic 19(6):687–697 pain. Pain 1996;64(1):153–159 32 Smyth JM, Pennebaker JW. Exploring the boundary conditions of 51 Greenwood KA, Thurston R, Rumble M, Waters SJ, Keefe FJ. Anger expressive writing: In search of the right recipe. Br J Health Psychol and persistent pain: current status and future directions. Pain 2008;13(Pt 1):1–7 2003;103(1–2):1–5 33 Seminowicz DA, Wideman TH, Naso L, et al. Effective treatment of 52 Oliveira TH, Oliveira VC, Melo RC, Melo RM, Freitas AE, Ferreira PH. chronic low back pain in humans reverses abnormal brain anato- Patients in treatment for chronic low back pain have higher my and function. J Neurosci 2011;31(20):7540–7550 externalised beliefs: a cross-sectional study. Rev Bras Fisioter 34 Hashmi JA, Baliki MN, Huang L, et al. Shape shifting pain: chron- 2012;16(1):35–39 ification of back pain shifts brain representation from nociceptive 53 Coughlin AM, Badura AS, Fleischer TD, Guck TP. Multidisciplinary to emotional circuits. Brain 2013;136(Pt 9):2751–2768 treatment of chronic pain patients: its efficacy in changing patient 35 Abbass A, Lovas D, Purdy A. Direct diagnosis and management of locus of control. Arch Phys Med Rehabil 2000;81(6):739–740 emotional factors in chronic headache patients. Cephalalgia 2008; 54 Vlaeyen JW, Linton SJ. Fear-avoidance and its consequences in 28(12):1305–1314 chronic musculoskeletal pain: a state of the art. Pain 2000;85(3): 36 Woolf CJ. Central sensitization: implications for the diagnosis and 317–332 treatment of pain. Pain 2011;152(3, Suppl):S2–S15 55 Waddell G. Low back pain: a twentieth century health care 37 Call-Schmidt TA, Richardson SJ. Prevalence of sleep disturbance enigma. Spine (Phila Pa 1976) 1996;21(24):2820–2825 and its relationship to pain in adults with chronic pain. Pain Manag 56 van Tulder MW, Koes BW, Bouter LM. A cost-of-illness study of Nurs 2003;4(3):124–133 back pain in The Netherlands. Pain 1995;62(2):233–240 38 Zarrabian MM, Johnson M, Kriellaars D. Relationship between 57 Iles RA, Davidson M, Taylor NF. Psychosocial predictors of failure to sleep, pain, and disability in patients with spinal pathology. Arch return to work in non-chronic non-specific low back pain: a Phys Med Rehabil 2014;95(8):1504–1509 systematic review. Occup Environ Med 2008;65(8):507–517 39 Reynolds CF III, Frank E, Houck PR, et al. Which elderly patients 58 Bruns D, Disorbio JM. The psychological evaluation of patients with remitted depression remain well with continued interper- with chronic pain: a review of BHI 2 clinical and forensic interpre- sonal psychotherapy after discontinuation of antidepressant med- tive considerations. Psychol Inj Law 2014;7(4):335–361 ication? Am J Psychiatry 1997;154(7):958–962 59 Buchbinder R, Staples M, Jolley D. Doctors with a special interest 40 Linton SJ. A review of psychological risk factors in back and neck in back pain have poorer knowledge about how to treat back pain. Spine (Phila Pa 1976) 2000;25(9):1148–1156 pain. Spine (Phila Pa 1976) 2009;34(11):1218–1226, discussion 41 Carragee EJ, Alamin TF, Miller JL, Carragee JM. Discographic, MRI 1227 and psychosocial determinants of low back pain disability and 60 Mayer TG, Gatchel RJ, Brede E, Theodore BR. Lumbar surgery in remission: a prospective study in subjects with benign persistent work-related chronic low back pain: can a continuum of care back pain. Spine J 2005;5(1):24–35 enhance outcomes? Spine J 2014;14(2):263–273 42 Wertli MM, Rasmussen-Barr E, Held U, Weiser S, Bachmann LM, 61 Sinikallio S, Aalto T, Airaksinen O, et al. Depression is associated Brunner F. Fear-avoidance beliefs—a moderator of treatment with poorer outcome of lumbar spinal stenosis surgery. Eur Spine J efficacy in patients with low back pain: a systematic review. Spine 2007;16(7):905–912 J 2014;14(11):2658–2678 62 U.S. Preventive Services Task Force. Screening for depression. 43 Chaichana KL, Mukherjee D, Adogwa O, Cheng JS, McGirt MJ. 2009. Available at: http://www.uspreventiveservicestaskforce. Correlation of preoperative depression and somatic perception org/page/document/final-evidence-summary20/depression-in- scales with postoperative disability and quality of life after lumbar adults-screening. Accessed November 1, 2015 discectomy. J Neurosurg Spine 2011;14(2):261–267 63 Safren SA, O’Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. 44 Main CJ, Wood PL, Hollis S, Spanswick CC, Waddell G. The Distress Cognitive behavioral therapy for adherence and depression (CBT- and Risk Assessment Method. A simple patient classification to AD) in HIV-infected drug users: a randomized controlled identify distress and evaluate the risk of poor outcome. Spine trial. J Consult Clin Psychol 2012;80(3):404–415 (Phila Pa 1976) 1992;17(1):42–52 64 Daubs MD, Patel AA, Willick SE, et al. Clinical impression versus 45 Block AR, Ohnmeiss DD, Guyer RD, Rashbaum RF, Hochschuler SH. standardized questionnaire: the spinal surgeon’s ability to assess The use of presurgical psychological screening to predict the psychological distress. J Bone Joint Surg Am 2010;92(18): outcome of spine surgery. Spine J 2001;1(4):274–282 2878–2883 46 Chou R, Shekelle P. Will this patient develop persistent disabling 65 Richmond H, Hall AM, Copsey B, et al. The Effectiveness of low back pain? JAMA 2010;303(13):1295–1302 Cognitive Behavioural Treatment for Non-Specific Low Back 47 Young AK, Young BK, Riley LH III, Skolasky RL. Assessment of Pain: A Systematic Review and Meta-Analysis. PLoS One 2015; presurgical psychological screening in patients undergoing spine 10(8):e0134192

Global Spine Journal Vol. 5 No. 6/2015 504 Cognitive Behavioral Therapy to Treat Chronic Low Back Pain Hanscom et al.

Editorial Perspective

Our reviewers were appreciative of the attention placed on development of chronic pain to facilitate early interven- the topic of CBT by Hanscom and colleagues, as use of these tion rather than requiring late and costly interventions. In forms of therapy should be very important to spine care light of the high direct and indirect costs of low back pain professionals and have been largely unappreciated in the care, the integration of such mental health and distress past. The initially submitted idea for a Systematic Review of screening programs into the basic primary care evalua- CBT regarding CLBP management turned out to be impos- tions would be of high public health interest. sible to perform in light of the magnitude and diversity of • CBT is not one single entity but an array of therapeutic the literature on this subject. After discussions with the interventions directed at specific aspects of patient dys- authors, Evidence-Based Spine-Care Journal (EBSJ)/Global function. This distinction is important as future research in Spine Journal (GSJ) agreed to a resubmission of the study as spine using CBT-type intervention can be rightfully a Narrative Review on the topic of cognitive behavioral expected to provide more differentiated details on the health in the management of CLBP. Hopefully, the reader- type of therapies administered and the timing and ship will agree that the authors provide a helpful introduc- duration of such interventions. tion and overview of this area of care. There are several • Attempts at comparing surgical treatment for CLBP and valuable take-home points from this article: CBT are probably misguided. There is little reason to not • Concepts of pain, and especially chronic pain, are probably make some form of CBT part of routine elective spine care not adequately taught in medical schools around the and utilize screening tests to better identify patients at risk world. These subjects are certainly not part of the curricu- for poor outcomes based on psychosocial comorbidities. lum in the training of most spine surgeons. Similarly, identifying risk factors for the emergence of chronic pain EBSJ/GSJ thanks the authors for their efforts at educating are also not part of routine medical practice. This article spine surgeons around the world on this important topic and highlights that in the future, primary care providers ideally hopes that they will use this platform for more in-depth would be trained to identify patients at risk for the studies on this topic.

Global Spine Journal Vol. 5 No. 6/2015 October 1, 2016

Southern Pain Society New Orleans - 2016 Non-opiates for Chronic Pain Management

Harry J. Gould, III, M.D., Ph.D. Department of Neurology LSU Health Sciences Center, New Orleans Director, Pain Mastery Center of Louisiana

Disclosures

Speaker has nothing to disclose

1 October 1, 2016

Initial Considerations

• What is your first thought?  Is this person a drug seeker or drug addict?  What am I going to give him/her for the pain? • Medications are the easiest form of treatment for physicians and are often their first thought  when considering pain the are the logical choice  “pain meds” the and non-opioid analgesics  most familiar, greatest training  BUT – many times ‘pain meds’ are the most problematic Will I be able to treat at all?

Initial Considerations

• In many cases pain is acute, incidental, simple to assess and readily treated by any healthcare professional without difficulty. • Unfortunately, simple complaints presenting with acute pain may result from more significant problems that if not adequately assessed, accurately diagnosed or effectively treated may become a life-long problem affecting the patient, the family, and society as a whole. • Important to conduct an unbiased and comprehensive assessment • Important to consider alternative options, non-pharmacological options and adjuvant medications early in the treatment plan • Important to get the patient involved

2 October 1, 2016

Objectives

• Be able to identify essential elements of a comprehensive pain evaluation that are often overlooked yet important in developing an effective treatment plan • Understand the importance of the multidisciplinary approach to pain care • Be able to list non-opioid pharmacologic treatment options and alternative therapies • Be able to develop a rationale treatment plan that may eliminate the need or minimize the amount and duration of opioid use

Pain Evaluation

• Quality, intensity, location, distribution, temporal pattern, and duration

• Consider known pain syndromes and pathophysiology

Verbal Pain Intensity Scale

No Mild Moderate Severe Very Worst pain pain pain pain severe possible pain pain

0–10 Numeric Pain Intensity Scale

0 1 2 3 4 5 6 7 8 9 10

No Moderate Worst pain pain possible pain

3 October 1, 2016

Pain Evaluation

• Pain quality helps determine which of the major classifications of pain might be involved in the presenting complaint • A place to start for selecting pharmacologic options  nociceptive, neuropathic, psychogenic, idiopathic • Since many common painful conditions include pain of both neuropathic and nociceptive quality and may also include a psychogenic component, it is important to at least consider the use of alternative treatments and adjuvant medications early in the management of any pain problem

Pain Evaluation

• Results of previously attempted treatment options  What has worked in the past for this and other ? • Exacerbating and ameliorating conditions  Are there things you can do to make the pain better?

4 October 1, 2016

Pain Evaluation

• Comorbid medical conditions, previous and current level of functioning, and psychosocial situation  What would you like to do most that your pain keeps you from doing?  How much pain relief would make that possible?  Are you employed? At what? How does pain affect your work?  Do you have any hobbies? What are they?  Do you have a spouse, children, pets? How does pain affect them?  How well do you sleep?  Provide a baseline for developing a reasonable treatment plan, for establishing rational expectations and evaluating treatment success.

Stratifying Risk

Low Risk Moderate Risk High Risk • No past/current • History of treated • Active substance history of substance substance abuse abuse abuse • Significant family • Active addiction Noncontributory history of substance • Major untreated abuse • family history of psychological substance abuse • Past/comorbid disorder psychological • No major or untreated Significant risk disorder • psychological to self and disorder practitioner

• (Webster and Webster , Pain Med 2005)

5 October 1, 2016

Treatment Considerations Comprehensive Therapeutic Strategy

• Where possible treat the underlying cause • Choose appropriate treatment modality – pharmacologic (non-opioid, opioid, adjuvant), surgical, anesthetic, stimulation, psychological, physiatric • Address co-morbid conditions and psychosocial situations • Assess risk and apply Risk Evaluation and Mitigation Strategies (REMS)

Non-pharmacologic Options Non-invasive

• Training in alternative forms of coping and pain control, e.g., meditation, guided imagery, self-hypnosis and relaxation • Physical modalities – topical ice/heat, massage • Physical evaluation to determine a routine regimen for improving strength, range of motion and endurance. Gradual steady progress – NOT “no pain, no gain” • Consider work and living environment. Tailor to minimize but not necessarily eliminate ergonomic stress and over-exertion; eliminate high risk conditions • Plan for participation in social activities and encourage participation in hobbies and things enjoyed

6 October 1, 2016

Non-pharmacologic Options Non-invasive

• Regular healthy diet with a goal to optimize BMI • Encourage daily activity. Regular progression of activity from baseline to 30-60 min/day tailored to patient’s ability to tolerate activity without backward slide • Schedule time for self • Encourage good sleep hygiene • Offer patient the opportunity to suggest possible options in their treatment plan • Education of patient, family members, care-givers about the treatment plan, condition being treated and the importance of monitoring response

Pharmacologic Options

• Previous approach utilized medications to treat painful syndromes, e.g. low back pain, trigeminal neuralgia, cancer pain, post- herpetic neuralgia. • Current approaches employ symptom identification and management through the multimodal modification of presumed mechanisms underlying the transduction, transmission, modulation, perception, interpretation and behavior associated with nociception, and the ability to match the mechanism of action of potential treating agents with the condition to be treated. Using this approach several options for pain management have been introduced had heretofore not been considered.

7 October 1, 2016

Pharmacologic Options Sites Affecting Signal Transmission

• Alter stimulus transduction or neuronal firing thresholds • Modify action potential generation and conduction • Alter the release of neurotransmitters from primary afferent terminals • Reduce the dedicated transmission of signal through the central nervous system • Modifiable mechanisms  modulation, intracellular calcium augmentation, central inhibition, modify membrane sensitivity and correction of underlying patholophysiology of disease

Non-opioid Pharmaceuticals Weak Analgesics

• Acetaminophen, , NSAIDs, Cox-2 selective NSAIDs • Generally the first choice for nociceptive pain • Use lowest effective doses for limited periods of time  prudent pre-emptive dosing may be help in reducing overall dose • Remember weak analgesics have an analgesic ceiling. Dosing above the analgesic ceiling significantly increases the risk of adverse events without improving analgesia. Counsel patient to beware of over the counter medications that frequently contain doses of weak analgesics as part of the combination formulation.

8 October 1, 2016

Non-opioid Pharmaceuticals Adjuvant Medications

• Adjuvant medications have analgesic properties although they were designed and approved for treating conditions other than pain • Generally the first choice for neuropathic pain • Adjuvant medications frequently produce analgesia at doses below those recommended for treating the condition for which the drug was designed • The selection of adjuvant medication is guided by an understanding of how nociceptive processing is altered by injury and disease and the ability to match the adjuvant’s mechanism of action to be able to modulate the change

Non-opioid Pharmaceuticals Adjuvant Medications

• Most adjuvant medication have similar efficacy. Thus, selection is frequently based on desired adverse effect profile that can be beneficial in managing a co-morbid condition or avoided if potentially problematic  anti-epileptic medications – neuropathic adjuvants that also treat seizures  tricyclic anti-depressants – neuropathic adjuvant that produce somnolence and help with insomnia • We should keep in mind that direct modification of one pathway may significantly affect other aspects of pain processing indirectly. Give sufficient time to determine the extent of drug effectiveness.

9 October 1, 2016

Non-opioid Pharmaceuticals Adjuvant Options

• Anti- – older formulations  , , , , , , , , , clonazepam, • Anti-convulsants – newer possibilities  vigabatrin, ezogabine, clobazam, perampanel, eslicarbazepine, brivaracetam • Anti-convulsants have been associated with an increased risk of suicidal ideation

Non-opioid Pharmaceuticals Adjuvant Options

• Anti-depressants  tricyclics – , , ,  SNRI – duloxatine, milnacipran, venlafaxine, desvenlafaxine  SSRI – , paroxetine, sertraline, citalopram, escitalopram • Anti-spasmodics – tizanidine, • Anti-hypertensives – clonidine • Local anesthetics – , mexilitine • Anti-anginal agents – • NMDA-agonists – memantine, , • Miscellaneous – , cannabanoids,

10 October 1, 2016

Non-pharmacologic Options Interventional/Invasive

• Minimally invasive  percutaneous electrical nerve stimulation (TENS), acupuncture, cryotherapy, epidural/intrathecal infusion • Surgical intervention  surgical decompression, deep brain/motor cortex stimulation, lysis of the dorsal root entry zone, myelotomy • Timing for invasive therapies depends on diagnosis, functional impairment and prognosis for survival

Principles of Pain Management Study Case

• A 56 year old male presents to clinic with a complaint of “severe” back pain. The patient had been experiencing daily low back pain that began approximately 6 years ago after a lifting injury at work. The pain was generally deep and achy and was initially managed with OTC analgesics at an intensity level averaging 3/10. Over the last 5 years the intensity of pain had increased, now requiring daily dosing of “maximum” doses of to maintain a level of 3/10. Three days ago the patient experienced an episode of coughing and sneezing during which he felt a sharp, stabbing pain and spasms his the low back.

11 October 1, 2016

Principles of Pain Management Study Case

• The patient’s pain levels spiked to 9/10 in intensity with best levels reaching only 6/10. Only with great difficulty was he able to move and ambulate. He has been treating the pain unsuccessfully with ibuprofen – 2 tabs every 3 hours, extra strength acetaminophen – 2 tabs every 4 hours and warm water soaks. He called for an appointment because yesterday he noticed a new burning pain that extends into his left leg.

Principles of Pain Management Study Case

• His wife died of cancer about 5 years ago. • He now lives alone with his Labrador retriever, his companion for 12 years. They enjoyed going for walks but this recent pain has kept that from happening. • He runs a local hardware store with his son who has begun to take over the business; fortunate because he has needed to miss some work. • He enjoys being outdoors and working in his garden; not in last 2 years. • He usually sleeps 6-8 hrs per night but now that is interrupted by pain. • ”What else would you like to know?”

12 October 1, 2016

Pain Evaluation What Do We Need to Know?

• Why does the patient have pain? Why now? • Is it a new problem or an exacerbation of a pre-existing condition? • How might the patient’s current condition, planned diagnostic testing, treatment or clinical intervention affect any pre-morbid pain condition or management protocol? • What is the likely underlying cause and how it is being and/or has been managed? • Are there complicating medical co-morbidities or psychosocial situations that may affect the pain complaint or treatment? • What was the patient’s baseline prior to the current problem?

Principles of Pain Management Study Case – Past Medical History Current Medications

• Medical Conditions • Medications  Hypertension  Lisinopril  Hypercholesterolemia  Atorvastatin  Esophageal reflux   Father died of MI  ASA 81mg  Mother died of breast cancer   30 pk/yr smoker  OTC analgesics, Cold/Flu preps as needed

13 October 1, 2016

Principles of Pain Management Study Case – Physical Exam

• Restless, agitated and demonstrates dyspnea at rest • Antalgic gait with difficulty getting onto exam table • Mildly obese with dyspnea exacerbated when getting onto exam table • Subcutaneous petechia and ecchymotic patches • Mild dependent edema • Palpation of spine reveals lumbar tenderness with paraspinal spasms • Remainder of exam normal with the exception of  heart sounds: RRR, S3; lungs: diminished breath sounds mild wheezing; neurologic: guarding, normal strength, sensation, reflexes  allergies: NKA  BP: 157/88 (RA, sitting); HR: 105; RR: 22; T: 98° F; BMI: 32

Principles of Pain Management Study Case – Diagnostic Evaluation

• MRI of lumbosacral spine – mild left L4/L5 disc bulge • Chest X-ray - normal • Abdominal CT – normal • Consider EMG/NCS and sleep study • Serum chemistry – Cr: 1.7

14 October 1, 2016

Principles of Pain Management Study Case – Setting Goals

• What are we treating?  acute herniated nucleus pulposus  chronic low back pain strain  depression and possible unresolved grieving issues  polypharmacy medication duplication  addressing co-morbidities  hypertension  mild renal insufficiency  insomnia  current smoker; possible COPD  GI reflux

Principles of Pain Management Study Case – Setting Goals

• Treatment goals  manage acute pain  improve function – increase activity, reduce work absences  address psychosocial concerns  address co-morbid pathology – hypertension, renal insufficiency, possible COPD, insomnia  address concerns about polypharmacy and medication duplication

Goal – ”First, do no harm” – reduce pain levels, increase psychosocial functioning, and improve quality of life

15 October 1, 2016

Principles of Pain Management Study Case – Treatment Plan

• Consider intervention with epidural steroid injection for acute pain management • Pharmacologic considerations – check prescription monitoring program and risk assessment  D/C ibuprofen, OTC Cold and Flu, acetaminophen, lorazepam  zonisamide 100 mg at bedtime (AE – weight loss); consider topiramate or gabapentin pending response  add tizanidine 4 mg at bedtime for spasm and sleep • Non-pharmacologic treatments  warm water soak 30 minutes after ibuprofen 200 mg, 2 tabs  of choice topical  walking daily, increase duration and distance slowly as tolerated

Principles of Pain Management Study Case – Treatment Plan

• Additional assessment  psychiatric evaluation for mood, unresolved grief and coping status  consider sleep study and pulmonary function test • Patient education  discuss the dangers of self-medication and the use of multiple medications that can produce additive or antagonistic effects  OTC combination drugs with ‘hidden’ ingredients • Keep a daily pain record • Return to clinic in 2 weeks with family member if possible

16 October 1, 2016

Monitoring Treatment Four “A’s” of Pain Reassessment

• Analgesia “Faces” Scale  monitor pain intensity  pain rating scales  patient diary 0 1 2 3 4 5  brief pain inventory including perceived improvement  mood rating  how much relief and how long does it last? • Activities of Daily Living  determine functionality and quality of life, including interpersonal relations and work disturbance

Monitoring Treatment Four “A’s” of Pain Reassessment

• Adverse effects – when do they occur?  decreased functionality and quality of life  lead to systemic side effects  interfere with compliance, resulting in increased pain intensity  increase psychological morbidity  impede progress toward rehabilitative goals, affect work habits • Action  continue or modify treatment  change, titrate, adjust medication, manage side effects  discontinue treatment

17 October 1, 2016

Principles of Pain Management Study Case – 2 Week Follow-up

• Analgesic assessment  pain better controlled – range 2-6/10, average 4/10  burning pain has decreased but is still disturbing  sleeping better without morning hangover; awakened less by pain • Pharmacologic assessment reveals no adverse effects • Non-pharmacologic assessment  walking daily, 15 minutes at a slow pace without pain exacerbation or shortness of breath

Principles of Pain Management Study Case – 2 Week Follow-up

• Physical assessment  patient appears more comfortable with minimal agitation and no dyspnea at rest  BP: 142/84 (RA, sitting); HR: 85; RR: 18; T: 98° F; BMI: 32; Cr: 1.2  lumbar tenderness and paraspinal spasms have improved • Is scheduled for counseling to address depression • Son is present and reports that his father has been less irritable at work, has missed fewer days and has not exhibited excessive drowsiness

18 October 1, 2016

Principles of Pain Management Study Case – 2 Weeks Follow-up

• Pharmacologic treatments  increase zonisamide to a max. of 400 mg at bedtime as tolerated  continue tizanidine 4 mg at bedtime  naproxen 200 mg at bedtime • Non-pharmacologic treatments  continue daily walks and warm water soak regimen  physical therapy evaluation for routine exercise program to improve strength, endurance and range of motion  elicit patient thoughts on treatment needs and progress to goal • Family education on current status, reducing fall risks in home (throw rugs, cane support) and how to support and monitor progress • Follow-up in 4 weeks

Principles of Pain Management Study Case – 4 Week Follow-up

• Analgesic assessment  pain better controlled – range 2-4/10, average 3/10  burning pain improved but is still irritating and limits activity  sleeping better; still interrupted but no longer awakened by pain • Non-pharmacologic assessment  patient indicates that he thinks counseling and guided imagery is helping  walking daily, 20 minutes at a faster pace without shortness of breath or pain exacerbation; tolerating exercise plan  has started to walk with his dog

19 October 1, 2016

Principles of Pain Management Study Case – 4 Week Follow-up

• Pharmacologic assessment  zonisamide dosing 200 mg at bedtime  no adverse effects but no additional benefit noted at 300 mg dose • Physical assessment  BP: 138/78 (RA, sitting); HR: 70; RR: 16; T: 98° F; BMI: 30; Cr: 1.0  no trouble getting onto the examination table  dependent edema, petechia and ecchymosis have resolved  sleeping better; still interrupted (early awakening) but no longer awakened by pain • Son reports that his father has been more like himself. He has not missed work and has been interacting more with customers.

Principles of Pain Management Study Case – 4 Week Follow-up

• Pharmacologic treatments  change naproxen to acetaminophen 500 mg at bedtime with naproxen as needed before strenuous or prolonged activity  continue tizanidine 4 mg at bedtime  add gabapentin 300 mg 3 times daily • Non-pharmacologic treatments  continue daily walks and routine exercise  encourage taking time for light gardening and time for self  continue counseling  applaud weigh reduction, consider dietary consultation and cessation • Follow-up in 4 weeks

20 October 1, 2016

Principles of Pain Management Study Case – 4 Week Follow-up

• Analgesic assessment  continues with acceptable pain control – range 2-4/10, average 3/10  naproxen is needed infrequently, 1-2 times a week  burning pain has resolved  sleeping 7-8 hours a night, uninterrupted • Non-pharmacologic treatments  walking daily, 30 minutes without pain exacerbation or shortness of breath and continues with exercise program  noticing weight reduction, requesting assistance with smoking cessation • Son reports that his father is doing well and is more socially involved

Principles of Pain Management Study Case – 4 Week Follow-up

• Pharmacologic treatments  change bedtime and pre-emptive analgesics to be taken as needed  continue zonisamide, gabapentin and tizanidine with plan to wean off as tolerated in 6-9 months • Non-pharmacologic treatments  continue daily walks, time with dog and time for self  arrange for physical therapy re-evaluation in 6 months to reassess and modify exercise plan as indicated  patient thoughts on treatment needs, status and progress to goal • Return to clinic 1 month after PT evaluation – check on progress toward goal

21 October 1, 2016

Principles of Pain Management Study Case – Key Points

• Acute pain not controlled with high dose weak analgesics complicated by history of chronic pain • Unrecognized or unaddressed co-morbid hypertension, renal insufficiency, abnormal bleeding, depression; adjuvant medications and alternate therapies not tried • Smoking history, benzodiazepine use and signs of early COPD • Dangerous OTC self-medication for pain and insomnia  Multiple medications with same mechanism of action  Medications with additive and/or antagonistic effects  Combination medications with accumulating dosages

Pain Management in the 21st Century What Will We Choose?

The Pits and the Pendulum Apologies to Edgar Allan Poe Based on current perspective the choice is not intuitive, but with the consideration of fresh options with proper motivation the right choice can be made.

Hopefully, “the ‘war on drugs’ will not be fought on the backs of legitimate patients using legitimate treatments to escape the torture of chronic pain.” • (Maginn, M Living with Pain: Washington State’s Opioid Law Goes Too Far. American News Report; May 21, 2012)

22 October 1, 2016

Axiom implicit in the ‘Oath of ‘ “First, do no harm”

Corollary – Doing Nothing Can Be Harmful

Intractable pain is physically and psychologically harmful

23 September 30, 2016

Opioid Pharmacology

Alan David Kaye, M.D., PhD., DABA, DABPM, DABIPP Editor-in-Chief Pain Physician and Scientific American Professor & Chairman Department of Anesthesiology Director Interventional Pain Services ABA, ABIPP, ABPM Special Certificates Pain Management Professor, Dept of Pharmacology Louisiana State University Health Sciences Center, New Orleans, Louisiana

DISCLOSURE Alan David Kaye, MD PhD

--FDA Advisory Board Member for Anesthesia, Analgesia & Addiction Medicine, 2012-Present

--Pain Physician, Editor-in-Chief, 2013-Present

--ABA, ABIPP, and ABPM certified in Pain Management

--ASIPP and ABIPP, Board of Directors 2013-Present

1 September 30, 2016

46 death/day from in US

2 September 30, 2016

Comment from FDA Feb 2016

deaths, driven largely by overdose from prescription opioids and illicit drugs like and illegally-made , are now the leading cause of injury death in the United States.

What is your level of risk?

3 September 30, 2016

There is no hiding! Upon autopsy/toxicology consistent with controlled substance overdose:

-- If Opioid related, the Prescription Drug Monitoring Program is investigated by law enforcement & other agencies will identify every prescriber and their level of responsibility. --This includes heroin overdose which may include your previous prescriptions.

Southern California doctor sentenced in overdose deaths of 3 patients

Los Angeles (CNN) Hsiu-Ying "Lisa" Tseng, 46, a Southern California doctor convicted of murder in connection with the overdose deaths of three of her patients was sentenced to 30 years to life in prison Friday by a judge in Los Angeles. Feb 5th, 2016

4 September 30, 2016

“Pill mill” doctor sentenced to seven years in prison

Hussein “Sam” Awada, 46, of Royal Oak, Michigan sentenced to serve 84 months in prison, and ordered to forfeit various assets in order to pay $2.3 million in restitution to Blue Cross and Medicare. Federal agents said Awada ran16-month “pill mill”for 80,000 and Roxicodone, along with other medications sold on the street.

Kansas doctor, wife sentenced to prison in overdose deaths

WICHITA, Kan. (AP) — A Kansas doctor and his wife were given decades-long prison sentences Thursday for their convictions in a moneymaking conspiracy linked to 68 drug overdose deaths, with the judge saying the couple was motivated purely by greed.

5 September 30, 2016

Terminology

1. : a mixture of alkaloids from the poppy seed 2. Opiate: a naturally occurring alkaloid such as or 3. Opioid: refers broadly to all compounds that work at the opioid receptors 4. Narcotics: derived from the Greek word for stupor. • Once used to describe medications for sleep • Then used for opioids • Now a legal term for drugs that are abused

Terminology..

. Definitions • Tolerance: reduction in the response to a drug after repeated administration • Dependence: altered physiological state caused by repeated drug exposure such that cessation of drug leads to a withdrawal syndrome characterized by serious physical disturbances, CNS hyperarousal, & emotional symptoms • Abstinence Syndrome, e.g. Withdrawal: signs/symptoms in response to the abrupt removal of the drug of dependence  e.g. piloerection, N/V/diarrhea, abd. cramps, hypertension, tachycardia, tachypnea, back and bone pain, yawning

6 September 30, 2016

Opium History

. Cultivated in ancient civilizations of Persia, Egypt and Mesopotamia . Fossilized poppy seeds suggest Neanderthals used >30,000 years ago . Egyptian Eber papyrus (1552 B.C.) advises use of juice from the unripe seed pod “to prevent the excessive crying of children”

Opium History

. Homer conveys its effects in the Odyssey: "...had a happy thought. Into the bowl in which their wine was mixed, she slipped a drug that had the power of robbing grief and anger of their sting and banishing all painful memories. No one who swallowed this dissolved in their wine could shed a single tear that day, even for the death of his mother or father, or if they put his brother or his own son to the sword and he were there to see it done..."

7 September 30, 2016

Opium History

. Morphine, after Morpheus – Greek god of dreams - was isolated in 1805 by German pharmacist, Wilhelm Sertuner Wilhelm Sertürner (1783-1841) . In 1898, Bayer launches “non-addictive” alternative to opium & morphine, diacetylmorphine or Heroin (German for hero) . Bayer halts production in 1914 & writes drug out of company history

Heinrich Dreser (1860-1924)

Opium History . First Opium War: Britain vs. China • Treaty of Nanjing of 1842 – China cedes Hong Kong . Second Opium War (1856): Britain vs. China • 25% adult Chinese males addicted . Thomas Jefferson cultivated opium poppies at Monticello . Opium Poppy Control Act of 1942 bans US production

8 September 30, 2016

Papaver somniferum • Morphine – Principal constituent of opium – Acetylated to form diacetylmorphine (Heroin) – 12% used directly; 88% converted to codeine + derivatives • Codeine – principal starting material for & – no analgesic properties itself; converted to semi-synthetic opioids: oxycodone, , , , , , dihydromorphenone, hydrocodone

Basic Opioid Pharmacology

• Structure • Action • Receptors • Routes of Administration • Endogenous Opiates • Synthetic Opiates

9 September 30, 2016

Opioids . Codeine is morphine O- methylated at position 3, Nitrogen/methyl Known as Codeine, also known as 3-methylmorphine . Heroin is morphine O- acetylated at position 3 and 6 . Making nitrogen quaternary decreases analgesia Position 3 Position 6 . Changes to the methyl group creates antagonist, e.g. naloxone.

10 September 30, 2016

Codeine, also known as 3- methylmorphine

11 September 30, 2016

Opioid Action

. Inhibit adenylyl cyclase • Inhibits release of: • Substance P • Acetylcholine • Norepinephrine • Glutamine • Serotonin . The mechanism for stimulation is often depression of an inhibitory neuron

12 September 30, 2016

Opioid Receptors

Identification of opioid receptors (1975)

Opioid Receptors

Presynaptic (75%)

13 September 30, 2016

Opioid Receptors

Postsynaptic (25%)

Opioid Receptors

RECEPTOR PROPOSED LOCATION PROPOSED EVENTS Supraspinal, peripheral analgesia, spinal cord, Analgesia, improved Mu1 substantia gelatinosa, periductal gray, locus ceruleus mood Spinal trigeminal nucleus, limbic area, Sedation, pruritis, prolactin release, Mu2 reticular activating system, medullar raphe vomiting, urinary retention, nucleui respiratory depression, euphoria, miosis, dependence, anorexia, decrease GI motility, histamine release Kappa K1 spinal cord Spinal analgesia, dyspnea, K2 poorly defined resp depression, miosis, sedation,

K3 supraspinal diuresis (lower ADH release), dependence, endocrine events Delta D1 spinal, supraspinal D2 frontal cortex, limbic area, olfactory tubercle, spinal Sigma Psychomimetic effects, dysphoria

14 September 30, 2016

BASIC OPIOID PHARMACOLOGY

Opioid peptides are found naturally in the circulation & elevated levels found in the plasma during CV stress situations, such as hypovolemia, exercise, excitement, pain, and orgasm.

Pre-Pro-0piomelanocortin (267 amino acids) precursor is cleaved to form endorphins and metorphamide. An enkephalin is a pentapeptide endorphin, & denoted as either leu- or met-enkephalin. (32 amino acids) is cleaved to form dynorphin.

These peptides are in the brain, spinal cord, GI tract, adrenal gland, the myocardium & elsewhere in the body.

Endorphins

. Over the past 3 decades, research has led to the discovery of endogenous opiates: 1.  endorphin (31 amino acids)-Mu 1 agonist  Gamma and Alpha endorphins mechanisms speculative  capsacian releases endorphins 2. Dynorphin (17 amino acids)- receptor agonist 3. Pre-pro-enkaphlin (267 amino acids) derivatives:  Leu-enkaphalin (5 amino acids)-Delta receptor agonist  Met-enkephalin (5 amino acids)-Delta receptor agonist  Metorphamide (8 amino acids)-Mu receptor agonist

15 September 30, 2016

Met-Enkephalin Structure

Receptor Affinity

16 September 30, 2016

Opioid Therapy: Routes of Administration

. Oral and —PREFERRED!! . Oral transmucosal—available for fentanyl & used for breakthrough pain . Rectal route—limited use . Parenteral—SQ and IV preferred & feasible for long-term therapy . Intraspinal—intrathecal over epidural generally preferred for long-term use

Opioid Administration Routes

17 September 30, 2016

Oral Therapy: Opioids

. Site of action is the opioid receptors.

. Commonly divided into “weak” & “strong” based on their classification

. Used to treat moderate-severe pain.

Opioid Analgesics

. Binding at , ,  receptors . Highly efficacious . May be combined w/ anti-inflammatory agents . Effects may be reversed . Side effects common

. Subtype agonists being developed, e.g. 1 agonists

Fishman SM, Borsook D. In: Benzon HT, et al, eds. Essentials of Pain Medicine and Regional Anesthesia; 1999:51–54.

18 September 30, 2016

Adverse Effects of Opioids

• CNS & respiratory depression, sedation •  GI motility, nausea, vomiting • Urinary retention • Pruritus

Oral Therapy: “Weak” Opioids

. All are combination drugs containing the opioid (hydrocodone, codeine, ) plus acetaminophen, ASA or ibuprofen. . All have ceiling doses secondary to the nonopioid combination drug, e.g. liver toxicity acetaminophen. . Propoxyphene (Darvon, Darvocet) withdrawn in 2010 linked to fatal heart rhythms.

19 September 30, 2016

Oral Therapy: “Weak” Opioids-most not available presently • Lortab 5, 7.5, 10/500 • Lorcet 10/650—650 mg of acetaminophen • Vicodin 5/500, 7.5/750, 10/660 • Norco 5, 7.5, 10/325 • Zydone 10/400—400 mg of acetaminophen • Vicoprofen 7.5/200 • Darvon • Darvocet • Tylenol #2, #3, #4—codeine preparations

Codeine & Dihydrocodeine:

. Merely pro drugs for Morphine, & exert their action through metabolism to this compound. . Given that a significant number of the population do not have the metabolic pathway to facilitate this, it is not surprising that there is a significant failure rate to produce any analgesia at all & that patients getting analgesia seem to get limited relief.

20 September 30, 2016

21 September 30, 2016

22 September 30, 2016

Oral Therapy: “Strong” Opioids

. Indicated for severe pain. . Do not have ceiling doses except: • percocet (acetaminophen & oxycodone) • percodan (aspirin & oxycodone). . Most come in sustained-release & immediate-release formulations.

Oral Therapy: “Strong” Opioids • Morphine: MSContin, MSIR, Oramorph • Oxycodone: OxyContin, OxyIR, Percocet, Percodan • (Dilaudid) • • Meperidine (Demerol) • Oxymorphone (Opana) • Hydrocodone extended Release

23 September 30, 2016

Employ Controlled-Release Pain Medications When Possible

. Many of the cases that make media attention regarding prescription abuse involves immediate-release combined analgesic (Norco, Percocet). . Even though there are a greater number of choices, clinicians are often unfamiliar with controlled-release medication options such as Kadian & Opana. . Even though these medications are NOT abuse-proof, they certainly are involved in less cases of overdosages or drug diversion. . The exception – Oxycontin – was abused primarily due to aggressive & inappropriate drug-marketing by its manufacturer, Purdue Pharma. FDA required REMS.

Examples of Extended Release Pain Medications

Brand Name Control-Released Contents Frequency Taken / Changed

MS Contin / Oramorph Morphine BID to TID

Avinza D/C’ed Morphine QDay

Kadian Morphine Qday or BID depending on desired effect Opana Oxymorphone Qday or BID depending on use of extended & immediate release forms Exalgo Hydromorphone QDay

Duragesic Fentanyl Topical Q72 Hours or Q48 Hours depending on results Oxycontin Oxycodone BID

24 September 30, 2016

MS Contin / Ora-Morph

• Available in controlled release tablets from 15 mg to 200 mg strength • Also available in generic format • Duration of action is 8 to 12 hours, depending on unique pharmaco- dynamics of your patient • Opiate naïve starting dose is: MS CONTIN 15 MG PO Q 12 HR • Available in generic for less cost

Avinza-Discontinued . Avinza is a form of morphine sulfate extended release available since 2002. . Avinza employs the SODA (spheroidal oral drug ) system of by having beads of ammonio-methacrylate polymers coated with morphine. These polymers attract fluid from the G.I. tract, slowly dissolving morphine & releasing it over 24 hours.

 Avinza available in 30mg - 120mg capsules  Opiate naïve starting dose is: AVINZA 30 MG PO QDAY (ONCE)

25 September 30, 2016

Avinza-Discontinued July 2015

• Avinza is manufactured by King Pharmacueticals but the SODA system was developed by Elan Corporation, which has sold rights to use the SODA system to several pharmaceutical companies developing new extended-release products.

Capsule Fluid drawn in

Morphine SODA Beads dissolves • Companies are currently employing the SODA system for extended- release drug delivery of , theophylline, , naproxen, & methylphenidate.

Kadian . Kadian is another form of extended-release morphine. It employs a polymer-coated pellet technology that also uses polymer coated pellets using methacrylic acid.

 The pellets in Kadian dissolve at a faster rate – on average – than the SODA system in Avinza. Therefore Kadian can be dosed once or twice daily.  Kadian is a very effective pain medication for patients who suffer from opiate-induced constipation if Kadian is used just once daily.

26 September 30, 2016

U.S. panel backs approval of Egalet's abuse- resistant Morphine Sulfate ER painkiller August 2016

• ARYMO ER-physical & chemical features resistant to manipulation. • Egalet's proprietary Guardian Technology is a polymer matrix technology (plastic injection molding). • Tablets very difficult to chew, resistant to particle size reduction, and inhibit/block attempts at chemical extraction .

Opana ER / IR System

. Two pain medications recently released by Endo Pharmaceuticals that uses oxymorphone to provide pain relief.

. The Extended-Release formulation uses a TimeRx-N system of drug delivery. This system was developed by PenWest Corp. & licensed to Endo.

 TimeRx-N uses a hydrophillic matrix containing xantham gum and locust bean gum. The exact matrix can be manipulated and changes the time course of drug delivery.  Opana extended release has a duration of action of about 12 hours & is meant to be dosed twice daily.

27 September 30, 2016

Opana ER / IR System • Opana immediate release contains oxymorphone in a dissolvable tablet. • It is designed to be used for breakthrough pain relief while titrating extended-release Opana.

 The release of Opana has been particularly useful as an alternative to the use of Dilaudid (hydromorphone).  Not infrequently, patients will state that they received good pain relief from IV or PO Dilaudid in the hospital but get side effects from equivalent doses of morphine.  However, prescribing high quantities of immediate release Dilaudid for patients often presented unacceptable risks of drug abuse, theft, or diversion.

Exalgo . Recent release of Exalgo – a form of extended release hydormorphone (Dilaudid) . Taken once daily & capsules available in 8mg, 12mg, & 16 mg strengths. . Uses the OROS technology to provide a steady release of hydromorphone.

 The osmotic push layer absorbs water from the GI tract, pressing hydromorphone through a laser-drilled hole at a constant rate.  OROS® technology has been utilized for more than 30 years in CV, endocrine, urologic, & CNS therapeutics

28 September 30, 2016

New Extended Release Hydrocodone: . No Acetaminophen in preparation:

1. Zohydro ER®10, 15, 20, 30, 40 & 50mg doses 2. Hysingla ER™20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 100 mg &120 mg film-coated tablets • Hysingla is taken every 24 hours rather than every 12 hours like Zohydro. 3. Vantrela ER 15, 30, 45, 60 & 90 mg doses approved summer 2016 at FDA turns into highly viscous can’t snort or inject IV.

Intravenous Therapy

. Use on a scheduled or prn basis for post-op pain. . Should be made available when oral therapy is not effective. . Avoids the variable absorption that is common w/ IM dosing. . MSO4, Demerol, Fentanyl & Dilaudid are most common. In general, Demerol being phased out.

29 September 30, 2016

Patient Controlled Analgesia

• Eliminates variable absorption from the injection site. • Bypasses the unavoidable delays that occur when an opioid is requested. • Unique in that patients titrate their analgesic needs against sedation & other side effects of opioids. • Appropriate for patients requiring >48 hours to recuperate. • Not a “Set and Forget” technique. • Can be combined with epidural infusions (PCEA).

Patient Controlled Analgesia

. “Ideal” Analgesic • Rapid onset • High analgesic efficacy • MSO4, dilaudid, & meperidine most commonly used.

. Pain perceived is inversely related to control patient has

. Sample Test: heroin addict postop needs increase in basal level; also, . Increase needed after 2 days, tachyphylaxis to opioid.

30 September 30, 2016

Patient Controlled Analgesia

Side Effects

Analgesia

Pain Concentration MEAC

Time

Ferrante and Vadeboncouer. 1993.

Patient Controlled Analgesia

. Contraindications:

• Patient’s inability to push button. • Patient’s inability to comprehend functioning of machine. • Patient’s desire not to participate in own care.

31 September 30, 2016

Classification of Opioids

A. Full Agonists - bind opioid receptors  MSO4, oxycodone B. Partial Agonists- bind opioid receptors at a lower level  Buprenorphine (30X as potent as Morphine), (Veterinary only, e.g. elephants; Veterinary-strength etorphine is fatal to humans; one drop on the skin can cause death within a few minutes. ) C. Mixed agonist/antagonists - agonist effect at one receptor and antagonist effect at another receptor  Nalbuphine,  Agonist at the kappa receptor  Antagonist at the mu receptor D. Antagonists - bind to opioid receptors but have no activity  Naloxone, naltrexone

Chemical Classes of Opioids 1. Phenanthrenes 2. Benzomorphans 3. Phenylpiperidines 4. Diphenylheptanes

32 September 30, 2016

Chemical Classes of Opioids 1. Phenanthrenes  Prototype of opioid  Not tolerated by some because of 6-OH group  Causes nausea and hallucinations  * indicates lack of 6-OH  (may decrease nausea sensitivity)  Morphine is glucoronidated in liver to Morphine 3-glucoronide 80% (not active) & Morphine 6-glucoronide 10% & eliminated via kidney and it is an active metabolite, DO NOT GIVE TO PATIENTS WITH KIDNEY FAILURE; mild to mod cirrhosis, no effect on glucoronidation only if SEVERE CIRRHOSIS

Chemical Classes of Opioids

2. Benzomorphans  Pentazocine  Agonist/antagonist  High incidence of dysphoria  Poor choice for chronic pain

33 September 30, 2016

Chemical Classes of Opioids

3. Phenylpiperidines  Fentanyl  Of all the opioids, has the highest mu affinity & the least histamine activity  Least allergenic, 80-100X as potent as Morphine  Meperidine  Only has a 2-3 hour duration, 1/10th as potent as morphine, highly addictive.  Metabolized to normeperidine  Renally excreted  Symptoms of normeperidine accumulation progress from irritability, to tremors & myoclonus, to generalized seizures, not reversable with naloxone

Meperidine Drug Interactions

. CYP2DG inducers- Increase in normeperidine, e.g. carbamazapene, , phenytonin, rifampin. . Ritonavir-Increase in meperidine levels . SSRIs, MAOi’s-Serotonin Syndrome . Larger doses, decrease myocardial contractility . Atropine like: mydriasis

34 September 30, 2016

Chemical Classes of Opioids

4. Diphenylheptanes  Propoxyphene  Available with (Darvocet) or without APAP (Darvon)  High incidence of liver toxicity, fatal heart rhythms  Withdrawn from market 2010  Methadone  Long acting, 23 hour half life  NMDA receptor inhibitor  Neuropathic pain  Cheap; Millions of people take daily  Need baseline ECG to reduce incidence of torsades de pointes demonstrating not a QTc greater than 450 ms

Sample Test: Methadone

. St. John’s Wort-47% reduction in methadone levels as CYPR3A4 inducer, case reports of opioid withdrawal! . When change to methadone, may only need 1/3 to 1/5 of equianalgesic dose equivalent

35 September 30, 2016

NMDA Receptor

The NMDA receptor is an inotropic receptor for glutamate & is distinct in that it is both ligand-gated & voltage-dependent.

Sample Test: NMDA

. Site for tolerance . Glutamate or Asparate will activate NMDA & Glycine

36 September 30, 2016

NMDA Receptor

The NMDA receptor is an inotropic receptor for glutamate & is distinct in that it is both ligand-gated & voltage-dependent.

“NMDA is a glutamate receptor”

. Forms a heterotetramer between 2 NR1 & 2 NR2 subunits; 2 obligatory NR1 subunits & 2 regionally localized NR2 subunits. . A related gene family of NR3 A & B subunits have an inhibitory effect on receptor activity. . NR2B unit most involved in nociception & is thus the area of greatest study for pain reducing modalities as pharmacologic target.

37 September 30, 2016

NMDA Receptor • Site of opioid tolerance

Methadone is an example of a NMDA antagonists, which reduces the incidence of tolerance to morphine. Examples include:

1. Dextromethorphan 2. Methadone 1. Ketamine 3. 4. Memantine: Role in advanced Alzheimer’s Disease 5. : Epsom -minor myalgias & arthralgia 6. Amantadine: Parkinson’s treatment

Opioid Antagonists

. Naloxone • Pure, competitive antagonist at , , &  receptors • Rapidly reverses opioids but short lived, therefore the potential for “renarcotizing” • Increases catecholamine release 30X normal level, reason we see increase in HR & in BP. . Naltrexone • Used orally in high doses in treatment of opioid addicts  Long term can increase liver enzymes  Data demonstrates decrease in opiate cravings • Primary effect is from metabolite, 6--naltrexol

38 September 30, 2016

Opioid Agonist-Antagonists

. Two types • Partial agonist at µ receptor  Buprenorphine has high affinity but low efficacy at µ receptor; half life of preparations 37 hrs; 30x as potent at morphine, in preparations with naloxone, when used IV, the naloxone is released precipitating withdrawal, when taken oral, withdrawal not precipitated. • Agonist/partial agonist at  receptor  , pentazocine, nalbuphine, butorphanol  Act as  agonists but competitive µ antagonists

Suboxone . Buprenorphine & Naloxone • Buprenorphine is a partial agonist at the mu- & an antagonist at the kappa-opioid receptor. • Naloxone is an

antagonist at the mu- opioid receptor deterrent for IV misuse. Buprenorphine

. Buprenorphine now has

substance abuse and pain indication, it has a very long half life, 37 hours

Naloxone

39 September 30, 2016

Buprenorphine/Naloxone Choices

1. Suboxone tablet 2. Suboxone sublingual

Belbuca is a New Buprenorphine buccal for chronic pain-7 dosages

40 September 30, 2016

3. Butrans System (The only active ingredient is buprenorphine) • Available in 5 -20 mcg/hr doses • Each patch is applied for 7 days & is now also indicated for use in chronic pain states • “Management of pain severe enough to require daily, around-the-clock, long-term analgesia for which alternative opioid therapies are inadequate.”

DEA Classification . Schedule 1 - no legitimate medical use • Heroin: given in Netherlands, UK, Switzerland, Germany, Denmark much like methadone or buprenorphine for opioid replacement therapy. . Schedule 2 (CII) - high risk of abuse • Written Rx only, no refills • Oxycodone, morphine, and now hydrocodone . Schedule 3 (CIII) - intermediate risk of abuse • Telephone, up to 6 refills • Codeine (usually with tylenol) . Schedule 4 (CIV) - lower risk of abuse • BZP’s, Ambien, Soma: varies by state changing • Tramadol

Some of this is pure politics, Soma has a high abuse potential

41 September 30, 2016

Opioid Therapy: Prescribing Principles

• Prescribing principles – Drug selection – Dosing to optimize effects – Treating side effects – Managing the poorly responsive patient

– Never self-prescribe opioids, it is against the law! – Document why you are increasing dosage of opioids – Only one physician prescriber per opioid agreement – Do not prescribe muscle relaxants or BZP’s with them

42 September 30, 2016

Opioid Therapy: Drug Selection

Immediate-release preparations – Used mainly • For acute pain • For dose finding during initial treatment of chronic pain • For “rescue” dosing – Can be used for long-term management in select patients – Recently, FDA approving IR Abuse Deterrent Formulations, e.g. Apadaz, a prodrug of hydrocodone that only will convert to active ingredient in gut, therefore will not work nasally or IV

Serum Levels

43 September 30, 2016

Opioid Therapy: Drug Selection Extended-release preparations  Preferred because of improved treatment adherence and the likelihood of reduced risk in those with addictive disease  Morphine, oxycodone, fentanyl, buprenorphine, methadone all in Extended-release preparations  Adjust dose q 2–3 d  Rapidly, FDA approving abuse deterrent formulations for each extended release formulation as well!

Opioid Selection: Poor Choices for Chronic Pain . Meperidine • Poor absorption, high incidence of addiction, and toxic metabolite . Propoxyphene • Poor efficacy and toxic metabolite to the liver, heart rhythm issues withdrawn from market 2010 . Mixed agonist-antagonists (pentazocine, butorphanol, nalbuphine, ) • Compete with agonists  withdrawal • Analgesic ceiling effect • Produce psychotomimetic effects • Butorphenol (stadol) recently discontinued by manufacturer

44 September 30, 2016

Unscheduled and C IV Opioids

Medication drug APAP Ultram 50 none Ultracet 37.5 325 Fioricet 50 325 Fiorinal 50 none (ASA) Talwin NX (pent/naloxone)50 none Talacen (pentazocine) 25 650

The maximum daily dose was 4000 mg per day (now reduced to 2600 mg/day), even though can purchase OTC to 650 mg/tab.

C III Opioids

Medication drug APAP Fioricet #3 50 325 Tylenol #3 30 300 Darvocet-100* 100 650

* withdrawn from market 2010

45 September 30, 2016

Hydrocodone Medication drug APAP Lortab 7.5 7.5 500 Lorcet Plus 7.5 650 Vicoden ES 7.5 750

Zydone 10 400 Norco 5-10 325

Acetaminophen . Vicoden ES = 750mg/tablet . Sig: one to two q 4 to 6 hours . 2 tablets q 4 hours = 9000mg/day . 1 tablet q 6 hours = 3000mg/day FDA is now limiting the amount of acetaminophen per pain pill to 325 mg. Each year, acetaminophen overdose is linked to about 400 deaths and 42,000 hospitalizations.

46 September 30, 2016

C II Opioids - Short Acting Medication drug APAP Percocet 5 5 325 Tylox 5 500 Percocet 7.5 7.5 500 Percocet 10 10 650/325

CII Opioids - Long Acting . Sustained release . Sustained release oxycodone morphine • OxyContin • MSContin . Transdermal • Kadian fentanyl • Oramorph • Duragesic Avinza • . Buprenorphine . Methadone

47 September 30, 2016

Opioid Pharmacology and Drug Interactions

"If it were not for the great variability among individuals medicine might as well be a science and not an art”

William Ostler (1892)

48 September 30, 2016

Cytochrome P450 System

49 September 30, 2016

Codeine Metabolism

. Pro-drug . Metabolized by CYP2D6 to morphine . Multiple drug interaction . Low doses cause more nausea than higher doses (“tickle the CMZ”)

Propoxyphene Metabolism

• Weak opioid • Metabolized by CPY2D6 to active metabolite (norpropoxyphene) which has local anesthetic effects & can cause seizures with accumulation

Withdrawn from Market 2010

50 September 30, 2016

Morphine Metabolism

. Glucuronidation to Morphine-3- glucuronide (M3P) 80% & Morphine-6- glucuronide (M6P) 10% and normorphine . M6G adds to analgesia . M3G is hyperalgesic

Morphine is glucoronidated to active metabolites; these are eliminated from the kidney & therefore, should not be given in renal failure.

51 September 30, 2016

Hydrocodone Metabolism

. Metabolized by CYP2D6 to hydromorphone . One of the most abused of all opioids . Nevada doctors in 2000 wrote >42 million doses (about 17 pills for every adult in the state)

Hydrocodone, trade names

. Vicodin, Symtan, Anexsia, Dicodid, Hycodan (or generically Hydromet), Hycomine, Hycet, Lorcet, Lortab, Norco, Novahistex, Hydrovo, Duodin, Kolikodol, Orthoxycol, Mercodinone, Synkonin, Norgan, Zydone, & Hydrokon.

United States uses 99% of hydrocodone worldwide!

52 September 30, 2016

Metabolism of Hydrocodone

hydrocodone Hydromorphone (Dilaudid)

Hydromorphone (Dilaudid) Metabolism

. About 5 times more potent than morphine . Very water soluble which allows for very concentrated . Less risk than morphine of accumulation in renal failure; no metabolites

53 September 30, 2016

Oxycodone (Oxy Contin) Metabolism

• Metabolized by glucuronidation to noroxycodone • Metabolized by 2D6 to oxymorphone (OPANA) • Oxycodone has activity at multiple receptors

Troxyca ER approved summer 2016 by the FDA (oxcodone with naltrexone)

Oxymorphone (Opana) Metabolism

. Oxymorphone has a very high affinity for the µ receptor . 1mg oxymorphone equivalent to 10mg morphine . Extensively metabolized by liver, but not affected by 2D6 or 3A4 metabolism

54 September 30, 2016

Methadone Metabolism

. Metabolized by 3A4 primarily and 2D6 secondarily . L-isomer is the opioid. D-isomer affects the NMDA receptors . Slow onset of action (half life from 12 to 150 hrs; average 24 hrs in literature)

Six Enzymes Involved in Methadone Metabolism

Decreased gastric PH with a proton pump inhibitor, increased rate of Methadone absorptionw/St. John’s wort, can withdraw from methadone St. John’s wort is a CYP3A4 inducer!

55 September 30, 2016

Metabolism: Liver, also kidneys, lungs, GI tract convert pharmacologically active lipid-soluble drugs to water soluble, mostly inactive drugs.

Fentanyl (Actiq, Duragesic, Fentora) Metabolism . Metabolized by 3A4 to inactive compounds . Extremely lipophilic, 800X versus morphine, with rapid crossing of blood-brain barrier; 80-100X as potent as morphine! . IV, transdermal, intranasal, transoral . Being processed with heroin on the street & now almost 40% of overdose deaths associated with fentanyl in 2016. . New Orleans 36/81 OD deaths with fentanyl, as of Sept 12 of 2016.

56 September 30, 2016

Topical Fentanyl / Duragesic

 Duragesic patch employs fentanyl mixed in a gel of hydroxy-ethyl-cellulose & held in the patch’s drug reservoir.

 The fentanyl (& the gel) travels from the drug reservoir through the release membrane. The release membrane is made of an ethylene- vinyl acetate copolymer membrane.  Depending upon three parameters – the surface area of the membrane, the concentration of fentanyl in the gel, & the total amount of fentanyl in the reservoir - fentanyl is delivered at a constant rate for 48 hours. The rate of drug delivery is less predictable in hours 48-72.  Patches offered in strengths of 12.5, 25, 50, 75, &100 micrograms/hr.

Transdermal Fentanyl

57 September 30, 2016

Topical Fentanyl

 Patch is placed on a flat, hairless, area of the body. OK to change placement on body between patches. Heat increases release!

 Sometimes the fentanyl patch is considered “safer” than oral pain medications. The patch is not safer, but does provide a valuable alternative to oral pain medications. The patch is especially useful in patients who have pain & problems with G.I. absorption, or have pain but are not consistently verbal or responsible about taking oral pain medications.  Frequently used in nursing homes – patch placed on the back of the residents & date placed written on the patch.  25 mcg/hour delivers 600 micrograms / day of topical fentanyl which is equivalent to approximately 100 mg / day of morphine.

FDA Approves First Fentanyl for Cancer Pain

June 30, 2011 — The FDA has approved fentanyl nasal spray (Lazanda) for the management of breakthrough pain in adults with cancer. It is indicated for patients aged 18 years & older who are already receiving opioid therapy but who have developed resistance to their regimen. The most common adverse events associated with its use were consistent with opioid treatment & include vomiting, nausea, pyrexia, & constipation. This specific formulation is also not equivalent to other fentanyl products that are used to treat breakthrough pain. There are differences in the pharmacokinetics, which could potentially result in clinically important differences in the amount of fentanyl absorbed, possibly resulting in a fatal overdose.

58 September 30, 2016

Meperidine (Demerol) Metabolism

. Metabolized by glucuronidation to normeperidine . Accumulates in renal failure or with high doses (T1/2 of 8-12 hrs) . Causes CNS stimulation and seizures - not reversed by naloxone . 1/10th as potent as morphine

Tramadol (Ultram) . Tramadol is an analogue of codeine, it is a racemic mixture of two enantiomers • One form is a selective µ agonist and inhibits serotonin reuptake • The other mainly inhibits NE reuptake • Also known to inhibit serotonin reuptake & NMDA antagonist . Maximum dose 400mg/day of immediate release . Now available in Extended Release (1X a day, add what you are giving during the day, e.g. 50 mg BID IR=100mg ER) . 3 warnings in the package insert: • A. Seizure risk • B. Suicide risk • C. Serotonin syndrome risk (Avoid with MAOIs, TCAs, triptans, SSRI’s, SNRI’s)

59 September 30, 2016

Tramadol (Ultram) Metabolism

. Synthetic analogue of codeine . Metabolized by CYP2D6 to M1 metabolite (O- demethyl tramadol) which is more active than parent compound . Toxic amounts cause seizures

Tapentadol (trade name Nucynta)

. A centrally-acting analgesic with a dual mode of action as an agonist at the -opioid receptor & as a NE reuptake inhibitor. . Not as weak as tramadol but not as strong as morphine. . In 2015, bought for 1 billion dollars by Depomed, Inc.

60 September 30, 2016

Naloxone

• Antagonist at all opioid receptors – Highest for the µ receptors – Low dose reverses respiratory depression before reversing analgesia • 0.4mg vial diluted to 4cc = 100µg/cc

Methylnaltrexone

. First quarternary ammonium opioid receptor antagonist that does not cross the blood-brain barrier. . It can reverse the effects of peripheral opioid receptors while not effecting the CNS opioid receptors. . Very useful to reverse constipation & reducing gastric emptying. . Since it does not cross the dura, it might have the potential to reverse the peripherally mediated side effects of epidural opioids. . New ones on market, e.g. Movantik () . 2 retrospective studies Feb, 2016, patients with advanced cancer treated with opioids lived 20 days longer if received instead of placebo (opioids, cause increased propagation of cancer, so makes sense) .

61 September 30, 2016

Opioid Adverse Effects

. Central Nervous System • Direct effects on dorsal horn • Activation of inhibitory descending pathways • Euphoria, drowsiness, difficulty concentrating • Dysphoria & agitation

Opioid Adverse Effects

. Respiratory system

• Initial opiates significantly decrease CO2 chemoreceptor response • Direct effect on brainstem • Dose-dependent decrease in respiratory rate

62 September 30, 2016

Respiratory Depression

Opioid Adverse Effects

. Gastrointestinal • Direct stimulation of CTZ • Spasm of smooth muscle • Biliary & anal spasm • Constipation 80% • Delayed gastric emptying • Nausea

63 September 30, 2016

Other Opioid Adverse Effects

. Ocular - miosis . Musculoskeletal . GU • Ms rigidity • Urinary retention • Myoclonus • Sexual dysfunction . Immune system secondary to • Itching (direct histamine hypogonadism, e.g. release) hypo testosteronism • Not an allergic reaction . CV • Infections/CA • Decreased central proliferate sympathetic tone . Pregnancy & neonates • Vagal stimulation . Decreased oral secretions • All opioids cross placenta • No teratogenic effects Dry mouth • • Neonatal respiratory • Dental issues depression . Excessive sweating

The Rationale for Tamper-Resistant Formulations . A study of prescription opioid abusers in a drug rehabilitation program found that 80% tampered with opioid tablets to accelerate drug release by chewing or administering the drug intranasally or intravenously

Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation.Passik SD, Hays L, Eisner N, Kirsh KL J Pain Palliat Care Pharmacother. 2006; 20(2):5-13.

64 September 30, 2016

Current Tamper-Resistant Opioid Formulations: Advantages and Disadvantages AE = adverse event; FDA = Food and Drug Administration.

Opioid formulation Advantage Disadvantage Physical barriers Prevent abusers from crushing or Does not deter abuse of intact chewing their opioid to facilitate tablets Only 1 FDA-approved rapid release into the system formulation available resist crushing, chewing, Prevent accidental crushing or dissolution, or chemical chewing in compliant patients No extraction. AEs in compliant patients FDA- approved formulation available

Aversive components May prevent abuse by chewing or Potential for AEs in compliant crushing opioids May limit abuse of patients who take the product as intact tablets because taking too intended Adverse events with Niacin is example much will amplify niacin AEs intact tablets may prevent legitimate dose increases to address increasing pain or decreasing efficacy over time Adverse events of niacin may not be sufficient to deter a motivated abuser No FDA-approved formulation

Sequestered antagonist Prevents abuse by chewing or Does not deter abuse of intact crushing opioids FDA-approved tablets Chewing or crushing the Narcan is example formulation available tablet may precipitate severe withdrawal symptoms Stanos S, et al. Mayo Clin Proc. 2012 Jul; 87(7): 683–694.

Physical barriers (resist crushing, chewing, dissolution, or chemical extraction).

1. Remoxy (King Pharmaceuticals, Inc, Bristol, TN), ER formulation of oxycodone delivered in a viscous formulation matrix resists abuse by crushing & dissolution in water or .

2. Reformulated Opana ER (Endo Pharmaceuticals Inc, Chadds Ford, PA), formulation of ER oxymorphone with a polyethylene oxide (PEO) matrix (INTACTM) designed to resist crushing, oxymorphone ER-PEO.

3. Egalet Morphine (Egalet Ltd, Værløse, Denmark), once-daily ER morphine formulation in which opioid is embedded in water-soluble matrix, keeping tablet intact until it reaches GI tract.

4.Q-1015 (TheraQuest Biosciences, Inc, Blue Bell, PA), TQ-1015 is proprietary formulation of CR tramadol difficult to crush or extract for intravenous injection.

5. OXECTA (King Pharmaceuticals, Inc, Bristol, TN), a short-acting oxycodone formulation designed to discourage common methods of tampering associated with opioid abuse & misuse. OXECTA is formulated using a proprietary AVERSION Technology (Acura Pharmaceuticals, Inc, Palatine, IL) incorporates commonly used pharmaceutical ingredients that can be irritating if ingested or inhaled.

65 September 30, 2016

FDA NEWS RELEASE For Immediate Release: April 16, 2013

. FDA approves abuse-deterrent labeling for reformulated OxyContin -Agency will not approve generics to original OxyContin . The U.S. Food & Drug Administration today approved updated labeling for Purdue Pharma L.P.’s reformulated OxyContin (oxycodone hydrochloride controlled-release) tablets. The new labeling indicates that the product has physical & chemical properties that are expected to make abuse via injection difficult & to reduce abuse via the intranasal route (snorting). This product has polyethylene oxide.

FDA approves Purdue's abuse-resistant Hysingla ER, a hydrocodone pill November 20, 2014 . According to the FDA, newly approved Hysingla tablets are difficult to crush, break, or dissolve & cannot be easily prepared for injection because it forms a thick gel. However, these products are only expected to reduce, not completely eliminate, abuse. . It uses a RESISTEC platform for extended- release solid oral dosage formulations, which uses unique polymer & processing that confers tablet hardness & viscosity when dissolved in aqueous solutions.

66 September 30, 2016

FDA approves tamper-resistant reformulation of Zohydro in continuing battle against opioid abuse February 4, 2015

. The FDA approved a reformulated version of Zogenix's painkilling Zohydro ER designed to be abuse resistant (not actually in labelling from FDA as a ADR), marking another step in the battle against opioid abuse using BeadTek, a technology that turns the drug into a viscous gel if it's crushed & dissolved in or . The products added are polyethylene oxide and povidone.

Examples of Abuse Deterrent Formulations - US Market Only 6 actually FDA approved • Reformulations: (crush/extraction resistant)

• Zohyro ER (reformulation launched in 2015) • Hysingla ER (formulation launched in 2014) • OxyContin® ER (reformulation launched in 2010) • Opana® ER (reformulation launched in 2012) • Exalgo® (Hydromorphone ER-crush/extraction resistant) • Suboxone® (Buprenorphine/naloxone) • Embeda® (Morphine/naltrexone-recalled 2011) • Acurox® (Oxycodone/niacin--irritant/unpleasant systemic) • Targniq® (Oxycodone and naloxone) • Morphabond® (Morphine sulfate) • Xtampza® (Oxycodone) Risk Evaluation & Mitigation Strategies (REMS)

67 September 30, 2016

68 September 30, 2016

69 September 30, 2016

70 September 30, 2016

71 September 30, 2016

Opioid Withdrawal (we see all of these symptoms during UROD-should be aware if seen in clinic setting as well)

. Yawning . Nasal discharge . Flu-like symptoms . Nausea/vomiting . Diarrhea . Muscle pains . Goosebumps . Severe anxiety . Increase in heart rate, blood pressure . Potential for myocardial ischemia, infarction, stroke, death

Neonates opioid withdrawal, increase mucous secretions

UROD-Ultra Rapid Opioid Detoxification —Kaye technique—Done in ICU . Premed w/clonidine (deplete catecholamines by 65- 70%), Vitamin C & mini bowel prep . Rapid Sequence induction w/ Propofol & rapid onset neuromuscular blocker, no significant change BP or HR . Nasogastric tube placement . Maintenance w/Propofol (spontaneous ventilation; titration w/ sedation monitor to 30-40); naloxone iv bolus, followed by 24 hr infusion—total 85 mg., naltrexone PO following AM and then for next 3-4 months O morbidity/ 0 deaths in 14 years, 100% detoxed from opiates, 70% abstinence at 6 months vs. 5-8% success with conventional detoxification techniques.

72 September 30, 2016

FDA Unveils Sweeping Changes to Opioid Policies Feb 2016 • “In response to the ongoing opioid abuse epidemic, top officials at the US Food and Drug Administration announced plans to reassess the agency's approach to opioid medications.” • "This plan contains real measures this agency can take to make a difference in the lives of so many people who are struggling under the weight of this terrible crisis."

The plan will focus on policies aimed at reversing the epidemic: 1. Re-examine risk-benefit paradigm for opioids & ensure agency considers wider public-health effects; 2. Convene an expert advisory committee before approving any new drug application for an opioid that does not have abuse-deterrent properties; 3. Assemble and consult with the Pediatric Advisory Committee regarding a framework for pediatric opioid labeling before any new labeling is approved;

73 September 30, 2016

Plan... 4. Develop changes to IR opioid labeling, including additional warnings & safety information that incorporate elements similar to those of the ER/LA opioid analgesics labeling that is currently required;

5. Update REMS requirements for opioids after considering advisory committee recommendations & review of existing requirements;

6. Expand access to, & encourage the development of, abuse- deterrent formulations of opioid products;

7. Improve access to naloxone & medication-assisted treatment options for patients w/ opioid-use disorders;

8. Support alternative pain management treatments.

CDC Opioid Guidelines April 2016

“Considerations for Tapering Opioids. Although the clinical evidence review did not find high-quality studies comparing the effectiveness of different tapering protocols for use when opioid dosage is reduced or opioids are discontinued (KQ3), tapers reducing weekly dosage by 10%–50% of the original dosage have been recommended by other clinical guidelines and a rapid taper over 2–3 weeks has been recommended in the case of a severe adverse event such as overdose. Experts noted that tapers slower than 10% per week (e.g., 10% per month) also might be appropriate and better tolerated than more rapid tapers, particularly when patients have been taking opioids for longer durations (e.g., for years). Opioid withdrawal during pregnancy has been associated with spontaneous abortion and premature labor. When opioids are reduced or discontinued, a taper slow enough to minimize symptoms and signs of opioid withdrawal (e.g., drug craving, anxiety, insomnia, abdominal pain, vomiting, diarrhea, diaphoresis, mydriasis, tremor, tachycardia, or piloerection) should be used.”

74 September 30, 2016

CDC Opioid Guidelines April 2016

“A decrease of 10% of the original dose per week is a reasonable starting point; experts agreed that tapering plans may be individualized based on patient goals and concerns. Experts noted that at times, tapers might have to be paused and restarted again when the patient is ready and might have to be slowed once patients reach low dosages. Tapers may be considered successful as long as the patient is making progress. Once the smallest available dose is reached, the interval between doses can be extended. Opioids may be stopped when taken less frequently than once a day. More rapid tapers might be needed for patient safety under certain circumstances (e.g., for patients who have experienced overdose on their current dosage). Ultrarapid detoxification under anesthesia is associated with substantial risks, including death, and should not be used. Clinicians should access appropriate expertise if considering tapering opioids during pregnancy because of possible risk to the pregnant patient and to the fetus if the patient goes into withdrawal. Patients who are not taking opioids (including patients who are diverting all opioids they obtain) do not require tapers. Clinicians should discuss with patients undergoing tapering the increased risk for overdose on abrupt return to a previously prescribed higher dose. Primary care clinicians should collaborate with mental health providers & with other specialists to optimize nonopioid pain management, & psychosocial support for anxiety related to the taper. If a patient exhibits signs of opioid use disorder, clinicians should offer treatment and consider offering naloxone for overdose prevention."

FDA News Release August 30, 2016 • FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use.

75 September 30, 2016

Summary

. Opioid pharmacology is in its infancy. . Many drugs out there, with different absorption, metabolism, & elimination. . A basic appreciation of dosing, drug interactions, side effects, & governmental regulations/policies is paramount to the practice of a pain physician. . Guidelines suggest opioids not a magic bullet in the treatment of long term chronic pain. . Surging prescriptions, surging Overdose deaths; prescription opioids direct link to heroin epidemic

Alan D. Kaye, MD, PhD E-mail: [email protected]

76 11:00 – 11:45 am – Treating Chronic Pain: A Whole Person Perspective David A. Hanscom, MD Saturday, October 1, 2016 No Handout per Speaker NOTES

9/19/2016

Sanford M. Silverman, MD Comprehensive Pain Medicine Pompano Beach, FL Southern Pain Society Annual Meeting October 2016

Interventional Pain Management is the discipline of medicine devoted to the diagnosis and treatment of pain- related disorders principally with the application of interventional techniques in managing sub-acute, chronic, persistent, and intractable pain, independently or in conjunction with other modalities of treatment NUCC Definition 2002/2003

2

1 9/19/2016

Interventional pain management techniques are minimally invasive procedures, including percutaneous precision needle placement, with placement of drugs in targeted areas or ablation of targeted nerves and some surgical techniques, such as laser or endoscopic discectomy, intrathecal infusion pumps and spinal cord stimulators, for the diagnosis and management of chronic, persistent or intractable pain

MedPAC Report, 2001

Regenerative Medicine Lumbar endoscopic spinal decompression Minimally invasive lumbar decompression (MILD) Spinal cord Stimulation

2 9/19/2016

• Regenerative medicine is a broad definition for innovative medical therapies that will enable the body to repair, replace, restore and regenerate damaged or diseased cells, tissues and organs. (Mayo Clinic) • Science Merges with Technology to Achieve Self-Healing • Regenerative medicine uses procedures to repair or replace. Tools and applications • Tools of Regenerative Medicine (Ultrasound, Fluoro) Stem cells Plate Rich Plasma (PRP) Amniotic Fluid • Applications: o Discs & other spinal structures o Joints o Ligaments o Cosmetic

3 9/19/2016

Stem Cell

7

Cells which have the capacity to divide symmetrically to expand their numbers and asymmetrically to self renew and give rise to a differentiated progeny.

4 9/19/2016

Germ cells – most primitive cells of the body, truly pluripotent and can give rise to identical cells and can also produced differentiated cell lines.

Embryonic Stem cells (ESc)– derived from the fetus; pluripotent and can differentiate to any tissue type. Cells are derived from the human embryo, aborted or left over from in vitro fertilization.

Mesenchymal stem cells (MSCs) – derived from adults a. Bone marrow Aspirate b. Adipose Tissue c. Amnion d. Cord Blood/Placenta e. periosteum f. synovial membrane g. dental pulp

Induced Pluripotent Stem Cells (iPS) – derived from non-pluripotent somatic cells such as dermal fibroblasts, which then transformed and genetically engineered into a pluripotent state.

PLURIPOTENTIAL

DERIVED FROM HUMAN EMBRYO

ABORTED OR LEFT OVER FROM IN VITRO FERTILIZATION

CONTROVERSIAL DUE TO MORAL AND ETHICAL ISSUES

DIFFERENT DNA FROM THE HOST

FORMATION OF TERATOMAS

TRANSPLANT REJECTION

5 9/19/2016

US-guided Regenerative Medicine

• No RADIATION EXPOSURE to patients or staff • Visualization of SOFT TISSUES; nerves, vessels, muscles,… and bony surfaces. • Allows REAL-TIME needle advancement & monitor the spread of injectate. • DIAGNOSIS of various joint (shoulder) disorders, nerve entrapment syndromes, …

Medial/lateral knee

6 9/19/2016

• PRP: Platelet Rich Plasma Therapy • Concentrate Platelets from Patients Blood Sample • Platelets Contain Cytokines and Growth Factors • PRP Accelerates Healing and Reduces Pain

14

7 9/19/2016

Easy to obtain Potentially limitless in supply Patients can use their own stem cells for treatment and therapy Adult stem cells are politically neutral Not offensive to any major interest group nor do they generate controversy.

Following extraction of either bone marrow (top row) or adipose tissue (bottom row), MSCs can be isolated and subsequently transplanted (black arrows) to discs in need of regeneration Stem Cells Cloning. 2015; 8: 117–124. 16

8 9/19/2016

Stem Cells Cloning. 2014; 7: 1–17. Published online 2014 Jan 16. doi: 10.2147/SCCAA.S42880PMCID: PMC3897321 Current perspectives in stem cell research for knee cartilage repair Patrick Orth,1 Ana Rey-Rico,2 Jagadeesh K Venkatesan,2 Henning Madry,1,2 and Magali Cucchiarini2

Numerous controversies Lack of reimbursements by third party payers FDA Regulations Poor evidence Medscape Medical News > Conference News Platelet-Rich Plasma for Pain: Evidence Still Lacking Nancy A. Melville March 30, 2015

18

9 9/19/2016

19

10 9/19/2016

Historically Speaking: 1934 – First Micro discectomy Mixter and Barr 1951 – Nucleotomy – Less aggressive decompression 1960’s – Chemonucleolysis 1973 – Micro discectomy Parvis Kambin 1975 - Percutaneous posterolateral nucleotomy Hijikata

1983 – First Visualized micro discectomy with modified arthroscopy Forest and Housman 1988 First Discoscopic views within the disc Kambin 1990 – Kambin triangle Larger working cannucs 1993 Endoscopes with an enlarged optic: allows dorsal vision around an annular tear 1996 – 30o Endoscope Kambin and Zhou

11 9/19/2016

1998-1999 – Popularization of Transforaminal approach Foley, Mathes, Ditsworth 1999 – Yess – Young Endoscopic Spine System 2001 – Endoscopic Foraminotomy with laser Knight et al

Transforaminal Endoscopic Lumbar Decompression & Foraminoplasty: A 10 Year prospective survivability outcome study of the treatment of foraminal stenosis and failed back surgery Martin TN Knight, MD, FRCS, MBBS, Ingrid Jago, RGN ONC RNT Cert Ed FETC, Christopher Norris, PhD MSc MCSP, Lynne Midwinter, MCSP, and Christopher Boynes, BEd (Hons) PE, MCSP, MACPSM, MSOM, MAACP, Lic Acu, HPC

Results VAP scores improved from a pre-operative mean of 7.3 to 2.4 at year 10. The ODI improved from a mean of 58.5 at baseline to 17.5 at year 10. 72% of reviewed patients fulfilled the definition of an “Excellent” or “Good Clinical Impact” at review using the Spinal Foundation Outcome Score. Based on the Prolo scale, 61 patients (77%) were able to return and continue in full or part-time work or retirement activity post-TELDF. Complications of TELDF were limited to transient nerve irritation, which affected 19% of the cohort for 2 – 4 weeks. TELDF was equally beneficial in those with failed back surgery. Conclusions TELDF is a beneficial intervention for the long-term treatment of severely disabled patients with neuro- claudicant symptoms arising from spinal or foraminal stenosis with a dural diameter of more than 3mm, who have failed to respond to conventional rehabilitation or chronic pain management. It results in considerable improvements in symptoms and function sustained 10 years later despite co-morbidity, ageing or the presence of failed back surgery.

12 9/19/2016

Neurosurgeons Orthopedic Surgeons Interventional Pain Physicians Interventional Radiologists

Education Training Certification Guidelines

13 9/19/2016

14 9/19/2016

15 9/19/2016

A safe, minimally invasive option to treat LSS patients suffering with neurogenic claudication due to hypertrophic ligamentum flavum Treats underlying cause of LSS through a percutaneous decompression laminotomy achieved through a portal smaller than a baby aspirin (5.1mm) Outpatient procedure Fluoroscopically-guided = extremely safe No general anesthesia required No stitches required No implants left behind

16 9/19/2016

17 9/19/2016

Proven History FDA cleared Approximately 20,000+ commercial cases performed to date Well studied- 12 clinical trials (887 patients) 18 published peer-reviewed journal articles (2010- 2016) Safe- Low complication rates: No dural tear, nerve root damage or blood loss requiring transfusion reported in clinical trial Adverse event rate <0.1% in 20,000+ commercial cases

Pain Physician; 2016; 19:25-37

18 9/19/2016

19 9/19/2016

20 9/19/2016

Efficacy— The results of all primary and secondary efficacy outcome measures achieved substantial clinical improvement that was statistically significantly superior in the MILD group versus the ESI group. Efficacy Achieved with Co-Factors Present — MILD group experienced significant relief by treating just one of the LSS co- factors. Safety— MILD & ESI have an equivalent safety profile. There was no statistically significant differences in the safety profile between study groups. Level I Evidence— This prospective, multi-center, randomized controlled clinical study provides Level I evidence of the safety and effectiveness of MILD versus ESI

21 9/19/2016

3100 BCE Nile Catfsh (Electrogenic) Fish 3-400V** 43 CE Scribonius Largus – first TENS for medical use of with electric ray 150-200 Galen – torpedo fish in tx of gout & headache 1799 Volta – first battery 1871 Beard/Rockwell – ‘Faradization’ to stimulate ms & nn 1874 First brain stimulation – ms contractions via motor cortex stim 1882 Faradic Electrifier 1919 Electreat – first electrical stimulation for therapeutic use 1948 First successful brain electrode implant for psychiatric disorder 1958 First integrated circuit & First Pacemaker by Siemens; similar technology used for SCS in the 70s

22 9/19/2016

Pain Pathways ; circa 1965

23 9/19/2016

Practical consequences: TENS SCS Peripheral nerve stimulation Acupuncture Counter irritation

Types of nerve fibers A delta fibers (fast) Sharp, prickling Well localized A beta fibers C fibers (slow) Dull, aching diffuse Modulation Local anesthetic May respond to AEDs

24 9/19/2016

1965 Melzack & Wall Led to development of SCS Pain perception = balance of spinal cord impulses through large myelinated (Aβ) vs smaller (AΔ & C) nerve fibers synapsing at dorsal horn Useful operational framework but neuromodulation is a more complex phenomenon

1965 Melzack & Wall - Gate Control Theory 1967 Shealy – First ‘dorsal column stimulator’** 1968 Medtronic Myelostat – First commercially available (RF) SCS 1970s Spinal cord stimulation widely utilized 1970 Intradural pocket 1971 Avery Labs First epidural single lead (RF) SCS 1976 Cordis – First totally implantable SCS (in epoxy with mercury battery) 1978 Medtronic percutaneous implantable lead 1980 Neuromed RF Quatrode - First programmable electrode system 1981 Medtronic PISCES 4 electrode percutaneous lead 1984 Medtronic Itrel – totally implantable primary cell SCS with 4 electrodes on single lead

25 9/19/2016

Dorsal Column Stimulation 1967 Pt w metastatic lung ca: chest wall & abdominal pain External RF transmitter / transmitting antenna (sends electrical signal of selected frequency, amplitude and duration) Electrode implanted connected by lead to receiver (may be implanted) Bilateral T2-3 laminectomy = requiring general anesthesia Receiver placed over the clavicle w SQ tunneling over the shoulder to the laminectomy site

26 9/19/2016

27 9/19/2016

1986 Neuromed Octrode 8 electrode lead 1992 Medtronic Itrel 2 with 8 electrode lead 1994 Neuromed Dual Octrode lead RF SCS 2004 Boston Scientific Precision – First transdermal rechargeable, multisource, fully implantable SCS 2011 Medtronic RestoreSensor with accelerometer to detect body position 2013 Medtronic SureScan – First full body MRI Compatible SCS 2014 SJM Protégé first upgradeable programmer stimulator 2015 SJM Prodigy first Pulse Burst stimulator 2015 Nevro Senza HF10 – First High frequency paresthesia-free & 3T MRI compatible SCS 2016 SJM Axium – First DRG stimulator 2016 StimWave – First Wireless SCS

28 9/19/2016

Lower incidence of hardware failure Longer battery life, primary & secondary battery options Less lead migration Up to 16 contact lead / 32 contact paddle Waveforms: Tonic, burst or high frequency patterns Paresthesia vs no paresthesia IPG vs No IPG (RF vs Wireless) Complex programming Apple app compatible – increased trial to perm ratio

29 9/19/2016

Paresthesia free Anatomic placement High frequency 10 Khz

30 9/19/2016

Regenerative Medicine has promise with very few RCT’ s MILD procedure has excellent evidence, and great promise for pts with LSS Endoscopic decompression has promise for Minimally invasive decompression techniques for contained HNP “ Paresthesia free” high frequency SCS has promise, FDA approved

Sanford M. Silverman, MD Comprehensive Pain Medicine 100 East Sample Rd, Suite 200 Pompano Beach, Florida 33064 Phone: 954-545-0106

31 9/19/2016

Questions & Discussion

32 October 1, 2016

Update in Headache Management for the Pain Provider 2016

Michelle Brown MD Medical Director Unifour Pain Treatment Physicians Hickory, North Carolina

Update in Headache Management

Objectives • List the clinical characteristics of migraine

• Recognize the modifiable factors that lead to the chronification of migraine

• Discuss preventative and abortive strategies for migraine

• Review recently developed products and what’s in the pipeline for 2017

Disclosures

• Consultant for Depomed, Purdue, AstraZeneca, Pernix, Daiichi Sankyo

• Conflict of Interest: None

1 October 1, 2016

45 year old woman with headaches since age 13  Slow progression in frequency over the years but over the last 2 years complains of . “Tolerable Headaches” on 10-15 days per month . Mild to mod headache, mild photophobia, mild phonophobia . Full-blown migraines on 10 days per month . Severe headache, photophobia, phonophobia, osmophobia, nausea . Complete headache freedom – rare

 Treatment . No prophylactic . Ibuprofen - 20 days per month . Triptan - 10 days per month

What is her headache diagnosis???

1. Episodic Migraine

2. Episodic Migraine and Episodic Tension-Type Headache

3. Chronic Tension-Type Headache

4. Chronic Migraine

5. Chronic Migraine with Medication Overuse

2 October 1, 2016

Headache is Common . - 70-80% of adults will suffer from headache . sometime during lifetime

. - 38% of children will have a headache

. - 4% of all visits to a doctor

. - 28 million adult migraine sufferers in USA . - 21 million female vs. 7 million male

. - Migraine prevalence peaks ages 25 to 55

Sinus Headache is Commonly Reported as a Diagnosis in Patients Meeting IHS Migraine Diagnostic Criteria

9

3 October 1, 2016

Do this 3-step test andDo find out you in less havethan 30 seconds! Migraine?

It is likely that you have migraine if you have recurrent 'sick' headaches or bilious attacks that last anything between a fe w hours to a few days and you are other w ise w ell.

If you're not sure, take the I-D Migraine test 1 :

During the last 3 months did you have any of the following symptoms together with a headache?

I

I

If you answered YES to two or Question 1 You felt nauseated/sick? more questions it was most Question 2: Light bothered you (a lot more than likely migraine. If you answered when you didn't have a headache)? YES to one or no question Question 3: Your headache limited your ability to only it might have been work, study, play or do what you wanted for at migraine, but we suggest least one day? discussing it with a doctor to make sure. l 1 Lipton RB, Dodick D, Sadovs ky R, al. e. A self-administered screener for migraine in primary care: the ID l\1igraine validation study. Neurology 2003 61:375-382

Classification of Headache

International Headache Society (IHS)

• - Began with classification schema in 1988 • - Revised 2004 • - Beta test 2013 - anticipated final 2018 • - Guideline for diagnosing headache types • - Research oriented

4 October 1, 2016

Classification of Headache

 PRIMARY HEADACHE DISORDERS

– - Migraine with and without aura

– - Tension type headache

– - Cluster headache and other trigeminal autonomic cephalgias

. SECONDARY HEADACHE DISORDERS

– - Brain tumor

– - Intracranial hypertension/hypotension

– - Temporal arteritis

– - Sub-arachnoid hemorrhage

– - Sinus Headache

IHS Definition Tension Headache At least 2 of the following pain characteristics:  - Pressing/tightening (non-pulsating) quality

 - Mild or moderate intensity (may inhibit but does not prohibit activities)  - Bilateral location

 - No aggravation from climbing stairs or similar routine physical activity

Both of the following:  - No severe nausea or vomiting  - Photophobia and phonophobia absent or only one present

International Classification of Headache Disorders, 2nd Ed. ICHD-II 2.3 & A2.

5 October 1, 2016

IHS Definition Chronic Migraine • A. Headache (tension-type and/or migraine) on >15 days per month, for > 3 months, with over half lasting > 4 hours, fulfilling the following criteria for migraine:

• At least 2 of the following: 1) unilateral location, 2) pulsating quality, 3) moderate/severe pain intensity, 4) aggravation by routine physical activity

• At least 1 of the following: 1) nausea and/or vomiting, 2) photophobia and phonophobia

• B. Probable chronic migraine: headache meeting criteria for chronic migraine but in the presence of recent medication overuse.

International Classification of Headache Disorders, 2nd Ed. ICHD-II 1.5.1 & A1.5.1

Migraine can be defined by how often headaches happen

One type of migraine occurs with fewer than 15 headache days per month, some of them being migraine. This is called episodic migraine

The second type is when headaches occur 15 or more days per month, over half being migraine. This is called chronic migraine

Over a 3-month period, people with Chronic Migraine are more likely than those with episodic migraine to miss 5 or more days of: work or school, household work, and family activities

6 October 1, 2016

Migraine Headache Tension Headache Lasts: 4 to 72 hours Lasts: 30 min to 7 days

Migraine includes at least two of the Tension headache includes at least following symptoms: two of the following symptoms: Located on one side of the head Located on both sides of the head Intense throbbing pain Dull achy , non-pulsating pain

Pain that increases with activity Not aggravated by normal activity

Pain that is moderate to severe with at Mild to moderate pain and neither of least one of these: the following:

• nausea and/or vomiting • sensitivity to light and I or sound • sensitivity to light • nausea and/or vomiting Adapted from the International • sensitivity to sound Classification of Headache Without aura: at least five attacks Disorders, 2nd ed. 4 With aura: at least two attacks

7 October 1, 2016

Medication Overuse Headache ICHD-II

Headache present on ≥15 days/month fulfilling these criteria: 1.1. Regular overuse for ≥3 months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache Ergotamines OR triptans > 10 days/month Opioids OR combination analgesics > 10 days/month Simple analgesics > 15 days/month

2.2. Headache has developed or markedly worsened during medication overuse 3.3. Headache resolves or reverts to its previous pattern within 2 months after discontinuation of overused medication

International Classification of Headache Disorders, 2nd Ed. ICHD-II 8.2 & A8.2

RISK FACTORS FOR CHRONIFICATION OF MIGRAINE Not Modifiable Modifiable Gender Attack Frequency Migraine Obesity

Low Education Medication Overuse Low Socio-economic Stressful life events status Head Injury Snoring Depression Abuse Other Pain Disorders Diet

8 October 1, 2016

I Migraine diagnosis t Patient Education Assessment of Severity t ', t I Mild to Moderate I Associated w/ nausea, ISevere I vomiting, diarrhea , , , Simple Analgesics : ' Triptans' ' Add an antiemetic I DHE nasal spray aspirin, APAP ± antiemetic Inadequate response ...- , Opioid analgesics' Combination• analgesics , " Butorphanol & caffeine Consider' preventive I therapy , Inadequate response Corticosteroids' " i.v. . . I I Manage as severe m1gra1ne Adapted from Silberstein SO eta/., 2000

6 UNIFOUR PAIN TREATMENT PHYSICIANS

Need for Miqraine Prop_h_ylaxis: • An unsatisfactory response to acute therapy • Two or more attacks per month that interfere with patients daily routine • Contraindications to acute treatments or adverse effects related to them • The use of abortive medications > 2 times per week

Choose a conventional igraine preventative medicine (consider co-morbidity & relative contraindications)

Amitriptyline Blockers Antiepileptic Drugs Yes : Depression Yes : Hypertension• Yes : Hypertension, angina Yes : Epilepsy, Anxiety, Mania No. Mania No. Asthma or No. Depression No: Liver Disease Depression

If no efficacy, increase dose slowly

If adverse effects If no efficacy at maxjmal dose develop Adapted from -...., J Galletti eta/. 2009 Try a different conventional migraine drug 1---

Consider a combination of two drugs

Try alternative agents : 5-HT antagonists , ARBs, atypical antipsychoucs , etc

9 October 1, 2016

International Classification of Headache Disorders 3

• - Beta Test • - Coordinate with ICD-11 • - Definition Chronic Migraine • - Medication Overuse Headache secondary diagnosis • - Secondary Headaches better defined

FROM CROSSWALKS DEVELOPED BY AAN AND COMPLETE PRACTICE RESOURCES: COMMONLY USED NEUROLOGIC DIAGNOSIS https://www.aan.com/uploadedFiles/Website_Library_Assets/Documents/3.Practice_Management/ 1.Reimbursement/1.Billing_and_Coding/2.ICD-10-CM/ICD10Crosswalk_PDF%20final.pdf accessed June 21, 2016.

10 October 1, 2016

• Botulinum toxin injection sites for treating chronic migraines

P F28 0 ·:,.. The Impact of OnabotulinumtoxinA on Severe Headache Days: PREEMPT Pooled Analysis 0 Sheena Aurora,' Rashmi Halker,2 Patricia Pozo-Rosich,3•4 Ronald DeGryse,5 Aubrey Manack Adams,' Manjit Matharu' 'Department of Neurology, Stanford University, Stanford, CA; 2Department of Neurology, Mayo Clinic, Phoenix, AZ; 3 Headache and Pain Research Group, lnstitut de Recerca, Universitat Aut6noma de Barcelona, Barcelona, Spain; 4 Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain; 5Af/ergan pic, Irvine, CA; 6/nstitute of Neurology, Headache Group, London, UK

• At the end of week 24, onabotulinumtoxinA was associated with a significantly • In the responder analysis, significantly more patients in the onabotulinumtoxinA INTRODUCTION RESULTS greater reduction from baseline vs placebo in the number of severe headache group experienced a 2:1-grade improvement in ADHS score from baseline to week • Chronic migraine (CM), characterized by headaches occurring on i!::15 days/month days per 28-day period (LS mean difference= -1.4 days, 95% Cl-2.03, -0.86; 24 (35.8% vs 23.1%; P<0.001) and week 56 (53.9% vs 47.7"/o; P=0.02; Fi gur e 3) for 2:3 consecutive months {i!::8 daysfmonth involving headache typical of Patients P<0.001), which was sustained In the open-label phase (Fi gur e 2) migraine),1 affects approximately 1.3% to 4.1% of US adults 2 • A total of 1384 patients were randomized to treatment Including 688 In the Figure 3. Percentage of Patients Experiencing Improvement From onabotulinumtoxinA group and 696 in the placebo group • CM is associated with a significant and pervasive burden on patients' lives, Figure 2. Change From Baseline in the Number of Severe Headache Baseline of 1 Grade in Average Daily Headache Severity including severe disability , lower health-related quality of life, and increased • Baseline demographic characteristics and the frequency and severity of Days Per 28-day Period Score at Week 24 and 56 healthcare resource utilization compared with those with episodic migraine headache and migraine days were similar between treatment groups (Table 1) (le, <15 headache days/month) 3" - The onabotulinumtoxinA group had fewer headache and migraine episodes • OnaboWOnaOOtA (Ns6118 ) • OnabotulinumtoxinA (BOTOXl>, Allergan pic, Dublin, Ireland) is the only headache and a larger total number of cumulati ve headache hours on headache days • Pia<:eboi'Onabo1AlN=696 ) prophylaxis FDA-approved for CM in the United States 5 -+- OnaboWOMbo!Al N =686) than the placebo group -+- P1acebo/Onat>otA(N=696) • In the previously published pooled PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) Studies , onabotulinumtoxinA was shown to Table 1. Pooled PREEMPT Baseline Patient Demographics and significantly reduce headache-day frequency compared with placebo,u but Characteristics additional research is needed to understand its effect on other headache characteristics (eg, severity) OBJECTIVE • To assess the effect of onabotulinumtoxlnA on headache-day severity using pooled data from the PREEMPT Studies M ean(SD)frequencydheadachedar.o 19.9(3 .7) 19.8(3.7 )

METHODS Mean(SD)frequencyo f migralnel 19.1(4.0) 16.9(4.1) Study Design probable m igraine days Mean (50) frequency ol moderate/ 16.0(4.3) • Two multinational , phase 3, 24-week, double-blind , parallel-group studies each severe headache days 16.1 (4.1) followed by a 32-week open-label phase (Fi gur e 1) • OnabotulinumtoxinA (155-195 U) or placebo was administered every 12 weeks M ean(SD)frequencydto lal cumulalive S " " " '9 f' da l l yh oa d ad lo 11&'/orily: OnabolA hou , . o f heada c h eo=. .r ringon 295.9( 118.9) 28 1.2 ( 114.7 ) " 'Oa b o l u llnumiO 1 ch;ongoo!roada<:l1e dayspor213--llh e lnlomatlonal HN d ache Society. Ce p h o l l>lghl . 201J;J3(9):629-808 diagnostic criteria Nato11JL, e1ai. Copha/a/glll.20t0:30(5):S99-l!09. I Onabot Placebo/ - At week 56, the percentage of patients in the ADHS category of severe was 61umenfeld A . e l ai. Ce >hala gla. 2011;J1(3):301·315 • Participants were required to have 2:15 days of headache during the 4-week OnabotA Placebo OnabotA Placebo OnabotA Onabo tA significantly lower in the onabotulinumtoxinA group than placebo group . a ...li A.ot ai. Ho- c ho. 2016:5e(2):306 -322. baseline period, with each headache day consisting of 2:4 hours of continuous day Sove r rty• (n•688) I (n •696) PVa luo' (n• 688) (n • G96) PVa lua• (n•688) (n•696) ' 60TOX"(ona l>olullnumlo•lnA) fot Injection, lot lnlramuso ular, lnUOOfiOriafrom O=none, 1=mlld, 2=moderate , 3=severe 5,557 5,712 11.343 10.287 13.596• • 13,241 AIIOirll" n.Avanir,eNeura. Mitrck. andNup.a the and speaker's free days, (28.8) (29.3) (58.9) (52.8) (70.6) (87.9) bureau particip-atio n for Allergon. Rashmi " a l k e rtla s recei....cl • Number of severe headache days per 28-day period n(%) • honoru l a from MeOfiOria "' "' "' from Aller{131'1. Ronald DeGryse and Aubrey M a n ack Adams - ADHS was defined as the 28-day average of daily headache severity scores, 5.252 5.316 3.011 3.378 2.078 2.227 are employee s o!AIIer {131'1 plcandownstock ln t he company. headache 187(27 . 2 )2 06 (29.6) 278(51.6)274(49.4) 153(38.3) 154(40.4) weighted to account for headache days without a severity report (27.3) (27.3) (15.6) (17.3) (10.8) (11.4) Manji1Matharuha s , ..caived consul ngfee sltlonoraris from To obtain a PDF of this poster: days. n (%) All..-9"n,StJud e Medicai,Medlronlc and olectroC.,..., 460(66.9)435 (62.5) 100(18.6) 131 (23.6) 52(13.0) 45(11.8) ScantheQRcode Severe Data Analysis 7,183 7,2 14 4,095 5,122 2 ,987 3,389 headaclle (37.3) (37.0) (21.3) (26.3) (15 .5) (17.4) OR • Missing values were Imputed using modified last observation carried forward d a y s.n(%) 41 (6.0 ) 55 (7.9) 19(3.5) 42(7.8) 9(2.3) 20(5.2) ACKNOWLEDGEMENTS Vi s it • Between-treatment binomial comparisons were determined by Pearson's This s tu cl ywu sponsoredbyAIIerganplc (Oublin . lrelana tootA.•onaotootul"""" to•M. PharmD.a na bOIA.•onai>Olul""-' mtox iM. • Comparisons of continuous variables were conducted by covariate analysis of 1P vai'-"'Oior'>el-ii $ 10 e 0<11 - o t y 'Pvalue• for t>e l > l n o m l . . r:ompao-loonouolnQPea<•or f octoi OQY< e te &tswilhot....ctloew rily category (Dublin, lreland).AIIauthonr riMitths iCMJEauthors h l p c r ilflrla variance with baseline score as covariate cotO<}O on raol< -11001 \881 ooh hoadachoo day oov""'yd islrb.Jooo Nelth-erhonorat1anorpaymentaw er emadeloraulho rshlp. 'PvMJe o forbe oup rompar i3omusirovWolr:o>conraoi<·•Lrmtest onh hoo

Prasantad at lha Amancan Haadacha Soc1aty (AHS) 58th Annual Sc anllfic Maatmg Juna 9- 12 2016 San Otago CA

11 October 1, 2016

Supraorbital n.

Auriculotemporal n.

Sphenopalantine Ganglion Catheters • - Sphenocath® • - Tx360®, and

• - AllevioTM

12 October 1, 2016

What’s New in 2016? Pharmacotherapy

• - Semprana - inhaled DHE • FDA rejected • - Onzetra Xsail - Powdered sumatriptan • - Lasmiditan - 5-HT1F receptors in trigeminal pathway – phase III

What’s Changed in 2016? Pharmacotherapy

• - ZECUITY -- iontophoretic transdermal system • - delivers 6.5mg sumatriptan over 4 hours • - FDA approved January 2013 • - available late 2013

13 October 1, 2016

What’s Changed in 2016? Pharmacotherapy

ISSN 0017-8748 Headache doi: 10.1111/head.12732 © 2015 American Headache Society Published by Wiley Periodicals, Inc. Research Submission

Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study

14 October 1, 2016

Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine

➢ - CGRP is a cardiovascular peptide that works as a potent vasodilator ➢- 2 forms of the CGRP molecule, alpha and beta, throughout the central and peripheral nervous system ➢ - initially identified about 35 years ago

➢ - CGRP in sensory neurons of the face and head, mostly concentrated in the trigeminal nerve ➢ - CGRP content is higher in the blood during a migraine attack and CGRP infusion into migraineurs can bring on a migraine attack

➢ - May be associated with cluster headaches

Calcitonin Gene-Related Peptide (CGRP) Antagonists  -- different types of medications that interact with this molecule

• - anti-CGRP antibodies

• - anti-receptor antibodies

• - receptor antagonists

-- May be used to abort acute attacks or as preventative therapy

15 October 1, 2016

CGRP Monoclonal Antibodies for Prevention • CGRP monoclonal antibodies prevent migraine by:

• - binding with the CGRP released from trigeminal • sensory nerve fibers

• - preventing activation of trigeminal nerves

• - preventing CGRP induced activation of sensitized • central trigeminal pathways

• - preventing attacks in migraine susceptible individuals

16 October 1, 2016

Preventative GCRP Monoclonal Antibody Medications (MABS) in Development ➢ ALD403 targets CGRP, ➢ - administered via IV injection. ➢ - In clinical trials, ~20% reduction in migraine and headache ➢ days compared with placebo. ➢ LY2951742 targets CGRP ➢ - SQ q 2 weeks for 12 weeks in clinical trials, ➢ - 25% reduction in migraine and headache days compared with ➢ placebo. ➢ - Being investigated for preventing cluster headaches. ➢ TEV-48125 targets CGRP, ➢ - SQ q month. ➢ - In clinical trials, it has been found beneficial for both episodic ➢ and chronic migraine. ➢ AMG 334 targets CGRP receptors, ➢ - SQ q month. ➢ - Statistics from clinical trials are not yet available.

CGRP Receptor Antagonists for Aborting Migraine ➢ - Molecule small enough to cross BBB ➢- blocks pain transmission to the trigeminal nerve and ➢ the surrounding blood vessels

➢ - three of these being tested currently

➢ - MK-1602 (ubrogepant) entering Phase III

➢ - potential risk is possibly affecting other organs

➢- telcagepant – liver

17 October 1, 2016

45 year old woman with headaches since age 13  Slow progression in frequency over the years but over the last 2 years complains of • - “Tolerable Headaches” on 10-15 days per month • - Mild to mod headache, mild photophobia, mild phonophobia • - Full-blown migraines on 10 days per month

• - Severe headache, photophobia, phonophobia, osmophobia, • nausea • - Complete headache freedom – rare

 Treatment

• No prophylactic • Ibuprofen - 20 days per month • Triptan - 10 days per month

What is her headache diagnosis???

1.1. Episodic Migraine

2.2. Episodic Migraine and Episodic Tension-Type 3. Headache

3. Chronic Tension-Type Headache

4. Chronic Migraine

5. Chronic Migraine with Medication Overuse

18 October 1, 2016

An Update in Headache Management Summary

• - Think MIGRAINE FIRST with most headaches • that cause disability • - Look for modifiable risk factors for chronification • of migraine: obesity, medication overuse, snoring, • depression

• - Treatment: prevention, acute medication • strategies, non-medication strategies • - Difficult cases—consider help from neurologist or • pain specialist

19 October 1, 2016

UNUSUAL DRUG POISONINGS IN PAIN MANAGEMENT

James H. Diaz, MD, MHA, MPH, DrPH,

DABA, FCCM, FACMT

LSUHSC Schools of Medicine & Public Health

[email protected]

Unusual Drug Poisonings in PM: Introduction

Editorial. AMERICAN ACADEMY OF PAIN MEDICINE PRESIDENT'S MESSAGE Pain Medicine 2015; 16: 1455–1456. doi: 10.1111/pme.12851

Bill McCarberg, MD

“These are difficult times for the pain practitioner. Long held beliefs about efficacy of interventions with a steady patient flow to our offices is being challenged by the payers including Medicare and Medicaid. Traditional medications including antidepressants, anticonvulsants, nonsteroidal anti-inflammatories show questionable benefit especially in long-term use. Physical therapy, chiropractic, massage, pool therapy is limited or poorly reimbursed. The much discussed and supported cognitive behavioral therapy and intensive, interdisciplinary pain rehabilitation is available to almost no one. And the current hot button item to the media is inappropriate prescribing of opioids with unintentional overdose deaths.”

1 October 1, 2016

Unusual Drug Poisonings in PM Outline 6. Ketamine & dextromethorphan I. Introduction & definitions 7. Butorphanol & gabapentin 1. Polysubstance dependence 8. Amphetamines & sleep drugs 2. Polysubstance abuse 9. Pentazocine & methylphenidate II. Epidemiology IV. Frequently abused non-opioids 1. Prevalence 1. Agonists-antagonists 2. Risk factors 2. OTC opioid agonists III. Polysubstance abuse 3. Amphetamines-bath salts combinations 4. Cathinones 1. Hydrocodone & carisprodol 5. Kratom 2. Clonidine & amitriptyline 6. Performance 3. Tramadol & gabapentin enhancement drugs 4. & pregabalin 7. Muscle relaxants 5. Gabapentin & buprenorphine 8. Anesthetic drugs 9. Benzos & z-drugs V. Conclusions

Unusual Drug Poisonings in PM: Definitions

Polysubstance dependence Polysubstance abuse 1. The individual is psychologically 1. The use of 3 or more groups of addicted to being in an addictive substances over a intoxicated state without a minimum period of 12 months. preference for one particular 2. The individual abuses several substance. substances in a short period of 2. Any combination of 3 drugs can be time in order to enhance the used, but alcohol is among the euphoric effects of a single drug to most common of the 3, especially achieve a more intense high. alcohol, , & heroin. 3. More common in men, ketamine 3. Others include combinations of abusers, PCP analog (3- & 4- amphetamines, methoxy-PCP) abusers, benzodiazepines, cannabis, & new psychoactive drug cathinones, hallucinogens, abusers. inhalants, & Rx opioids. 4. More common in women, Caucasians, smokers, & chronic pain patients.

2 October 1, 2016

Dx: Polysubstance Abuse-DSM-IV requires at least 3:

Tolerance: Use of increasingly Inability to stop using: Either high amounts of a substance unsuccessfully attempted to cut down or or they find the same amount stop using the drugs or a persistent less and less effective (the desire to stop. amount has to be at least 50% Time: Spending a lot of time studying more of the original amount drugs, obtaining drugs, using drugs, needed.) being under the influence of drugs, or Withdrawal: Either withdrawal recovering from the effects of drugs. symptoms when drug stops Interference with activities: Give up or being used or the drug is used reduce the amount of time involved in to prevent the unpleasant recreational activities, social/familial withdrawal symptoms. activities, and/or occupational activities Loss of control: Repeated use because of the use of drugs. of more drugs than planned or Harm to self: Continuous use of drugs use of the drugs over longer despite having a physical or periods of time than planned. psychological health problem caused by or made worse by the use of drugs.

Unusual Drug Poisonings in PM Epidemiology (Sources: NIDA, CDC)

Prevalence US, 2015 Risk factors for drug abuse 1. There were 28,000 deaths in the US 1. Any prior illicit drug or from opioid abuse in 2014. prescribed opioid abuse. 2. 10.2% of persons over age 12 used 2. Male gender for single drug any illicit drug in past month. abuse; female for 3. 2.5% of persons over age 12 used polysubstance abuse. a psychotherapeutic drug for non- medical reasons in past month. 3. One or more prior opioid, 4. 0.3-1.0% of persons over age 12 buprenorphine, methadone, or used heroin in the past month. other opioid Rx’s. 5. 19% of persons over age 12 used a 4. Family hx of opioid abuse.

non-heroin opioid in the past 5. Hx of mental illness or drug month. use-associated hepatitis. 6. Among illicit or non-prescribed 6. High levels of hopelessness & drug users, 80% abused drugs other than heroin. sensation seeking in adolescents & young adults.

3 October 1, 2016

Drug Epidemic: 1st Rx opioids & now heroin

Mechanisms of Abuse: Drug Receptor Combinations

Mu receptor GABA receptor

4 October 1, 2016

Drug Abuse Combinations 1.

Mu agonists GABA agonists All opioids Benzodiazepines All non-opioid agonists Gabapentenoids Tramadol Gabapentin Tapentadol Pregabalin All agonists-antagonists Propofol Buprenorphine Butorphanol GABA-ergic muscle relaxants Nalbuphine

Baclofen Dextromethorphan

Clonidine Carisprodol

Drug Abuse Combinations 2. Commonly encountered Less commonly encountered 1. Hydrocodone & carisprodol 1. Gabapentin & pregabalin 2. Clonidine & amitriptyline 2. Clonidine & amitriptyline 3. Tramadol & gabapentin 3. Tramadol & gabapentin 4. Tramadol & kratom 4. Tapentadol & pregabalin 5. Tapentadol & pregabalin 5. Gabapentin & buprenorphine 6. Gabapentin & buprenorphine 6. Buprenorphine/naloxone & 7. Ketamine, antihistamines, & clonidine & amitriptyline dextromethorphan 7. Butorphanol & gabapentin 8. Pregabalin & methadone 8. Ketamine & benzodiazepines 9. Methadone & benzodiazepines 10. Amphetamines & MDMA 11. Cocaine & heroin 12. Cocaine & bath salts 13. Amphetamines & sleep drugs

5 October 1, 2016

Unusual Drug Poisonings in PM Agonists & Agonist-Antagonists

Opioid and non-opioid agonists Agonists/antagonists 1. & Mechanisms of action: synthetic (antidiarrheals) drugs that are agonist at one 2. Meperidine & propoxyphene opioid receptor, either mu or (epileptogenic) kappa, & antagonist at another, usually mu; may precipitate 3. MPTP (Parkinsonism) & acute withdrawal in the opioid- pentazocine dependent. (psychomimetics) Examples: 4. Tramadol, tapentadol, & dextromethorphan 1. Butorphanol (Stadol®) (epileptogenic,  serotonin 2. Nalbuphine (Nubain®) = serotonin syndrome) 3. Buprenorphine (Subutex®) 5. Clonidine & imidazolines 4. Pentazocine (Talwin®, kappa (central alpha2 agonists) agonist & mu antagonist).

All exhibit the Opioid Toxidrome in OD

6 October 1, 2016

Special Opioids: Tramadol v. tapentadol

Tramadol (Ultram®) Tapentadol (Nucynta®) 1. A novel synthetic opioid that is 1. A synthetic opioid & centrally acting a combined mu opioid analgesic agonist that is agonist & a serotonin/NE equianalgesic with oxycodone. reuptake inhibitor; only partially antagonized by 2. Also a combined mu opioid naloxone. agonist & a NE reuptake 2. Can cause seizures in inhibitor; partially antagonized by therapeutic doses & more naloxone. often in ODs. Seizures may be 3. Not a potent central serotonin precipitated by naloxone, but reuptake inhibitor. respond to benzodiazepine suppression. 4. Avoid in opioid-dependent persons, in persons with seizure disorders & 3. Can precipitate serotonin head injuries, and in patients syndrome by blocking serotonin reuptake, especially concurrently takings serotonergic in patients on SSRIs& MAOIs. agents known to precipitate seizures and serotonin syndrome.

Tramadol abuse ↑, US, 2005-2011

7 October 1, 2016

Analgesic OD: Special Opioids Meperidine (Demerol®) Propoxyphene (Darvon®) 1. Normeperidine metabolite is 1. Both the parent drug & its neurotoxic  causing tremors, norpropoxyphene metabolite myoclonus, & seizures, have -like (Class IA) especially in patients with renal effects & cause  QRS insufficiency & the elderly. widening & dysrhythmias, that 2. Causes  presynaptic serotonin are responsive to sodium release  can precipitate the bicarbonate. serotonin syndrome 2. OD may produce acute (hyperthermia, muscle rigidity, neurotoxicity with seizures & CNS depression), especially responsive to benzodiazepines when combined with MAOIs or more so than to barbiturates. SSRIs. 3. Often formulated with 3. Tx for serotonin syndrome = acetaminophen, so suspect cooling, benzodiazepines, non- co-toxicities in OD, & monitor depolarizing muscle relaxants. serum [APAP].

The Serotonin Syndrome

8 October 1, 2016

Special Opioids Pentazocine (Talwin®) Methylphenyltetrahydropyridine 1. A synthetic agonist/antagonist (MPTP) that is agonist at the kappa &

1. A neurotoxic byproduct sigma receptors causing produced during the failed illicit dysphoria & psychomimesis, but lab synthesis of meperidine. antagonist at the mu receptor, thus producing little respiratory 2. IVDUs become “frozen depression. addicts” & develop classical Parkinsonism from selective 2. Formerly mixed with the blue destruction of dopamine- antihistamine, tripelennamine = secreting substantia nigra cells. “T’s for Talwin & Blues for tripelennamine”. 3. MPTP Parkinson’s is resistant to l-dopa tx. 3. Now mixed with the ADHD amphetamine, methylphenidate 4. MPTP is now used to induce (Ritalin®), for recreational abuse experimental Parkinsonism at all-night Rave parties in laboratory animals.

Special Opioids: Antidiarrheals

Diphenoxylate (Lomotil®) Loperamide (Immodium®) 1. Insoluble meperidine analog that delays gastric emptying, 1. An OTC insoluble coats gut, relaxes & immobilizes meperidine analog, like GI tract; used as a prescribed diphenoxylate, that also antidiarrheal. immobilizes GI tract; also used as an antidiarrheal. 2. Formulated with atropine for its antimuscarinic & antispasmodic 2. Safer than diphenoxylate effects; OD may manifest both because loperamide does anticholinergic (Mad Hatter) & not contain atropine or opioid toxidromes. delay gastric emptying, does not have a prolonged T1/2, & 3. Long T1/2 due to #1 & #2 dictates admission for lavage, is not associated with AC, & naloxone infusion. prolonged retention of pills in stomach like diphenoxylate.

9 October 1, 2016

Special Opioids: Alpha Agonists

Imidazolines (Afrin®, etc.) Clonidine (Catapress®)

1. Combined central & peripheral 1. Centrally-acting alpha2 agonist alpha2 agonists used as nasal & that produces an opioid toxidrome conjunctival decongestants (lethargy, miosis, bradycardia, & (oxymetazoline, tetrahydrozoline, respiratory depression) xylometazoline) that produce an indistinguishable from mu agonists opioid toxidrome (bradycardia, due to agonist activity overlap at hypotension, central CNS & the mu receptor. respiratory depression) 2. Used as a sympathetic blocker for indistinguishable from other mu HTN & RSD, in diabetic agonists due to agonist activity neuropathy, & to provide overlap at the mu receptor. sympatholysis during opioid 2. Partially naloxone-reversible, but withdrawal.

prolonged duration of action (4- 3. CNS & respiratory depression 8h) causes resedation. Tx OD: reversed by naloxone  Tx: admit naloxone infusion. for naloxone infusion 2° resedation.

Agonists/antagonists: Buprenorphine ± naloxone

1. Buprenorphine exhibits its highest 1. Suboxone® (buprenorphine + binding affinities for the mu- and naloxone) abuse has been kappa-opioid receptors with partial reported po; however, the agonism at the mu-receptor, partial combination of buprenorphine & to full agonism at the delta-opioid naloxone in sublingual strips receptor & the receptor, appears to be an effective way to & competitive antagonism at the continue opioid substitution kappa-opioid receptor. therapy (OST) & to reduce the 2. Constipation and CNS effects are possibility of illicit sale or abuse less frequent with buprenorphine of oral buprenorphine & oral than with morphine & other opioids. buprenorphine + naloxone. 3. Buprenorphine exhibits a ceiling 2. OST with Suboxone® strips is a effect for respiratory depression long-term treatment that should as a result of its partial agonism not pose a substantial risk with at the mu-receptor. continuous monitoring by a substance abuse professional.

10 October 1, 2016

Analgesic OD Tx: Opioid OD

Acute OD management Naloxone infusion

1. Low initial iv naloxone 1. If diagnostic naloxone boluses (0.1-0.4 mg), rather bolus is successful, than a single, large administer 2/3 of the initial therapeutic bolus (2 mg) to dose iv per hour. avoid precipitating acute withdrawal in addicts or 2. If withdrawal develops, causing non-cardiogenic stop the infusion to let pulmonary edema. symptoms abate & restart at 1/2 rate. 2. Aim is to reverse respiratory depression & restore RR > 8. 3. If respiratory depression recurs during infusion, re- 3. Intubate & ventilate if administer 1/2 the initial respiratory depression bolus, & increase infusion persists, administer 10 mg rate by 1/2. naloxone iv-no infusion, just prolonged mechanical ventilation.

Special Opioids: OTC

Dextromethorphan (Robitussin®) OTC opioid agonist abuse 1. An OTC synthetic opioid agonist with no analgesic activity used for cough suppression, like codeine. 2. In OD, causes miosis, CNS depression; & choreoathetosis & dystonia 2°  serotonin release. Also acts as a sigma agonist & can cause a PCP-like psychosis. 3. Formulated as a hydrobromide salt  bromism, CNS depression, ataxia, confusion, coma, & bromoderma acne. 4. Can precipitate serotonin syndrome, like meperidine, by  presynaptic release of serotonin.

11 October 1, 2016

OTC Drug Abuse: Dextromethorphan

DXM Chem: opioid analog, a DXM “ heads” SSRI, NMDA antagonist like ketamine, sigma agonist like PCP.

Street names: robo, robo- tripper, robotards, triple C (Coricidin D®), purple drank, syrup heads. Methods: ingestion > iv Clin: dissociative = an “out of body experience” with euphoria, vivid imagination, psychosis, hallucinations.

Non-opioid Rx drug abuse: Performance Enhancement

Performance enhancement: Miscellaneous prescription drug abuse (usually by athletes & sports figures):

1. Anabolic steroids: abused by weight-lifters, baseball players, other athletes. Street names include roids, juice, gym candy, pumpers.

2. Beta-agonists: all MDI beta-agonist bronchodilators have been abused to enhance performance by cyclists, runners. Ex. albuterol (Proventil®), etc.

3. Erythropoietin: abused to increase oxygen carrying capacity & stamina. Available as Epogen®, or epo.

4. Muscle relaxants: baclofen, carisprodol, methocarbamol, , tizanidine.

12 October 1, 2016

Prescription drug (Rx) abuse: Muscle relaxants Generic name Trade MOA AEs Comments

Baclofen Lioresal® GABA-A > Bradycardia Combined with alcohol GABA-B Arrhythmia Withdrawal effects: anxiety, agonism, A Seizures hallucinations, twitching, dominant Cogwheel DTs, insomnia, rigidity disorientation, & ataxia. Carisprodol Soma® Mepro- Somnolence Combined with hydrocodone bamate Euphoria Withdrawal effects: DTs = prodrug Dysphoria status epilepticus GABA-A Anxiety-depression, agonism insomnia Methocarbamol Robaxin® NMDA Ataxia No withdrawal syndrome antagonism Brady- Euphoria-dysphoria, like BZs tachycardia Probably the safest Skin rash prescribed oral MR Fever & jaundice Orphenadrine Norflex® Anti- Mad Hatter No withdrawal syndrome histamine & syndrome Euphoria, Mad Hatter syn. cholinergic ↑ IOP (A. muscaria mushroom-like)

Tizanidine Zanaflex® α2- Opioid syndrome Combined with alcohol adrenergic = fatal respiratory No withdrawal syndrome agonist depression Potent CYP1A2 inhibitor (avoid quinolones)

Drug Abuse: Amphetamines Outline

1. Amphetamine pharmacology & abuse

2. Prescription v. designer v. international amphetamines & their uses & abuses

3. Acute v. chronic amphetamine toxicity

4. Management of amphetamine toxicity

13 October 1, 2016

Drug Abuse: Amphetamines All start with ephedrine. Pseudoephedrine: all ephedrine-containing drugs can be used to make illicit methamphetamines (MDMA & others) in small meth labs, including all decongestants and antihistamines + decongestants-Sudafed®, Claritin D®, Zyrtec D®, Allegra D®. Bruxism = “meth mouth”.

Amphetamine Abuse Pharmacology Mech: (1) direct release of , particularly catecholamines Amphetamine abuse serotonin, NE & dopa, from 1. Prescription: used for ADHD, presynaptic terminals; (2) narcolepsy, & weight loss. competitive inhibition of catechol 2. Illicit: pure methamphetamine (ice, reuptake at adrenergic terminals; speed)-most common illicit drug (3) 5-HT release at higher doses. produced by clandestine drug labs, NE effects:  & -adrenergic 1° ingredient = ephedrine, adulterants stimulation produce anorexia & = Pb & Hg alerting effects. 3. Designer amphetamines: MDMA (Ecstasy, claity, lover’s speed, Adam), 5-HT effects: altered perception & Molly (pure MDMA) & MDEA (Eve) psychosis. 4. International sympathomimetics: (1) Met: lipid-soluble, high Vd,  T1/2 & khat: active agent = cathinone, active metabolites, no COMT Arabia & East Africa (Somalia) = biodegradation, massive euphoria, alertness, anxiety, vasopressin release = hyperactivity; (2) ma-huang: Chinese hyponatremia. ephedrine used as a bronchodilator for asthmatics & COPD.

14 October 1, 2016

Amphetamines: Rx v. Designer

Prescription amphetamines Designer amphetamines 1. ADHD & narcolepsy: d-l- All are potent serotonin releasers; racemic amphetamines, popular at all-night Rave Parties, dextroamphetamine; rock concerts. methylphenidate (Ritalin®), 1. Pure methamphetamine = ice popular drug for ADHD, is a or speed. 2. Dimethoxyamphetamine = phenylethylamine, not an DOM or STP. amphetamine, similar MoA. 3. Methylene dioxyamphetamine 2. Weight reduction: = MDA, love drug. 4. Methylene amphetamine, dioxymethamphetamine = dexfenfluramine, MDMA-Molly, Ecstasy, or phentermine, Adam. fenfluramine (phen-fen: 5. Methylene dioxyethamphetamine = MDEA, withdrawn by FDA). Eve.

Amphetamines: “Have you seen Molly?”

Pharmacology Mech: (1) pure MDMA that is not “Have you seen Molly?” adulterated with ephedrine, Madonna 2012 cathinones (bath salts), caffeine, marijuana, dextromethorphan (Robitussin), ketamine, or cocaine; (2) 5-HT release predominates. 5-HT effects: altered perception with social disinhibition, euphoria, psychosis, sexual arousal; followed by anxiety, depression, insomnia. NE effects:  & -adrenergic stimulation produce alertness, anorexia, increased HR & BP-fatal dysrhythmias, sweating, hyperthermia, teeth clenching = bruxism, seizures, rhabdomyolysis. Met: massive vasopressin release = hyponatremia + seizures.

15 October 1, 2016

Drug Abuse: Amphetamines Acute v. Chronic Toxicity

Acute toxicity Chronic toxicity CNS > CV > Pulm CV & pulmonary: catecholamine- induced dilated & valvular CNS: mydriasis, anorexia, cardiomyopathies, mitral euphoria, psychosis, regurgitation (phen-fen), hyperthermia  diaphoresis, pulmonary hypertension (phen-  HA, agitation-hyperactivity fen), necrotizing vasculitis  tremor, seizures  muscle ischemic colitis, permanent rigidity  choreoathetosis  dopaminergic & serotonergic rhabdomyolysis  neurotransmitter depletion myoglobinuria  ATN-ARF. encephalopathy.

CV: hypertension, tachycardia, Labs: hyperglycemia, tachydysrhythmias, vasospasm, leukocytosis,  LFTs,  CPK  angina, & MI. myoglobinuria. Pulm: tachypnea, pulmonary vasoconstriction & HTN.

Drug Abuse: Amphetamines Chronic Toxicity

Phen-fen: 3D-echo) Phen-fen: Color flow Doppler Valvular cardiomyopathy echo Mitral regurgitation

16 October 1, 2016

Drug Abuse: Amphetamines Chronic Toxicity Ruptured mitral valve

Diet therapy with phentermine-fenfluramine

Drug Abuse: Amphetamines OD Management

Specific treatment General management 1. Agitation & restlessness: BZs, 1. Restrain & sedate with BZs. iv diazepam. 2. Rapid external cooling with ice 2. Seizures: BZs > barbiturates. water baths. 3. Hyperthermia: sedation + 3. AC for recent oral ingestions. external cooling. 4. Administer coma cocktail, 4. Oral ingestions: AC + sorbitol,

without naloxone: 1 g/kg D50W both 1 g/kg. + thiamine 100 mg iv. 5. HTN: initially sedate with BZs,   5. Avoid all neuroleptics consider peripheral  temp, seizure threshold, vasodilators for ease of dystonia & choreoathetosis titration-phentolamine, with neuroleptic malignant nitroglycerin, & sodium syndrome, may precipitate nitroprusside. tachydysrhythmias. 6. Monitor for rhabdomyolysis.

17 October 1, 2016

What are Bath salts are amphetamine-like synthetic cathinone , “Bath salts”? primarily methylenedioxy- of “bath pyrovalerone (MDPV) with 4x the salts” potency of methylphenidate (Ritalin®, Concerta®); sold in gas stations & convenience stores as “bath salts” for recreational abuse by ingestion, insufflation, rectal & iv use. They cause a sympathetic toxidrome characterized by hallucinations, paranoia, & self- mutilation, often complicated by HTN & angina. MoA: inhibit reuptake of serotonin, dopamine, & norepinephrine. Street names: Ivory Snow, Ivory Wave, Bolivian Bath, Bliss, Purple Wave, Super Coke, Peeve, Magic.

Synthetic cannabis

Synthetic cannabis products are designer drugs sold in gas stations, K2 & Spice = synthetic cannabis head & smoke shops as herbal incense that are combinations of synthetic THCs (cannabicyclohexanol most commonly) & herbs (spice). When abused by smoking, spice mimics the effects of synthetic THCs & can cause chronic psychotic disorders, especially in susceptible individuals with family histories of mental illness. Metabolites can be detected in urine, but not with NIDA 5 screens. Street names: K2, Spice, Spice Gold, Kronic (Australia)

18 October 1, 2016

Natural cathinone (khat)

Synthetic cathinones’ parent compound, cathinone (khat), Khat suppresses appetite and its active metabolite, during Ethiopian famine. cathine, have been used as amphetamine-like euphoric stimulants & appetite suppressants for centuries, especially in the horn of Africa

(Ethiopia & Somalia; Khat is now sold illegally Blackhawk Down) and in throughout Europe. Yemen. In 2006, there were approximately 10 million chronic khat users worldwide. Khat users chew on the twigs or leaves of the khat plant, Catha edulis.

The Synthetic Cathinones

19 October 1, 2016

What is Flakka?

• “Flakka” is a synthetic cathinone that has emerged in south Florida and has spread to other areas in the US • Its chemical nomenclature is alpha- pyrrolidinopentiophenone (alpha-PVP). • It is a pink or white crystalline substance that can be ingested, smoked, snorted, injected, or vaporized. • It is often dispensed as “flakes” on sticky candy, hence its name “flakka”.

What are the effects of Flakka?

• The effects of Flakka are similar to other cathinones. • “Excited delirium” • Hyperstimulation • Paranoia • Intense hallucinations • Bizarre behavior including disrobing and streaking • Violent aggression • Adrenaline-fueled increases in strength, speed, and stamina • Often requires many police officers to subdue a Flakka user • Psychosis • Increased body temperature, heart rate, and blood pressure

20 October 1, 2016

What are the dangers of Flakka use?

• Addiction

• Extreme Violence

• Self-mutilation

• Kidney damage caused by increased temperature (rhabdomyolysis)

• Death • Suicide • Heart attack • Stroke • Kidney failure

What is kratom?? Is its use legal?? Kratom or “Krypton” (aka Thom, Ketum) is a legal Korth unregulated pulverized plant derived from Mitragyna speciosa Korth, a SE Asian tree that contains the plant alkaloid , which is similar to yohimbine & 13 times more potent than morphine. Smoked, ingested in capsules, or brewed into teas for chronic pain or opioid withdrawal; & combined with opioids, EtOH, & benzos for stimulant effects.

21 October 1, 2016

What are the effects & risks of kratom Kratom exposure calls to US use/abuse? PCCs, 2010-15 (Source: CDC) At low doses, kratom produces stimulant effects (analgesia, relaxation), but at higher doses opioid effects predominate with agitation alternating with somnolence, miosis, HTN, hypoventilation, psychosis progressing to seizures, death. The powder Krypton is mixed with tramadol (Ultram®), paroxetine, & lamotrigine & has caused several deaths.

Drug Abuse Anesthetic Drug Abuse

1. Nitrous oxide

2. Ketamine (cat Valium, special K, vitamin K)

3. Propofol (milk of amnesia)

4. Neuropathic pain drugs (anticonvulsants: gabapentin & pregabalin abuse)

22 October 1, 2016

Inhalant Abuse Nitrous oxide 2. Demi Moore: a repeated nitrous oxide abuser. Use: N2O is a colorless, non- flammable, sweet-smelling greenhouse gas used as an analgesic & induction anesthetic; & as a propellant for spray cans & race cars. It is abused for its euphoric effects. Chem: oxidizes dietary B12, a cofactor methionine (myelin component) & tetrahyrdofolate (DNA precursor) synthesis. Path: toxic B12 deficiency = subacute combined degeneration of dorsal columns & LMNs = chronic myeloneuropathy + megaloblastic non-pernicious anemia.

Inhalant Abuse Nitrous oxide 3.

Street names: laughing/sweet gas, Demi Moore was hospitalized for wank, whip-it, whippets, N20 abuse, Lennox Hill, 01/2012. whip , cream, nossies. High risk for abuse: medical personnel, adolescents, celebrities. Negative drug screens, no needle marks, difficult to diagnose. Clin: glove & stocking sensory loss, especially vibratory, but sparing most motor function, pain & temp sensation. Targets dorsal columns; ataxic, poor tandem gait, + Romberg sign. Dx: NCT, ↑↓B12 , ↑↑MMA & homocysteine. Tx: B12 iv, im, & po.

23 October 1, 2016

Anesthetic Drug Abuse: What is Propofol? Propofol is an alkylphenol Why “milk of amnesia”? derivative, 2,6- diisopropyl-phenol, marketed initially by AstraZeneca as Diprivan® (Diisopropyl iv anesthetic) & FDA-approved (1989) for use as a short-acting iv hypnotic-sedative for induction of GA, procedural sedation, & sedation for mechanical ventilation in an ICU .

Anesthetic Drug Abuse: Propofol Chemistry Due to its water insolubility, 1% “Milk of amnesia” propofol is formulated in a liquid of 10% soybean oil, 1.2% purified egg whites, 2.25% glycerol, with NaOH to alkalinize (causes ↑ pain on injection) & 1 of the following preservatives : EDTA, benzyl alcohol*, or Na metabisulfite**, depending on the drug manufacturer. The color is glistening opaque white due to light scatter by oil droplets of soybean & egg phospholipids = “milk of amnesia”. * “Gasping Baby” Syndrome in neonates. ** Allergic reactions to sulfites.

24 October 1, 2016

Propofol’s MoA? Propofol’s mechanisms of Like other sedative-hypnotics, action as a are unknown but propofol is a GABAA agonist. GABA inhibits CNS electrical may include: transmission in the CNS. 1. Direct activation of CNS GABAA receptors, ↓ channel closing time. 2. Inhibition of NMDA receptors. 3. Modulation of calcium influx through slow calcium-ion channels.

4. CNS sodium channel blockade?

Propofol Abuse

The recreational use & abuse of propofol has been increasing among medical personnel & insomniacs Michael Jackson (1958-2009) primarily for the following reasons (Charatan F, BMJ, 2009):

1. Propofol is not scheduled as Class IV by the FDA & is undetected by urine tox screens. 2. Propofol activates cannabinoid receptors & causes euphoria highs disinhibition, & hallucinations. 3. Propofol induces short & deep restful sleep in night shift workers & insomniacs. Long-term use is addictive.

4 deaths have now been reported from propofol self- administration (Kranioti EF, et al. Forensic Sci Intl 2005).

25 October 1, 2016

Propofol: The Michael Jackson Case On June 25, 2009, Dr. Conrad Murray administered 25 mg (2.5 mL) of propofol diluted in 1% lidocaine to Michael Jackson at his home, Neverland, in Beverly Hills, CA. In August 2009, the LA Coroner concluded that Michael Jackson died from respiratory arrest from a mixture of propofol and 2 benzodiazepines, (1) iv lorazepam on top of (2) po diazepam ingested earlier. On November 7, 2011, jurors found Dr. Conrad Murray guilty of involuntary manslaughter, and he was sentenced to 4 years in the LA County jail on November 29, 2011.

Death by Propofol

1. Prevalence: Over a 10-yr. period, 29 abuse cases with 6 IV propofol deaths in anesthesia residents abuse were reported in a survey study of all 126 US anesthesiology training programs. Surviving abusers = MD-Anesthesiologists(n = 6), Nurse Anesthetists-NAs (n = 3), Anesthesia Technicians (n = 2), Operating Room Nurses- ORNs (n = 2). 2. Reference: Wischmeyer PE et al. Anesth Analg 2007.

26 October 1, 2016

Deaths by propofol N Age in years Males: Females Propofol blood levels (mean ± SD) (ratios) in µg/mL (± SD) Accidental deaths 6 33 ± 9.6 4:2 (2:1) 1.52 ± 2.1 Suicides 2 33 ± 5.5 1:1 (1:1) 1.36 ± 1.6 Homicides 1 24 1 F 4.3 Intentional deaths 3 30 ± 6.6 1:2 (1:2) 2.34 ± 2.1 = Suicides + Homicides t-test values NA 0.482 NA 6.93 (unintentional v. intentional deaths) p-values NA 0.644 NA < 0.0001* (unintentional v. (no sig. (accidental cases used intentional deaths) differences in therapeutic doses of ages) 2.0-2.5 mg/kg v. massive ODs in intentional deaths)

Anticonvulsant Abuse: Gabapentin v. pregabalin

• Pregabalin (Lyrica®) Gabapentin (Neurontin®) 1. Pregabalin is a 3- 1. Gabapentin modulates the action • isobutyl derivative of the inhibitory of glutamate decarboxylase (GAD) neurotransmitter γ- aminobutyric and branched chain acid (GABA) that functions as a aminotransferase (BCAT), two calcium . enzymes involved in the 2. Potent and a close biosynthesis of GABA. structural analogue of GABA, 2. In human and rat studies, gabapentin gabapentin, , & was found to increase GABA baclofen. biosynthesis, but not bind GABA 3. Pregabalin has potential to be receptors. misused and abuse of the drug may 3. Gabapentin shares characteristics of lead to physical and psychological GABA-ergic medications associated dependence; it is a Schedule V drug. with misuse and addiction, in that it produces a withdrawal syndrome and certain psychoactive effects; it is unscheduled.

27 October 1, 2016

Insomnia drug abuse: Outline Benzodiazepines (BZs) are abused by insomniacs & often combined with mu opioid receptor agonists & amphetamines. The oral BZs & non-BZ agonists (Z- drugs) prescribed for sleep are most frequently abused. These are classified as follows:

1. Benzodiazepine agonists, immediate release

2. Nonbenzodiazepine agonists, immediate release

3. Nonbenzodiazepine, alternate delivery

4. Dual orexin receptor antagonist

5. Melatonin receptor agonist

6. Histamine 1 receptor agonist

Benzodiazepine agonists: Immediate release Generic (Brand) Name Indications Most Common Side Effects

Benzodiazepine Immediate Release Flurazepam (Dalmane) Treatment of insomnia characterized Dizziness, drowsiness, by difficulty in falling asleep, frequent lightheadedness, staggering, loss of nocturnal awakenings, and/or early coordination, falling morning awakening Temazepam (Restoril) Short-term treatment of insomnia Drowsiness, dizziness, lightheadedness, difficulty with coordination Triazolam (Halcion) “Short-term treatment of insomnia Drowsiness, headache, dizziness, lightheadedness, “pins and needles” feelings on your skin, difficulty with coordination Quazepam (Doral) “Treatment of insomnia characterized Drowsiness, headache by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings

Estazolam (ProSom) Short-term management of insomnia Somnolence, hypokinesia, dizziness, characterized by difficulty in falling abnormal coordination asleep, frequent nocturnal awakenings, and/or early morning awakenings; administered at bedtime improved sleep induction and sleep maintenance

28 October 1, 2016

Nonbenzodiazepine agonists: Immediate & ER Nonbenzodiazepine Immediate Release

Zolpidem (Ambien) Short-term treatment of insomnia Drowsiness, dizziness, diarrhea, characterized by difficulties with drugged feelings sleep initiation

Zaleplon (Sonata) Short-term treatment of insomnia; Drowsiness, lightheadedness, shown to decrease the time to dizziness, “pins and needles” sleep onset” feeling on your skin, difficulty with coordination

Eszopiclone (Lunesta) Treatment of insomnia; Unpleasant taste in mouth, dry administered at bedtime mouth, drowsiness, dizziness, decreased sleep latency and headache, symptoms of the improved sleep maintenance common cold

Nonbenzodiazepine Extended Release

Zolpidem ER (Ambien CR) Treatment of insomnia Headache, sleepiness, dizziness characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset)

Nonbenzodiazepine alternate delivery & dual orexin receptor antagonist Nonbenzodiazepine Alternate Delivery Zolpidem Oral spray (ZolpiMist) Short-term treatment of insomnia Drowsiness, dizziness, diarrhea, characterized by difficulties with sleep drugged feelings initiation Zolpidem Sublingual (Edluar) Short-term treatment of insomnia Drowsiness, dizziness, diarrhea, characterized by difficulties with sleep drugged feelings initiation Zolpidem Sublingual (Intermezzo) For use as needed for the treatment of Headache, nausea, fatigue insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Not indicated …when the patient has fewer than 4 hours of bedtime remaining before the planned time of waking Dual Orexin Receptor Antagonist Suvorexant Suvorexant is the first in a new class of Like other sleep medicines, there is a risk (Belsomra) drugs, orexin receptor antagonists from suvorexant of sleep-driving and (ORAs), in development for the treatment other involuntary, complex behaviors of insomnia. The tablets promote the while not being fully awake, such as natural transition from wakefulness to preparing and eating food, making sleep by inhibiting the wakefulness- phone calls, or having conversations. promoting orexin neurons of the arousal Although sleep driving has not been system. Suvorexant improves sleep reported with suvorexant, other onset and sleep maintenance. This observed adverse effects have included unique alternative has a favorable weird dreams, sleep walking, and muscle tolerability and limited side-effect profile. weakness.

29 October 1, 2016

Melatonin receptor agonist & Histamine 1 receptor agonist Selective Melatonin Receptor Agonist

Ramelteon (Rozerem) Treatment of insomnia Drowsiness, tiredness, characterized by difficulty dizziness with sleep onset

Selective Histamine H1 Receptor Antagonist

Doxepin (Silenor) Treatment of insomnia Somnolence/sedation, characterized by difficulties nausea, upper respiratory with sleep maintenance tract infection

Conclusions

Identify risk factors Suspect mu + GABA combinations 1. Hydrocodone & carisprodol 1. Any prior illicit drug or prescribed 2. Clonidine & amitriptyline opioid abuse. 3. Tramadol & gabapentin 2. Male gender for single drug abuse; female for polysubstance 4. Tapentadol & pregabalin abuse. 5. Gabapentin & buprenorphine 3. One or more prior opioid, 6. Ketamine & dextromethorphan buprenorphine, or opioid Rx’s. 7. Pregabalin & methadone 4. Family hx of opioid abuse. 8. Methadone & benzodiazepines 5. Hx of mental illness or hepatitis. 9. Hydrocodone & benzodiazepines 6. High levels of hopelessness & 10. Amphetamines & benzodiazepines sensation seeking in adolescence & young adults. 11. Cocaine & heroin 12. Cocaine & bath salts

30 October 1, 2016

References 1. Fong C, Matusow H, Cleland CM, Rosenblum A. characteristics of non-opioid substance abusers among patients enrolling in opioid treatment programs: A latent class analysis. J Addict Dis 2015. 2. Rice JB, White AG, Birnbaum HG, et al. A model to identify patients at risk for prescription opioid abuse, dependence, and misuse. Pain Med 2012. 3. Gahr M, Freudenmann RW, Eller J, Schonfeldt-Lecuona C. Abuse liability of centrally acting non- opioid analgesics and muscle relaxants—A brief update on a comparison of pharmacovigilance data and evidence from the literature. Int J Neuropsychopharm 2014. 4. Malmberg M, Overbeek G, Monshouwer K, et al. Substance use risk profiles and associations with early substance use in adolescence. J Behav Med 2010. 5. Gahr M, Freudenmann RW, Hiemke C, et al. Pregabalin abuse in Germany: Results from a database query. Eur J Clin Pharmacol 2013. 6. Seale JP, Dittmer T, Sigman EJ, et al. Combined abuse of clonidine and amitriptyline in a patient on buprenorphine treatment. J Addict Med 2014. 7. Romanelli F, Smith KM. Dextromethorphan abuse: Clinical effects and management. J Am Pharm Assoc 2009. 8. Liang HJ, Lau CG, Tang A, et al. Cognitive impairments in poly-drug ketamine users. Addict Behav 2013. 9. Backberg M, Beck O, Helander A. analog use in Sweden—Intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA Project. Clin Toxicol 2015. 10. Nasti JJ, Brakoulias. Chronic baclofen abuse and withdrawal delirium. J Royal Austral New Zealand College Psychiatrists 2011. 11. Perry HE, Wright RO, Shannon MW, Woolf AD. Baclofen overdose: Drug experimentation in a group of adolescents. Pediatrics 1998. 12. Weibhaar GF, Hoemberg M, Bender K, et al. Baclofen intoxication: A “fun drug” causing deep coma and nonconvulsive status epilepticus—A case report and review of the literature. Eur J Pediatr 2012. 13. Reeves RR, Burke RS. Carisprodol: Abuse potential and withdrawal syndrome. Curr Drug Abuse Rev 2010.

31 3:15 – 4:00 pm – Implications of the CDC Opioid Guidelines: A View From a Seat at the Table Sanford M. Silverman, MD Saturday, October 1, 2016 No Handout NOTES

October 1, 2016

Medical Marijuana Programs in the South

Southern Pain Society presents Pain Management: Are We Doing Anything Right? Cecilia Mouton, M.D., Louisiana State Board of Medical Examiners Mordecai Potash, M.D., Tulane University SOM, Louisiana State University HSC Saturday, October 1st, 2016 – 4-4:45PM

Objectives

 Review the rapidly changing landscape of state marijuana laws.  Examine just enacted regulations for medical marijuana in several Southern states.  Focus on state-by-state requirements for:  Type of medical marijuana products Charlotte’s allowed Web – a Florida  Qualifying conditions treated produced CBD oil  Training required for participating  Dispensing and monitoring of medical marijuana treatments  Inquire into Louisiana’s own emerging multi-agency medical marijuana program.

1 October 1, 2016

25 States and Counting…

Jurisdiction with legalized cannabis. Jurisdiction with legal non-psychoactive medical cannabis. Jurisdiction with both medical & decriminalization laws. Jurisdiction with decriminalized cannabis possession laws. Jurisdiction with legal psychoactive medical cannabis. Jurisdiction with cannabis prohibition.

What the Heck Did That Big Teal Map Mean?

 Alaska, Washington, Oregon and Colorado have legalized recreational and medical cannabis.

 California, Connecticut, Washington D.C., Maryland, Massachusetts, Michigan (somewhat) Pennsylvania (somewhat), and Vermont have decriminalized recreational marijuana possession and also have robust medical marijuana provisions.

 Arizona, Connecticut, Delaware, Hawaii, Illinois, Maine, Minnesota, Montana Nevada, New Hampshire, New Jersey, New Mexico, New York, and Rhode Island have established – but still relatively newly started - medical marijuana programs.

 Alabama, Florida, Georgia, Iowa, Louisiana, Mississippi, Missouri, North Carolina, Ohio, Oklahoma, South Carolina, Tennessee, Texas, Utah Virginia, & Wisconsin have newly approved medical marijuana legislation that are still taking shape into actual state programs.

 Arkansas, Idaho, Indiana, Kentucky, North Dakota, South Dakota have no provisions for either recreational or medical marijuana. But, even in these states, ballot initiatives are often being pursued by motivated state organizers.

2 October 1, 2016

What the Heck Did That Big Teal Map Mean?

 Alaska, Washington, Oregon and Colorado have legalized recreational and medical cannabis.

 California, Connecticut, Washington D.C., Maryland, Massachusetts, Michigan (somewhat) Pennsylvania (somewhat), and Vermont have decriminalized recreational marijuana possession and also have robust medical marijuana provisions.

 Arizona, Connecticut, Delaware, Hawaii, Illinois, Maine, Minnesota, Montana Nevada, New Hampshire, New Jersey, New Mexico, New York, and Rhode Island have established – but still relatively newly started - medical marijuana programs.

 Alabama, Florida, Georgia, Iowa, Louisiana, Mississippi, Missouri, North Carolina, Ohio, Oklahoma, South Carolina, Tennessee, Texas, Utah Virginia, & Wisconsin have newly approved medical marijuana legislation that are still taking shape into actual state programs.

Where most of the South finds itself presently

A Growing Hodgepodge of State Medical Marijuana Programs

Each state’s program has differences on many different issues including: Licensing required to prescribe or recommend marijuana Licenses required to dispense marijuana Patients allowed per caregiver Qualifying conditions treated with marijuana Required length of MD-Patient relationship Costs to patient

From SA Chapman et al. Capturing Heterogeneity in Medical Marijuana Policies: A Taxonomy of Regulatory Regimes Across the United States. Substance Use & Misuse Vol. 51, No. 9 Pages 1174-1184

3 October 1, 2016

Medical Marijuana Programs in the South  Nearly every state in the South has started a medical marijuana program within the past four years – with most legislation passed within the last two years.  That means that Southern states are building their medical marijuana programs right now – most of them not dispensing cannabis yet but building the infrastructure to do so.  Each Southern state is wrestling with similar thorny questions and trying to answer those questions based on the political landscape of their own state as well as learning from the experiences of “early state adopters” of medical marijuana such as Alaska, California, Oregon, and Washington state:  Who prescribes / recommends medical marijuana?  For which qualifying conditions?  How is the cannabis product made and dispensed?  Are the costs of production passed on to the purchaser or through other means?  How are records kept and who has access for those records?  And about a million other questions with each state coming up with their own unique solutions.

Texas

 Texas political observers were “stunned when both chambers passed Senate Bill 339 and Gov. Greg Abbott signed it into law” 1.

 Named The Texas Compassionate Use Act, it allows a Texas licensed physician to prescribe low-THC cannabis for patient suffering from Intractable Epilepsy.

 Low-THC cannabis is defined as not more than 0.5 percent by weight of and not less than 10 percent by weight of .

 Intractable Epilepsy is defined as a seizure disorder in which the patient's seizures have been treated by two or more appropriately chosen and maximally titrated antiepileptic drugs.

 The Texas Department of Public Safety hasn’t completed the process to permit the CBD businesses to start – anticipating the first permit to be granted in June 2017.

 Already, many advocates in Texas are pushing for the legislature to broaden both the conditions treated and potency of cannabis dispensed.

 Opponents state that this is foolish given that the 2015 legislation has not even been enacted yet!

1. Tim Eaton. Texas might be ready to expand medical marijuana use. Austin American-Statesman, 06/16/2016

4 October 1, 2016

Arkansas

 There is no medical marijuana law enacted in Arkansas.

 However, there are THREE petitions for ballot initiatives being circulated in the state right now2.

 These initiatives – if put on the ballot – would be voted upon in the November 2016 election.

 One of these initiatives have already received enough signatures to be put on the ballot with supporters of the Arkansas Medical Cannabis Act submitted more than 117,000 signatures to Arkansas Secretary of State Mark Martin on 06/20/2016.

 Interestingly, the supporters of the Arkansas Medical Cannabis Act do not want the other two ballot initiatives to also be on November’s ballot.

 They are worried that the confusion generated by three simultaneous ballot initiatives will lead many voters to vote “No” for all three.

 Arkansans for Compassionate Care have drafted one of the other proposals & have collected 85,000 signatures. Their proposal would set up 38 non-profit dispensaries regulated by the Dept. of Health.

2. John Moritz. Medical marijuana backers submit signatures to get proposal on Arkansas ballot. Arkansas Democrat-Gazette, 06/20/2016

Mississippi

 On April 17th, 2014, Mississippi Governor Phil Bryant signed House Bill 1231 "Harper Grace's Law," which allows for cannabis extract, oil, or resin that contains more than 15% CBD and less than 0.5% THC to treat debilitating epileptic conditions or related illnesses3.

 It allows for treatment of both children and adults. But the patient or patient's parent/guardian must execute a “hold-harmless agreement” with the state regarding all aspects of cultivation, processing, dispensing, prescribing or administration of CBD oil.

 The CBD oil must be obtained from or tested by the National Center for Natural Products Research (NCNPR) at the University of Mississippi and dispensed by the Department of Pharmacy Services at the University of Mississippi Medical Center.

 NCNPR has long been the sole supplier of cannabis for the federal National Institute on Drug Abuse’s (NIDA) research program on marijuana / cannabis products4. NCNPR is closely working in conjunction with with NIDA and the FDA to create a CBD oil research trial for qualified Mississippi patients – but trial has not started yet.

3.MISSISSIPPI LEGISLATURE REGULAR SESSION 2014. HOUSE BILL NO 1231 By Representatives Mims, Baria, Carpenter , Section 3, Lines 443-507. Accessed at http://index.ls.state.ms.us/2014Session.html 4. Evan Halper. Mississippi, home to federal government's official stash of marijuana. Los Angeles Times, 05/28/2014

5 October 1, 2016

Alabama

 On April 1st, 2014, Alabama Governor Robert Bentley signed Senate Bill 174, known as "Carly's Law" which allowed licensed Alabama physicians to recommend CBD oil by referring patients with debilitating epileptic conditions to the University of Alabama Division of Epilepsy5.

 That program has been established and is actively treating patients. It is supervised by Jerzy Szaflarski, M.D., Professor of Neurology and director of the Division of Epilepsy at the University of Alabama.

 Dr. Szaflarski is carefully evaluating referred patients with most enrolled patients suffering from ‘catastrophic epilepsy’ - having at least 100 seizures a month and have failed many types of epilepsy treatments including brain surgeries6.

 Initial results of the UAB study are promising and helped to encourage the Alabama legislature to pass “Leni’s Law” in April 2016. This law expands access to the CBD oil and also clarified some of the regulations from Carly’s Law7.

5.Alabama Senate Bill 174 "Carly's Law" authored by Senator Sanford. Accessed at URL http://medicalmarijuana.procon.org/sourcefiles/Alabama-2014-SB174-Enrolled.pdf 6. Martin Reed. Carly's Law patients start receiving marijuana-derived CBD oil to treat seizures. AL.com, 04/08/2015 7. Mike Cason. Alabama Legislature approves Leni's Law to decriminalize cannabis derivative. AL.com, 04/27/2016

Georgia

 On April 16, 2015, Georgia Governor Nathan Deal signed House Bill 1 “Haleigh's Hope Act” into law allowing the use of cannabis oil for specific medical conditions including seizure disorders, sickle cell anemia, cancer, Crohn's disease, ALS (Lou Gehrig's disease), multiple sclerosis, mitochondrial diseases and Parkinson's disease8.

 Potential participants have to be referred by a Georgia licensed physician in an on-going treatment relationship with the participant that includes quarterly documentation of treatment response.

 The production of the CBD oil is supervised by the University of Georgia. Participants are limited to a concentration no more than 5% and an amount no more than 20 fluid ounces. Participants are issued a registration card by the Georgia Dept of Public Health.

 Georgia parents of children with autism have been urging lawmakers to expand qualifying diagnoses to include autistic disorders, but this has not been approved the Georgia Commission on Medical Cannabis – a board with physician, pharmacy, law enforcement, & political repr.

8.Georgia House Bill 1 “Haleigh’s Hoep Act" authored by Rep. Peake & others. Accessed at URL http://medicalmarijuana.procon.org/sourcefiles/georgia-hb-1-enacted.pdf 9.Mike Brunker. 'No-Buzz' Medical Pot Laws Prove Problematic for Patients, Lawmakers. NBC News, published April 24 2016, Accessed at http://www.nbcnews.com/storyline/legal-pot/no-buzz-medical-pot-laws-prove- problematic-patients-lawmakers-n556196

6 October 1, 2016

Florida

 On June 16, 2014, Florida Governor Rick Scott signed Senate Bill 1030 into law – “The Compassionate Medical Cannabis Act of 2014”.

 It allows the use of non-smoked cannabis oil that is less than 0.8% THC and more than 10% cannabidiol for qualified participants with cancer, chronic seizures, or severe muscle spasms. This approved CBD oil is nicknamed “Charlotte’s Web”.

 Florida licensed physicians must first complete an 8-hour CME course and exam through the Florida Medical Association before they can recommend patients to the Florida Compassionate Use Registry. After successfully completing the course and exam, the physician can recommend qualified patients who are state residents. If participant is younger than 18, two FL physicians must recommend treatment.

 The FL Dept of Health created the Office of Compassionate Use which supervises the licensing of dispensing organizations and training of physicians.

 The Office of Compassionate Use’s director recently announced that Charlotte’s Web will begin to be dispensed this Fall11.

10.Florida Senate Bill 1030 “Haleigh’s Hope Act" authored by Rep. Peake & others. Accessed at URL http://medicalmarijuana.procon.org/sourcefiles/florida-sb1030-enrolled.pdf 11.Keith Morelli. Florida Health Department update on medical pot — long on jargon, short on new info. Published on 06/14/2016 at URL http://floridapolitics.com/archives/213517-florida-health-department- update-medical-pot-long-jargon-short-info

Tennessee

 On May 16, 2014, Tennessee Governor Bill Haslam signed Senate Bill 2531 into law. That bill allows the use of CBD oil containing no greater than 0.9% THC “as part of a clinical research study on the treatment of intractable seizures when supervised by a physician practicing at a Tennessee university having a college or school of medicine.”

 A follow-up bill – Senate Bill 280 – was signed into law the next legislative session to decriminalize low potency CBD oil produced outside of TN as long as it used for intractable seizures in the manner proscribed by SB 2531.

 Critics complain that these bills allow only very narrow access to the CBD/THC products – a low potency product restricted to seizures.

 Governor Haslam – as well as influential legislator & practicing surgeon Sabi "Doc" Kumar – counter that CBD/THC containing products such as Marinol, Cesamet, Epidiolex, & Sativex are FDA approved medications containing CBD &/or THC. Therefore, expanding TN’s laws will likely cause more harm than good.

 The on-going debate is regularly featured by The Tennessean staff reporter Dave Boucher. The newspaper also regularly features guest columns and letters to the editor on medical marijuana in TN.

7 October 1, 2016

Kentucky

 On April 10th, 2014, Kentucky Governor Steve Beshear signed Senate Bill 124. The law excludes from the definition of marijuana:

 “The substance cannabidiol, when transferred, dispensed, or administered pursuant to the written order of a physician practicing at a hospital or associated clinic affiliated with a Kentucky public university having a college or school of medicine… or for persons participating in a clinical trial or in an expanded access program, a drug or substance approved for the use of those participants by the United States Food and Drug Administration.“12

 There have been complaints that access to medical marijuana is extremely limited. Republican state Senator John Schickel, chair of the Kentucky Senate Standing Committee on Licensing, Occupations and Administrative Regulations, has been holding on-going hearings during the spring and summer months featuring physicians, legislators, and patient advocates urging greater access to medical marijuana13.

 Schickel recently stated “I received 20 to 40 telephone calls, emails and tweets per day... Overwhelmingly the messages were in support for the legalization of marijuana. For this reason it is important that we thoroughly vet this important issue before the 2017 legislative session.”14

12.Kentucky Senate Bill 124 from 14th Regular Session. Accessed at URL http://medicalmarijuana.procon.org/sourcefiles/kentucky- sb124-enrolled.pdf 13.Don Weber. Kentucky legislators will look at both sides of medical marijuana issue. Time Warner C/N News, published on 06/16/2016 and accessed at URL http://mycn2.com/politics/kentucky-legislators-will-look-at-both-sides-of-medical-marijuana-issue 14.Community Recorder section. Lawmakers to discuss medical marijuana. Cincinnati!.com (USA Today Network). Published on 06/04/2016 and accessed at URL http://www.cincinnati.com/story/news/local/union/2016/06/04/lawmakers-discuss-medical- marijuana/85412416/

South Carolina

 On June 2, 2014, South Carolina Governor Nikki Haley signed Senate Bill 1035 into law. "Julian's Law“. This law created a statewide drug trials using CBD oil to treat severe forms of epilepsy. The CBD trials must be supervised by a physician who is SC licensed, ABMS board certified and practicing at a SC academic medical center.15

 Julian’s Law also created a study committee to develop a plan for sale and use of medical marijuana should the DEA reclassify marijuana. Committee includes reps from Agriculture Dept., Health Dept., Revenue Dept., Law Enforcement, MUSC, Clemson University, SC Medical Association, and several political reps.

 Julian’s Law is dispensing CBD oil presently but there is a vigorous campaign among state residents to expand medical marijuana in the state to include a variety of conditions such as PTSD, cancer, glaucoma, HIV, fibromyalgia, spinal cord injury, & chronic pain complaints.16

 But on April 7th, a key SC Senate committee rejected considering a bill that would have expanded medical marijuana. Sen. Kevin Johnson said, "Back in my district, every single medical professional that contacted me about this bill is against it.“ Sen. Mike Fair said, "This is a bad idea. It's a pathway to recreational usage.“17 15.South Carolina Senate Bill 1035 from 2013-2014 Session. Accessed at URL http://medicalmarijuana.procon.org/sourcefiles/south-carolina-1035-enacted.pdf 16.Colin Demarest. Medical marijuana in S.C.? The T&D, published on 04/03/2016 & accessed at URL http://thetandd.com/medical-marijuana-in-s-c/article_55c4a843-d40b-53d1-be1e-d85da382aeaf.html 17.WLTX 19 Staff Report. SC Senators Reject Bill to Allow Medical Marijuana. Published on 04/07/2016 at URL http://www.wltx.com/news/local/sc-senators-reject-bill-to-allow-medical-marijuana/125299750

8 October 1, 2016

North Carolina

 On July 3, 2014, North Carolina Governor Pat McCrory signed into law House Bill 1220 - the North Carolina Epilepsy Alternative Treatment Act. This law allows the University of North Carolina at Chapel Hill and East Carolina University, and encourages Duke University and Wake Forest University, to conduct research trials on hemp extract to treat seizure disorders / intractable epilepsy18.

 Study participants were referred by a board certified neurologist who is affiliated with one of the four above academic medical centers and each NC voter support poll on medical marijuana participant’s treatments are recorded in the Intractable Epilepsy Alternative Treatment Pilot Study registry. The hemp extract is required to be greater than 0.3% or greater than 10% cannabidiol by weight.

 In July, 2015, Gov. McCrory amending HB1220 to expand qualified physicians to include any NC board certified in neurologist. NC’s influential U.S. Senator Thom Tillis is credited as an important developer of both the act & its amendments19.

 The bill also changed the required THC/CBD percentages to at least 0.9 % tetrahydrocannabinol by weight or at least 5% cannabidiol by weight. The law also has a ‘sunset clause’ to be enacted on July 1st, 2021, if NC conducted studies fail to show therapeutic relief from the product20.

18.General Assembly of North Carolina House Bill 1220 from 2013 Session. Accessed at URL http://medicalmarijuana.procon.org/sourcefiles/north-carolina-hb1220-ratified.pdf 19.Bertrand M. Gutiérrez. US Senator Tillis supports bill that would aid study of effectiveness of medical marijuana. Winston- Salem Journal, 06/16/2016 & accessed at URL http://www.journalnow.com/news/state_region/us-senator-tillis-supports-bill- that-would-aid-study-of/article_2d0b0929-1326-5290-aa79-e7ffe9d57542.html 20 . General Assembly of North Carolina House Bill 766 from 2015 Session. Accessed at URL http://www.ncleg.net/Sessions/2015/Bills/House/PDF/H766v6.pdf

Louisiana

 Louisiana actually has a long history of medical marijuana legislation – going back nearly 40 years!

 In 1978, Gov. Edwin Edwards signed into law legislation legalizing medical marijuana only for patients with glaucoma and undergoing chemotherapy for cancer treatment. Louisiana Dept of Health and Hospitals (DHH) was responsible for production and distribution but never followed through21.

 The Legislature amends the 1978 law in 1991, this time adding spastic quadriplegia to the list. The Legislature sets a January 1992 deadline for DHH to promulgate rules. In 1994, DHH concludes that they do not have statutory authority in the state’s constitution to create and manage a medical marijuana program.

 In 2014, state senator Fred Mills introduces legislation to both expand and enact Louisiana’s medical marijuana program. Sen. Mills is a former executive director of the Louisiana Board of Pharmacy & very knowledgeable about the multi-agency effort needed to enact such a program.

 His 2014 bill dies after being opposed by the state’s attorney general and the Louisiana Sheriff’s Association.

21. Emily Lane. A short history of medical marijuana in Louisiana. The Times-Picayune, published on 06/05/2015 & accessed at URL http://www.nola.com/politics/index.ssf/2015/06/medical_marijuana_louisiana_hi.html#0

9 October 1, 2016

Louisiana

 Later that year, Sen. Mills re-introduces legislation as Senate Bill 143. With opposition lifted by state law enforcement, the bill passes and then Governor Bobby Jindal signs The Alison Neustrom Act into law in 2015. Mrs. Neustrom suffered from pancreatic cancer and contacted Sen. Mills to testify on the bill’s behalf.

 When the bill was being re-considered in the next session, Mrs. Neustrom not only testified but also personally lobbied the leadership of the sheriff’s association which was instrumental in removing their opposition. Unfortunately, Mrs. Neustrom soon succumbed to her illness but naming the bill after her was seen as a fitting tribute22.

 The act divides responsibilities for implementing the marijuana program between three state agencies; the Louisiana State Board of Medical Examiners (LSBME), the Louisiana Board of Pharmacy (LABP) and the Louisiana Department of Agriculture and Forestry (LDAF) – removing much of DHH’s involvement in the process23. Both Dr. Mouton and I serve on the LSBME committee advising the program’s development. 22.Kris Wartelle. Mother's dying wish to legalize medical marijuana granted. The Advertiser, published 06/11/2015 & accessed at URL http://www.theadvertiser.com/story/news/2015/06/11/womans-dying-wish-legalize-medical- marijuana-granted/71074362/?hootPostID=%5B%27d53d8b8c551eb30f856ae8ace3a89054%27%5D 23.Senate Bill 143 by Senator Mills. 2015 Regular Session. Accessed at Louisiana Legislature Bill Search at URL http://www.legis.la.gov/legis/BillSearch.aspx?sid=LAST

Louisiana

 The LSBME is tasked with developing rules for the prescribing of medical marijuana.

 The LABP works with LSBME on prescribing rules as well as developing the process for dispensing medical marijuana & tracking dispensed products – using its existing prescription monitoring program & law enforcement resources to help keep track of dispensed product.

 The LDAF is tasked with developing a single production facility in conjunction with the LSU Agricultural Center & Southern University.

 Development of procedures in 2015 leads to several procedural and legal questions requiring subsequent legislation to clarify. Gov. Jon Bel Edwards signs Sen. Mill’s 2016 Senate Bills 180 & 271 into law to clarify these standing questions.

 These two bills provide immunity from prosecution for parents giving medical marijuana to their children through the state’s program…

24. Senate Bill 180 by Senator Mills. 2016 Regular Session. Accessed at Louisiana Legislature Bill Search at URL http://www.legis.la.gov/legis/BillSearch.aspx?sid=LAST

10 October 1, 2016

Louisiana

 … requires that physicians recommending medical marijuana must both be licensed by the LSBME and domiciled in Louisiana & that the LSBME develop specific regulations on this topic – which it published on September 20th, 2015 25.

 Defines treatable debilitating medical conditions as cancer, HIV+ status, AIDS, cachexia or wasting syndrome, seizure disorders, epilepsy, spasticity, Crohn's disease, muscular dystrophy, and multiple sclerosis.

 Specifies that the LABP will license up to ten dispensaries in the state that will be geographically spread throughout the state. Each dispensary will be required to hold an escrow account of up to $2 million in a Louisiana financial institution.

 LDAF develops regulations for the extraction, processing, and production of recommended marijuana, using food-grade extraction method that will produce food safe and pharmaceutical-grade products.

 On June 24th, the Board of Supervisors at LSU & Southern approved proceeding with the development of a medical marijuana production center in Louisiana. Both boards stressed that the facility will be built on private land, with transparent production processes and the schools will conduct vigorous research on the botanicals produced and their medicinal impact. The boards are actively consulting parish & state law enforcement & a private international security agency about facility security.

25.Louisiana Register, Volume 41, Number 9, Pages 1813-1817, Published by the Louisiana Dept of Administration & accessible at URL http://www.doa.la.gov/Pages/osr/reg/register.aspx 26.Tim Morris. LSU, Southern boards authorize medical marijuana production. The Times Picayune, published on 06/24/2016 & accessed at URL http://www.nola.com/politics/index.ssf/2016/06/lsu_medical_marijuana_producti.html

Louisiana

 The LSBME has outlined it’s requirements in the Louisiana Register. It is a proposal & conditional on further program development in conjunction with LABP and LDAF. However, it does clarify what will be the approach for participating physicians to recommend or request therapeutic marijuana in the treatment of their patients who are suffering from a qualifying medical condition.

 Although other conditions can be added, a qualifying medical condition is now defined as glaucoma, symptoms resulting from chemotherapy cancer treatment, and spastic quadriplegia.

 Prior to recommending or requesting marijuana for any patient, a participating physician must hold a Schedule I permit authority (research / experimental) on the Louisiana Control & Dangerous Substances (CDS) registry through the LABP.

 The physician must complete an on-line educational activity that will be accessed through the LSBME web site.

 The physician must pay a $75 initial registration fee and annual $50 renewal fee.

 Participating physicians are limited to no more than 100 patients in their practice receiving therapeutic marijuana under that physician’s request / recommendation. Exceeding 100 patients requires written permission from the LSBME.

11 October 1, 2016

Louisiana

 The physician must meet many of the same criteria now required in Louisiana when engaging in the management of chronic pain with controlled substances:

 Personally conduct an actual evaluation that leads to a qualifying diagnosis based on the physician’s independent judgment.

 The generation of a patient-specific treatment plan that documents failed treatments attempted prior to initiating therapeutic marijuana..

 Review the Louisiana PMP Rx Report for the patient and order drug screen testing periodically.

 Both explain the potential risks and benefits of therapeutic marijuana to the patient and obtain informed consent from the patient prior to formal recommendation / request.

 Have regularly scheduled follow-up visits with patients no greater than every 90 days.

 Address any aberrant patient behaviors & stop treatment immediately if diversion is substantiated.

 Maintain accurate and complete medical records on each participating patient that will be made available to the LSBME upon their request. Medical record will include dosage, route and frequency of use of marijuana.

 Participating physicians are limited to no more than 100 patients in their practice receiving therapeutic marijuana under that physician’s request / recommendation. Exceeding 100 patients requires written permission from the LSBME.

Where are we now? By “now” – I mean on 10/01/2016 at 4pm.

 We are seeing a national experiment that re-evaluates our legal, regulatory, and clinical relationship with marijuana that is being played out on a state-by-state level.

 States have spurred on by the August 23rd, 2013, U.S. Department of Justice’s memorandum redefining the federal government’s involvement in marijuana “to preventing the distribution of marijuana by criminal gangs, preventing the trading or bartering of marijuana for other drugs, and other otherwise preventing the use of marijuana profits to fund vice or corruption”27. The feds have also repeatedly clarified that these state initiatives do NOT extend to federal facilities located in these states28!

 We have come to see a patch-work of state initiatives that have ranged from legalizing recreational & medical marijuana, to decriminalizing marijuana use, to legalizing medical marijuana, to initiating evaluations for the use of medical marijuana, to prohibiting all marijuana use.

27.JM Cole. Memorandum: Guidance Regarding Marijuana Enforcement. Office of the Deputy Attorney General, US Department of Justice. Accessed at URL http:// www.justice.gov/iso/opa/resources/3052013829132756857467.pdf 28.Testimony of Barbra M. Roach, Special Agent in Charge, Denver Field Division, U.S. Drug Enforcement Administration, Before the Committee on Indian Affairs, United States Senate, March 31, 2015. Accessed at URL http:// www.dea.gov/pr/speeches- testimony/2015t/033115t.pdf

12 October 1, 2016

Where are we now? By “now” – I mean on 10/01/2016 at 4pm.

 Southern states have observed the process of early state adopters of marijuana laws and have decided to proceed carefully with medical marijuana regulations and programming.

 Many Southern states – including Louisiana – have reduced sentences for recreational marijuana possession but no Southern state is seriously considering legalizing recreational marijuana.

 In fact, the recent availability of marijuana-infused candies in North & South Carolina doomed efforts there to increase access to marijuana29.

 As seen in this presentation, these careful Southern efforts have real differences in patients / participants that can qualify for medical marijuana, the clinicians that can participate in these programs, the type of marijuana product manufactured, and the monitoring of response to treatment by state agencies and state research programs.

 Clinicians who elect to participate in these programs should expect regulations – including documentation and fees – to continue to change on an annual basis for many years to come! ? 29. WHNS Staff Report. Marijuana infused candy turns up in South Carolina. Fox 8 News, published on 06/21/2016 & accessed at http://myfox8.com/2016/06/21/marijuana-infused-candy-turns-up-in-south-carolina/

13 Phenylpiperidine Formulations and Their Role in Pain Management Ken P. Ehrhardt, Jr MD1, Nick Elbaridi, MD, PT2, Alan David Kaye, MD, PhD1, Stephanie Choi, MD2, James H. Diaz, MD, DrPH1, Richard D. Urman MD, MBA2 1Department of Anesthesiology, Louisiana State University HSC, New Orleans, LA 2Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Objective Phenylpiperidines are a chemical class of drugs with a phenyl moiety directly attached to piperidine. Some of these agents have significant roles in anesthesia and pain management, including meperidine, , , , and fentanyl. In recent years, different formulations of phenylpiperidines have been developed and marketed for pain relief. Methods This was a comprehensive review focused on various phenylpiperidine formulations currently marketed and being developed and their varied pharmacological properties. Results Phenlypiperidine-mediated or modulated responses involve action at the μ-opioid receptor as an agonist at the dorsal horn inhibiting ascending pain pathways in the rostral ventral medulla, increasing pain threshold, and producing both analgesic and sedative effects. Numerous routes of administration of these agents are available and each has varied pharmacokinetics, influencing clinical considerations in pain practice. Phenylpiperidine derivatives have been shown to potentiate propagation of infection or cancer. Because all opioids have complex physiological responses and potential drug-drug interactions, the clinician should appreciate all aspects of this drug class and consider all available options in appropriate clinical settings. Conclusion Phenylpiperidines are an important group of opioid agents that have many clinically important effects, including potentiating propagation of infection or cancer. Many phenylpiperidine formulations have been developed and successfully utilized for chronic pain patients. Pain practitioners should appreciate, therefore, the varied pharmacokinetics of this important class of opioid agents and drug interactions.

Keywords: Fentanyl; Remifentanil, Opioids; Analgesics; Phenylpiperidines

Summary Clinicians should appreciate that many phenylpiperidines uptake, metabolism, and elimination are varied. As well, phenylpiperidine-drug interactions should be considered when dosing. Many phenypiperidines are metabolized mainly via CYP3A4 and potential adverse effects can occur with concomitant use of any drug which affects CYP3A4 activity. Discontinuation of CYP3A4 inducers can also result in an increase in phenylpiperidine plasma concentration. High Frequency Spinal Cord Stimulation for Complex Regional Pain Syndrome: A Case Report

Joseph T. Crapanzano, MD1,2,4, Lisa M. Harrison-Bernard, PhD1,3, Ken P. Ehrhardt, Jr MD1,4, Mark R.

Jones, MD1,4, Alan D. Kaye, MD, PhD1,4, Erich O. Richter, MD1,5, Mordeci N. Potash, MD6

1Louisiana State University Health New Orleans, 2East Jefferson General Hospital, , 3Department of Physiology,

4Department of Anesthesiology, 5Department of Neurosurgery, 6Tulane University School of Medicine, Department

of Psychiatry

Objective

Complex regional pain syndrome (CRPS) is a chronic, debilitating, neuropathic pain condition which is often misdiagnosed, difficult to manage, and lacks proven methods for remission. Most available methods provide some relief to a small percentage of patients. Nevro Senza 10-kHz high frequency (HF10) spinal cord stimulation (SCS) therapy instead of traditional low-frequency spinal cord stimulation for treatment of chronic back and leg pain may provide a new interventional therapeutic option for patients suffering from CRPS.

Methods

We present a case report of a 54-year-old Caucasian female who suffered with CRPS in the right knee and thigh for over 7 years. The patient described intense 8/10, constant, and unbearable deep bone pain, as well as sharp and hot pain sensation to the associated muscle and skin with painful and weeping blisters.

Results

Implantation of the HF10 device provided over 90% relief of pain, erythema, heat, swelling, and tissue necrosis to the entire region within 1 month of treatment. After a successful HF trial of one week, a permanent implantation was performed two months later. The patient received marked pain relief. The skin on the affected area has returned to a normal appearance. The pain and stiffness of the shoulders and upper arms has also resolved. The patient continues to enjoy a much more active and enthusiastic life without pain in the knee and thigh region.

Conclusion

The role of neuromodulation in chronic pain conditions continues to evolve. SCS have proven to be an effective means of treating a variety of these conditions. As the devices and technology continue to evolve, added benefits are being revealed. The rapid, dramatic response of our patient’s myriad of symptomology to HF SCS is promising.

Further investigation into the mechanism of action of HF SCS in the treatment of CRPS is warranted in the future.

Keywords: Complex Regional Pain Syndrome, spinal cord stimulation, Nevro Senza HF10, knee, thigh

Summary

Because the HP10 therapy provides pain relief without paresthesia typical of traditional low-frequency, this system may provide relief for patients suffering from complex regional pain syndrome.

Functional Connectivity Alterations and Future Implications for Patients with Chronic Pain

Ken P. Ehrhardt, Jr MD1, Stephen L. Thorp2, MD, Thomas Suchy3, MD, Mohammad M. Piracha, MD1, Neel

Mehta, MD2, Nalini Vadivelu MD3, Alan David Kaye MD, PhD1

1Department of Anesthesiology and Pain Medicine, Louisiana State University, New Orleans, LA

2Weill Cornell Pain Medicine, New York Presbyterian Hospital, 525 East 68th Street ; Department of

Anesthesiology; New York Presbyterian Hospital New York, NY 10065

3Yale-New Haven Hospital, Department of Anesthesiology 333 Cedar Street, TMP 3, New Haven, CT 06520

Objective

Chronic pain is a major public health problem resulting in physical and emotional pain for individuals and families, loss of productivity. The lack of objective measures available to aid in diagnosis and evaluation of therapies for chronic pain continues to be a challenge for the clinician. Functional magnetic resonance imaging is an imaging technique which can establish regional areas of interest and examine synchronous neuronal activity in functionally related but anatomically distinct regions of the brain, known as functional connectivity.

Methods

The present investigation examines changes in functional connectivity in four common pain syndromes: chronic back pain, fibromyalgia, diabetic neuropathy, and complex regional pain syndrome.

Results

Utilizing functional imaging, patients with chronic back pain, fibromyalgia, chronic regional pain syndrome, and diabetic neuropathy have been shown to have significant structural and functional differences when compared to healthy controls. Functional connectivity, therefore, has the potential to assist in diagnostic classification of different pain conditions, predict individual responses to specific therapeutic interventions, and serve as a gateway for personalized medicine. Indirect activation of brain activity can be seen by the blood flow to the brain as specific sites with chronic pain patients having increased brain activity.

Conclusion

Functional connectivity has improved the understanding of mechanisms underlying pain perception and modulation.

Knowing and observing the brain’s activity as related to pain gives pain patients an opportunity to decrease pain related brain activity and decrease severe chronic pain. This modality can be used along with interventional pain management techniques in order to provide optimum pain relief.

Keywords: Functional Connectivity, fMRI, chronic pain, chronic back pain, fibromyalgia

Summary

Functional Connectivity is a potentially exciting new frontier which could advance treatments in pain medicine.

Patients with chronic pain exhibit significant structural and functional neuronal changes and these appear specific to various etiologies causing pain.

Ethical Dilemmas in Pain Management

Xiulu Ruan, MD1, Ken P. Ehrhardt, Jr MD2, Alan David Kaye MD, PhD3

1Adjunct Clinical Associate Professor of Anesthesiology, Dept. of Anesthesiology, Louisiana

State University Health Science Center, 1542 Tulane Ave. New Orleans, LA 70112

2Intern, Dept. of Anesthesiology, Louisiana State University Health Science Center

1542 Tulane Ave. New Orleans, LA 70112

3Professor, Program Director, and Chairman of Anesthesia, Dept. of Anesthesiology, Louisiana

State University Health Science Center, 1542 Tulane Ave. New Orleans, LA 70112

Objective

Chronic pain is pervasive, challenging, and costly. According to the landmark reports published by the prestigious Institute of Medicine, chronic pain affects more than100 million American adults, which is more than the total affected by heart disease, cancer, and diabetes combined

[1,2]. In many pain practices, conflict between the patients’ expectation/demand and the physicians’ judgment/decision are frequently encountered.

Methods

The present investigation examines the literature and ethical considerations regarding pain management aspects of patients with acute and chronic diseases worldwide. This evaluation builds on the mega report by Vos and colleagues [3] entitled “Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease

Study 2013”, published in the Lancet.

Results

Building on the Vos, et al. report, which is considered the most comprehensive and extensive assessment of the global burden of disease down to country level, the present investigation evaluated morbidity and disability burden data and there is a high prominence of pain, as well as diseases associated with pain, as a global cause of disability in both the developed and developing world [4]. While there is no debate over the short term use of opioids, their use for chronic non-malignant pain is controversial and there is growing reluctance among some physicians to prescribe them [5].

Conclusion

Despite the lack of convincing data for long term efficacy and the growing problem of prescription abuse, many physicians prescribe opioid analgesics for patients with chronic non- malignant pain. The reasons are complex, but many believe that it is unconscionable to withhold adequate treatment from any patient complaining of severe pain, whatever the cause, especially when alternative treatment has failed [5].

Keywords: Global pain, Opioids, prescription abuse, alternative nonopioid treatment

Summary

At a global level, chronic pain carries the largest disease burden. Taken long term, opioids have important physiological effects and consequences that are mostly well understood, such as shutting down endogenous opioid production, attenuation of hormonal production, propagation of infection and cancer, and alterations in central nervous system, cardiovascular, respiratory, gastrointestinal, and urinary function. In this regard, while a “patient-centered” approach is always preferred, there are times in managing patients with opioids for chronic pain where the provider needs to takes a “provider-centered” approach, which may threaten the therapeutic alliance. The provider and patient may need to “agree to disagree” on changes to the treatment plan. Ultimately, it is up to the provider to determine what is safe and effective for any given patient [6].

References:

1. Dzau VJ, Pizzo PA. Relieving Pain in America: Insights From an Institute of Medicine

Committee. JAMA. 2014;312(15):1507–8.

2. Institute of Medicine (US). Committee on Advancing Pain Research C. Relieving Pain in

America: A Blueprint for Transforming Prevention, Care, Education, and Research. National

Academies Press; 2011.

3. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F, Davis

A, Degenhardt L, Dicker D. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet.

2015;386(9995):743–800.

4. Rice AS, Smith BH, Blyth FM. Pain and the Global Burden of Disease. Pain. 2015;

5. Fields HL. The doctor’s dilemma: opiate analgesics and chronic pain. Neuron.

2011;69(4):591–4.

6. Alford DP. Opioid Prescribing: Can the Art Become More Science? J Gen Intern Med.

2013;28(10):1253.

Long-term pattern of opioid prescriptions after orthopedic surgery

Alan David Kaye MD, PhD1, Ken P. Ehrhardt, Jr MD2, Xiulu Ruan, MD3

1Professor, Program Director, and Chairman of Anesthesia, Dept. of Anesthesiology, Louisiana

State University Health Science Center, 1542 Tulane Ave. New Orleans, LA 70112

2Intern, Dept. of Anesthesiology, Louisiana State University Health Science Center

1542 Tulane Ave. New Orleans, LA 70112

3Adjunct Clinical Associate Professor of Anesthesiology, Dept. of Anesthesiology, Louisiana

State University Health Science Center, 1542 Tulane Ave. New Orleans, LA 70112

Objective

The development of persistent post-surgical pain is believed to be a multifactorial process that is influenced by physical, psychological, genetic, and social factors. Simanski et al. investigated the prevalence and determinants of persistent post-surgical pain in a general surgical patient population. Patients were followed at least 1 year postoperatively. By surgical discipline, 28% were general, 15% vascular, and 57% trauma/orthopedic surgery. Most often cited pain sites were joint (49.4%), incisional/scar (37.7%), and nerve pain (33.7%). Simanski et al. concluded that there was a high persistent post-surgical pain rate after 2 years, both generally and particularly in orthopedic/trauma (57%) patients. Previous studies have reported that 4-6 months after total knee and hip arthroplasty, 54 (58.7%) of patients reported none or mild pain, whereas 38 (42.3%) patients reported moderate to severe pain.

Methods

The present investigation examined the literature utilizing pubmed as a resource focused on persistent post-surgical pain after orthopedic procedures. A more detailed examination of the literature in the field included evaluation of the pattern of opioid prescriptions dispensed in patients with femoral shaft fractures. Results

Orthopedic surgeries included a significant delivery of opioids post procedure. The present investigation additionally revealed a pattern of opioid prescriptions dispensed in patients with femoral shaft fractures and found a significant proportion of patients continued to receive dispensed prescriptions for opioids for over 6 months (as high as 45%) and more than a third of them (as high as 36%) continued treatment for at least 12 months. It is likely, therefore, that the root of this complicated problem may be inadequately treated persistent post-surgical pain. Recently, Fuzier and colleagues reported their finding of prevalence and impact of post-surgical pain 3 months after orthopedic surgeries in a teaching hospital in France in a survey where 1292 patients responded. Among the responders, 48% suffered from chronic pain at 3 months. In another recent study, Veal and colleagues performed an observational prospective study which followed 87 patients who required orthopedic surgery. They found that post-discharge pain levels were high, with 97.4% of patients suffering pain at 10 days, 81.2% at 6 weeks, and 79.5% at 3 months. Twelve months after discharge, 65.5% of patients reported pain persisting at the surgical site, with 29.9% of all patients suffering moderate to severe incidental pain.

Conclusion

From these investigations, it may be reasonable to speculate that persistent post-surgical pain continues to affect a significant percentage of patients following their orthopedic surgeries including femoral shaft fracture, and that the extended opioid prescriptions from physicians observed in Dabbagh et al.’s study may, in part, represent physicians’ effort in trying to adequately control their patients’ persistent post-surgical pain.

Keywords: Femoral fracture, Opioids, multimodal analgesia, orthopedic surgery, preemptive analgesia

Summary

In postoperative orthopedic cases, multimodal therapies and preemptive analgesic techniques appear to reduce intensity and duration of persistent post-surgical pain and correlation with these strategies and long-term pain states may hasten clarification of best practice strategies for femoral shaft fractures and many other surgeries with long-term pain states.

Association between Social Integration and Suicide Among Women in

the United States

Ken P. Ehrhardt, Jr MD1, Alan David Kaye MD, PhD2, Xiulu Ruan, MD3

1Intern, Dept. of Anesthesiology, Louisiana State University Health Science Center

1542 Tulane Ave. New Orleans, LA 70112

2Professor, Program Director, and Chairman of Anesthesia, Dept. of Anesthesiology, Louisiana State University

Health Science Center, 1542 Tulane Ave. New Orleans, LA 70112

33Adjunct Clinical Associate Professor of Anesthesiology, Dept. of Anesthesiology, Louisiana State University

Health Science Center, 1542 Tulane Ave. New Orleans, LA 70112

Objective

In previous studies, it has been demonstrated that the incidence of suicide decreases with increasing social integration. These studies have concluded that women who were socially well integrated had a more than 3-fold lower risk for suicide over 18 years of follow-up. However, many of these studies have excluded participants with chronic pain as a potential confounding variable when using a multivariable regression model in conducing sensitivity analysis.

Methods

This investigation examines the effects of chronic pain on the suicidality of women. Pubmed related articles were evaluated with a focus on the terms women, chronic pain, and suicidality. As well, other risk factors, such as employment status, family history of alcoholism, weekly physical activity, alcohol intake, smoking status, and history of hypertension, and diabetes mellitus were evaluated in the literature search.

Results In general, chronic pain has long been considered an important risk factor for suicidal behavior and has been confirmed in many studies. A literature review by Tang et al. showed that relative to controls, the risk of death by suicide appeared to be at least doubled in chronic pain patients. The lifetime prevalence of suicide attempts was between 5% and 14% in individuals with chronic pain, with the prevalence of suicidal ideation being 20%. Despite the clear link, many other studies excluded patients with chronic pain states.

Conclusion

Chronic pain affects over 100 million Americans, more than heart disease, diabetes, and cancer combined. While studies by Tsai and other investigators have considered other severe medical conditions, including heart disease, stroke, and cancer with suicide risk and compromised social relationships, many of these studies failed to consider the effect of chronic pain on suicide and social integration. Thus, many of the studies identified may have results and conclusions significantly compromised related to residual confounding.

Keywords: Suicidal behavior, chronic pain, social isolation, depression

Summary

For those that have chronic pain, a significant number additionally have anxiety, decreased activity, inability to work, alcohol and substance abuse issues, insomnia, depression, and social isolation. In some of the studies identified evaluating suicidal behavior in women, even the word pain is not mentioned. This critically important factor should be considered in any investigation related to factors associated with suicidal behavior. A case of conversion disorder in the setting of unexplained chronic pain and nonepileptic seizure

Derek Y. Yuan1, MD, Andrew Deptula2, PhD, Louis N. Manganas1, MD, PhD, And Patricia Tsui2, PhD

1Department of Neurology, Stony Brook University Medical Center, Stony Brook, New York 2Department of Anesthesiology, Center for Pain Management, Stony Brook, New York

Objective: To report an atypical presentation of conversion disorder in the setting of unexplained chronic pain and nonepileptic seizure. We highlight challenges involved in making a diagnosis, subsequent management and individual outcome of the disorder

Case presentation: We report a 19-year-old left-handed male college student with no significant past medical history, who presented with a three-month history of pain over multiple areas of his body. The pain was described as burning with a bone crushing sensation. He was hypersensitive to touch as well as sound. He experienced diffuse muscle fatigue and occasionally had a poor focus of his vision. In addition, he complained of “brain fog”, which caused him to have difficulty remembering major events in his life. He then began to experience transient convulsions ranges from an arm or leg to his entire body. He remained aware during these events but could not communicate. He had trouble keeping up a full academic schedule as his symptoms progressed.

Extensive blood work revealed no acute infection. Prolonged video EEG monitoring showed no epileptiform activity during a typical event. The patient also had normal ECG and electromyographic and nerve conduction studies. His brain MRI revealed punctate and non-specific white matter lesions that were not consistent with demyelinating disease. The patient was started on duloxetine 60mg once daily as well as weekly individualized psychodynamic psychotherapy including hypnotherapy, reiki, massage, and biofeedback. In a three-month follow-up, the patient had significant improvement in his symptoms and was able to resume his full-time schoolwork.

Conclusion/Summary: Our case highlights a close relationship between conversion disorder and pain and neurological symptoms. Early recognition of this close relationship will limit unnecessary tests and medications. A comprehensive treatment approach is required for the long-term benefit of this disorder.

Key Words: conversion disorder, chronic pain, psychosocial factor in pain, nonepileptic seizure, and psychotherapy Use of Functional Restoration to Rehabilitate Injured Workers and Restore Quality of Life

Geralyn Datz PhD1,2 , Mallorie Carroll MA2, Carly Chadick MS2, David Gavel MS2,3,

Deirdre Paulson-Donvan MS2,4

1Southern Behavioral Medicine Associates PLLC; 2University of Southern Mississippi, Department of Psychology;

3Charles George Veterans Affairs Medical Center; William S. Middleton Memorial Veterans Hospital

Objective

In the wake of the opioid epidemic, the treatment of chronic pain patients with a primarily biomedical

(pharmaceutical and surgical) approach has been strongly questioned. The CDC Guidelines, medical treatment guidelines, and national insurance guidelines advocate to including non-pharmacological and self-management based approaches for chronic pain recovery. In personal injury, opioid and other medication-based approaches can often become the mainstay of pain treatment, due to multiple systems based issues. Unfortunately medication based approaches do little to teach the patient with injury how to adapt and overcome the all encompassing nature of injury, chronic pain and the physical and emotional sequelae that follow.

Interdisciplinary chronic pain treatment (functional restoration), offers an alternative to traditional chronic pain treatment.

Methods

Interdisciplinary chronic pain treatment as summarized by several large scale studies, has a robust literature supporting its efficacy on return to work (55% to 90%), and often dramatic improvements in physical and psychological function. The vital components of this treatment approach include intensive daily treatment with skilled professionals, and evidence based of provision of physical therapy and cognitive behavioral therapy for chronic pain. We will discuss the use of interdisciplinary pain rehabilitation in the treatment of pain patients in general. Pilot data from one facility in Mississippi will be presented, where the incorporation of wearable technology is added to the treatment protocol and outcome assessments.

Results

The treatment- and cost-effectiveness of interdisciplinary pain management programs have been well documented in the scientific literature. Interdisciplinary treatment has comparable benefit to successful spinal fusion. Chou and colleagues (2009) rated the use of interdisciplinary treatment for low back pain as a “strong” recommendation associated with a “high” quality of evidence. Results from this clinic’s1 functional restoration program demonstrate patients have significant decreases in catastrophizing, depression, and anxiety, as well as dramatic increases to physical activity after a coordinated 20-day intervention. With these strong endorsements in mind, coupled with the fact that there has been considerable additional clinical research in recent years, that has overwhelmingly supported the validity of this approach, it is worth evaluating the current state of interdisciplinary chronic pain management in greater detail.

Conclusion

Interdisciplinary pain treatment / functional restoration has a strong outcome literature and as well cost savings. However these programs are infrequently utilized, and poorly understood by providers and carriers.

Better dissemination of information related to these programs, both within healthcare settings as well as within insurance/ claims guidelines, will assist in providing a higher quality of care from patients who suffer with the debilitating effects of chronic pain. In addition, functional restoration has the strongest association with return to work of any pain treatment modality.

Keywords: Interdisciplinary, chronic pain, functional restoration, cognitive behavioral therapy